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STRESS MANAGEMENT FOR CANCER SURVIVORS USING A TECHNOLOGICALLY 
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Patients with cancer transitioning from completing their final cancer treatments to 
survivorship are particularly at risk for experiencing psychosocial stress, and the Institute of 
Medicine (IOM) has referred to these cancer patients as “lost in transition.” In this study, patients 
with cancer in their transition phase after completing their final radiation treatment were defined 
 
 
 
 
as cancer survivors (CS). CS must deal with chronic stressors such as the fear of cancer 
recurrence as well as the resumption of their roles in their family and work lives. Chronic stress 
impacts the nervous system and increases secretion of stress hormones (e.g. cortisol) from the 
endocrine system, which in turn influences immune function. These systems are particularly 
relevant for CS since research has shown associations between abnormal cortisol patterns and 
increased mortality in breast CS and immune dysfunction in CS can increase susceptibility to 
infections. The theoretical framework of psychoneuroimmunology (PNI), which describes the 
interactions between the psychosocial, neuroendocrine and immune systems, guided the choice 
of outcomes for this study. The IOM has identified a lack of theory-driven interventions for 
managing psychosocial stress in CS. We reviewed the literature and identified two major types 
of PNI-based psychosocial interventions for cancer patients, namely cognitive-behavioral and 
complementary medical. One promising brief and inexpensive psychosocial intervention was 
expressive writing, which involved participants disclosing their deepest thoughts and feelings 
regarding their cancer in four 20-30 minute writing sessions over four consecutive days. We 
conducted a two-arm randomized controlled trial to determine the efficacy of an online 
expressive writing (EW) intervention delivered to CS who were 2-12 months post-radiation 
treatment completion. The results of this study revealed that EW was effective in regulating 
stress in our sample of CS over a period of six weeks as measured by lowered salivary cortisol 
levels and lowered self-reported fear of cancer recurrence. Online EW is a low-cost and 
convenient approach for delivering stress-management interventions for CS during survivorship. 
However, coordinated efforts are needed from health researchers, professionals and policy 
makers to define standardized approaches for testing psychosocial interventions and using PNI 
biomarkers to help develop evidence-based psychosocial cancer-care for CS during survivorship.  
 
 
 
 
Keywords: Cancer, Survivors, Stress management intervention, Expressive writing, 
Randomized trial, Psychoneuroimmunology, Neuroendocrine-immune biomarkers 
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Chapter I. Introduction  
Cancer remains a significant cause of death and suffering for individuals on physical, 
mental and social levels, the world over. In the United States, 41% of individuals are faced with 
the possibility of a cancer diagnoses in their lifetime, and more than a million new cancer 
diagnoses are projected to occur this year. Advances in early detection and treatments have led to 
a consistent increase in individuals that have survived their cancer, currently estimated to be 
more than 13 million individuals in the US alone2. Cancer patients experience high levels of 
psychosocial stress across the cancer-care continuum, i.e. from diagnosis through survivorship 
care and palliative care3. Chronic psychosocial stress in cancer patients can have serious negative 
health consequences by impeding patient’s psychosocial functions (e.g. lowered ability to cope 
with cancer) as well as biological functions (e.g. increased susceptibility to infection due 
immune suppression), and represents a serious public health problem. In this study we describe 
psychosocial stressors faced by cancer patients, identify interventions to remediate psychosocial 
stress in cancer patients and conduct a randomized trial of psychosocial intervention called 
expressive writing for cancer patients who were transitioning off their last radiation treatment.  
What Psychosocial Stressors Exist in Patients Diagnosed With Cancer?  
Cancer patients are susceptible to mental health problems such as depression and anxiety.  
A recent meta-analysis suggest that the prevalence of depression in cancer patients is 16.3%; of 
which 14.9% of cancer patients are suffering major depression and 19.2%  minor depression, as 
defined by DSM criteria4. The same study found the prevalence of adjustment disorder to be 
19.4%, anxiety 10.3%, and dysthymia 2.7% in their sample of cancer patients4. In addition to 
mental health issues, cancer patients are also faced with a great amount of emotional distress, 
and four in ten patients with cancer report experiencing significant distress5. Cancer patients are 
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commonly faced with issues such as fear of death and the associated fear of losing close 
interpersonal relationships (e.g. family and friends) due to death. Other socio-emotional issues in 
cancer patients include interruption of life plans, chronic uncertainty, changes in body image and 
self-esteem, fear of cancer recurrence, and hopelessness3. These psychosocial problems affect the 
cancer patient’s ability to function productively at work and result in difficulty in maintaining 
employment and hence, a decrease in income1,6 A survey study revealed that more than one third 
of cancer patients and their family members reported that they were unable to perform at their 
job, and 19% lost or changed jobs or needed to work fewer hours because of the illness, while 
22% reported a lower income6.  
Medical expenses incurred due to cancer can exhaust patients and their families financial 
resources, and it is has been established in the United States that 62% of bankruptcies in 
Americans are medically related7. These financial problems lead to more stress in cancer patients 
and further exacerbate the existing psychosocial problems. Furthermore, physical and mental 
impairments (e.g. chronic fatigue and cognitive dysfunction) due to cancer related treatment 
regimens also add to the cancer patient’s psychosocial problems8. Treatment-related adverse 
effects can impact cancer patients several years after all treatments are completed. For example, 
a recent study demonstrated that survivors of breast cancer treated with adjuvant chemotherapy 
more than 20 years ago performed worse on neuropsychological tests of immediate and delayed 
verbal memory, processing speed, executive functioning and psychomotor speed, when 
compared to random population controls 9. Hence, patients with cancer are faced with range of 
unmet psychosocial needs depending on where they lie along the continuum of cancer care1. 
The Cancer Care Trajectory: Defining Cancer Survivors 
The NCI considers the cancer care trajectory to begin “from the time of diagnosis through 
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the balance of his or her life,”1[p. 29] and a patient can be considered to lie in one of the phases of 
this continuum, see Figure 1. The 
major phases of this trajectory are 1) 
diagnosis and staging, 2) treatment, 
i.e., intended to cure or palliative 
treatment, 3) survivorship care, 4) 
recurrence (or secondary cancers), 
and 5) death. The Institute of 
Medicine (IOM) has identified a 
considerable deficiency of cancer care 
specifically for the psychosocial issues faced by cancer patients in the survivorship care phase 1. 
Moreover, there are a growing number of cancer survivors, with figures from the NCI and CDC 
reporting that more than 11 million people are currently living with a history of cancer in the 
United States10. The numbers of cancer survivors are expected to increase even more due to 
advances in early detection and effective treatments along with an aging population. The office 
of survivorship at the NCI considers patients to be cancer survivors after a definitive initial 
diagnosis of cancer until the end of life, and this definition also includes family members, 
caregivers and friends, since they are affected by the cancer experience as well11. However, the 
NCI’s definition lacks specificity for defining cancer survivors for research protocols. This study 
directed its research focus towards cancer patients who were in the cancer-free survival phase. 
Specifically, we defined our target population as cancer patients who had completed their cancer 
treatments (intended to cure) and were declared disease-free (no recurrence or secondary 
cancers), and these cancer patients are hereafter referred to as cancer survivors (CS).  
       Figure 1: Cancer Care Trajectory1   
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Phases of Cancer Survivorship from a Psychosocial Perspective 
From a psychosocial perspective, the period of cancer-free survival can be assumed to 
have two phases, called re-entry and long-term survival, which were initially suggested by a 
physician who was diagnosed and treated for cancer12,13, and have been subsequently adopted by 
some psycho-oncology researchers14-16.  The re-entry phase of survivorship is considered to start 
from immediately after treatment completion up to approximately 12-18 months of cancer-free 
survivorship. Patients beyond 18-24 months of remission are considered to be in the long-term 
survivorship phase. Researchers have identified that that the re-entry phase is a period of 
heightened distress for CS and patients have many unmet psychosocial needs during this 
phase16,17. For example, a longitudinal study of distress in breast CS described that 15% of 
women reported experiencing heightened distress beginning at treatment completion until six 
months after treatment completion18. Moreover, psychosocial interventions have not been 
designed to meet the needs of CS in the re-entry phase. This may be due to the assumption that 
individuals in the re-entry survival phase experience relief after completing their treatment and 
from being free of their cancer diagnosis. However, these patients are faced with myriad of 
psychosocial stressors which includes the fear of cancer recurrence 12. 
Stressors Experienced by Cancer Survivors (CS) in the Re-Entry Phase  
CS in the re-entry phase experience stress due psychosocial problems and treatment 
related adverse effects. Research indicates that some pronounced psychosocial problems for CS 
during the re-entry phase include the fear of cancer recurrence, uncertainty about the future, 
interruption of life plans, impaired body image and self-esteem, and fear of death 1,3. Another 
source of stress for CS in the re-entry phase is the late and long-term adverse effects of cancer 
treatment regimens. Late effects of treatment regimens refer to unrecognized toxicities that were 
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absent or subclinical at the end of therapy1,19. These late effects manifest during survivorship 
subsequent to unseen injury because of any one or more of the following, a) developmental 
processes, b) the failure of compensatory mechanisms to act in due course, or c) organ aging1,19. 
Late effects can appear anytime, ranging from a few months to years after the completion of 
treatment. Long-term effects are side effects or complications of treatment that are recognized 
during treatment that continue beyond the end of treatment1,19. Common late and long-term 
effects of treatment for CS in re-entry phase include fatigue/ sleep disturbance, pain, sexual 
dysfunction, urinary/bowel problems, and cognitive problems1,16 Neuropsychological 
impairments such as memory problems and impairments in executive function are also common 
in CS9. Cancer treatments involving extensive surgery or radiation can also result in a range of 
impairments in physical function in CS, such as restrictions in movement of limbs, chronic pain 
and fatigue19. These functional impairments can lead to a decrease in daily activities and 
performance, which in turn leads to frustration and chronic stress in survivors.  
Why is the Re-Entry Phase a Particularly Stressful Period of Cancer Survivorship?   
 One reason for increased stress in the re-entry phase is the loss of interaction with health 
care providers and caregivers14,16. During the treatment phase, cancer patients are continuously 
interacting with their oncology care team, and therefore experience a sense of protection 17,19. 
There is also more interpersonal social support from caregivers for cancer patients during the 
treatment phase which decreases after completing treatment 20. After treatment regimens are 
completed, many patients perceive a decrease in social support because they are no longer in 
regular contact with the oncology team16,21. Therefore, the transition from active treatment to the 
re-entry phase becomes a particularly stressful period for patients. In addition, there is very little 
preparation for the re-entry phase by health care professionals or others, which results in unmet 
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needs for information and psychosocial health services1,14,22. During this transition phase, CS are 
often confronted with making sense of their identity and learning to cope with the stressful 
experiences during their diagnosis and treatment23. Concurrently, CS are expected to return to 
life as usual and reassume their original family and work roles and responsibilities. Therefore CS 
in the re-entry phase often face multiple stressors related to their cancer diagnosis and learning 
how to cope after treatment while perceiving a loss of social support and resources14. CS who are 
in the re-entry phase after completing their radiation treatments are particularly at risk for being 
distressed and having psychosocial problems.  
Psychosocial Stress Experienced by Cancer Survivors after Radiation Therapy  
 Numerous studies of CS populations have focused on the physical and psychosocial 
problems created by chemotherapy (e.g. fatigue and depression) and surgery (e.g. loss of 
organ(s) and impaired body image); very few studies have directed their attention to 
psychosocial effects of radiation treatments24. There is a growing body of evidence indicating 
that CS encounter many psychosocial stressors after completing radiation treatment25. A 
comparative study consisting of CS (5 years after initial treatment for cervical cancer, N=114) 
that had either received surgery (n=37) or radiation (n=37) and a control group (healthy patients 
with no cancer treatment, n=40), found that compared with CS of surgical treatments and the 
control group, radiation CS had significantly lower health-related quality of life (physical and 
mental health), increased psychosocial distress, and problems in sexual functioning26. 
Furthermore, longitudinal studies with cancer patients receiving radiation treatments suggest that 
depression and impairment in psychological well-being increase significantly after treatment27-30. 
Another longitudinal study found that negative perceptions of the survivorship experience and 
worry about the future increased significantly 6 months after completion of radiation therapy31. 
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This suggests that CS post-radiation have numerous unmet psychosocial needs that make them 
susceptible to chronic stress, which has very serious implications for CS since chronic stress 
impacts human biology, e.g. by influencing the nervous, endocrine and immune systems.  
How Does Psychosocial Stress Affect Biological Outcomes? 
Researchers across a variety of disciplines have investigated the nature versus nurture 
explanation for health outcomes in human beings. Advances in health and social sciences have 
established the field of bio-behavioral clinical research which investigates interactions between 
psychosocial factors and biological outcomes32. Over the past three decades scientists have 
specifically explored how chronic psychological stress affects physiological systems, 
specifically, the neuroendocrine and immune systems33-35. Chronic stress affects the functioning 
of the nervous system, which initiates secretion of glucocorticoids (e.g. cortisol) from the 
endocrine system36. Continued exposure to high concentrations of stress mediators causes 
decreased expression of glucocorticoid receptors, thereby leading to cortisol resistance37. Thus, 
normal cortisol regulation of the immune system is lost, leading to a pro-inflammatory state and 
immune system dysregulation37,38. 
These systems are particularly relevant for cancer populations because previous research 
has demonstrated that abnormal patterns of cortisol secretions (cortisol rhythms) are associated 
with increased mortality in breast cancer patients39. Dysfunction of the immune system also has 
critical consequences for cancer populations, such as increasing susceptibility to infection, and 
impacting the progression of cancer, thereby increasing the likelihood of cancer recurrence and 
development of secondary cancers3,40,41. Therefore, neuro-hormonal (e.g. cortisol) and immune 
functioning are very critical biological health outcomes for CS. The study of interactions 
between the psychological, neuroendocrine and immune systems has given rise to the inter-
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disciplinary field of psychoneuroimmunology (PNI).  
Psychoneuroimmunology (PNI) and Immune Function  
Studies suggesting the psychosomatic influence of mental disorders on biologic outcome 
measures were being published since the 1940s, however substantial progress in PNI research 
occurred only after 198042. The term psychoneuroimmunology (PNI) was coined in 198143,44, 
and in the subsequent 30 years, science has witnessed major advances in understanding how 
psychological factors affect the brain and central nervous system, which influence the production 
and release of certain hormones, e.g. glucocorticoids, which in turn affect the function of the 
immune system44-46. Two physiological pathways have been studied to understand how chronic 
stress exerts influence on immune function.  
The first is the hypothalamic-pituitary-adrenocortical (HPA) axis, which is also called the 
limbic-hypothalamamic-pituitary-adrenocortical axis (LHPA), due to the role of the limbic 
system of the brain (i.e. amygdala and 
hippocampus) in the human stress 
response47. Multiple hormones are 
involved the HPA axis pathway, which are 
released from different organ systems in 
the body. Acute and chronic psychological 
stress initiates the release of corticotropin-
releasing hormone (CRH) from the 
hypothalamus47. CRH then causes the 
release of adreno-corticotropin releasing 
hormone (ACTH) from the pituitary gland.  Figure 2:  Stress, HPA axis and immunity46 
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Subsequently, ACTH activates the release of cortisol and adrenaline from the adrenal gland47, 
see Figure 2. The immune system is affected by change in the levels of hormones secreted by the 
adrenal gland. Dysregulation of cortisol levels can give rise to persistent inflammation which 
alters the capacity of immune cells to combat infections and disease. Glucocorticoid/cortisol 
dysregulation causes immune suppression by inhibiting certain transcription factors (NF-κB) 
involved in the production of cytokines (e.g. Interleukins), which are cellular signaling 
molecules involved in modulating the immune response, see Figure 2.  
Another relevant physiologic pathway involved in the human stress response is the 
sympathetic nervous system (SNS)47. The SNS affects various systems (e.g. cardiovascular 
system) and glands (e.g. lymph nodes, salivary glands) in the body through direct innervation, 
which refers to a hardwiring of the body through a network of nerves. Stress causes the SNS to 
initiate the fight-or-flight response and releases the hormones epinephrine and norepinephrine. 
These hormones have a wide-ranging effect on the body, and also influence immune function, 
for example, a reduction in the cytotoxic activity of natural killer (NK) cells. The SNS is known 
to initiate secretion of salivary enzyme α-Amylase. This system of interrelated interactions 
between psycho-social factors and physiological systems comprises the PNI framework. This 
PNI framework views psychosocial factors as moderators of the neuroendocrine system that 
together influence immune function48,49. Further evidence in favor of PNI mechanisms is 
established through psychosocial intervention research, wherein interventions that were designed 
to reduce stress have demonstrated a decrease in cortisol secretion and have improved functional 
measures of the immune system such as cytokines 50,51. Studying the neuroendocrine and 
immunological effects of psychosocial stress management interventions for CS using the PNI 
framework is a needed area of research, since CS are predisposed to have immunosuppression.  
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Immune Suppression in Cancer Survivors  
It can be posited that the immune systems of cancer survivors are compromised by the 
combined impact of 1) late and long-term effects of treatment regimens such as surgery, 
chemotherapy and radiation, 2) negative immunologic effects due to the cancer itself and 3) 
chronic psychosocial stressors described above. Late effects of chemotherapeutic drugs such as 
methotrexate have been implicated to cause a reduction in all types of immune cells and 
insidiously affect bone-marrow production of immune cells in cancer survivors many years after 
treatment1. Long-term effects, i.e. side-effects or complications of treatment, on immune 
function are common in patients that are treated with immunosuppressive agents (e.g. 
cyclophosphamide treatment in transplant recipients), or hormonal therapy (e.g. corticosteroid 
therapy)1. All the treatment modalities for cancer, which includes surgery, chemotherapy and 
radiation, have the potential to cause varying degrees of immune suppression.  
Moreover, cancer itself can have immunosuppressive influences on patients. For 
example, many hematologic cancers (e.g. leukemia, lymphoma), and cancers that are likely to 
become metastatic, are known to alter the production of immune cells resulting in immature cells 
entering the blood stream, and this effect can continue into survivorship1,52 . Considering the 
evidence for chronic stress impacting immune function, it can be suggested that stress combined 
with the late and long-term effects of cancer treatments, and the cancer itself, can work 
synergistically to augment the immune suppression in the CS population, which can lead to very 
serious health consequences. Therefore, CS need interventions that are designed to regulate 
psychological and emotional stress, which in turn can alter the response from the HPA axis and 
SNS and result in beneficial changes to their immune function. However, rigorous empirical 
research is needed to establish evidence for the efficacy of psychosocial interventions for CS.  
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The Need for Psychosocial Intervention Research in Cancer Survivors 
Considerable advances have occurred in medical diagnosis and management for patients 
with cancer.3 Breakthrough innovations have occurred in areas such as radio-diagnostic imaging 
(e.g. positron imaging tomography/PET scan53), surgical procedures (e.g. robotic surgery54) and 
chemotherapeutic agents (e.g. targeted chemotherapy55) for cancer patients. However, 
interventions to manage the several unmet psychosocial needs of cancer patients and CS have not 
witnessed the same advances in their science and technological delivery3. Therefore the IOM has 
recommended that researchers and health practitioners in the oncology setting should work 
towards enhancing the science and delivery of psychosocial health interventions and generate 
evidence that can institutionalize the use of theory-driven psychosocial interventions as a part of 
routine cancer care3. Based on the IOM report, “interventions that enable patients, their families, 
and health care providers to optimize biomedical health care and to manage the 
psychological/behavioral and social aspects of illness and its consequences so as to promote 
better health,” 3 (p.69) can be considered to be psychosocial interventions. The PNI theoretical 
framework guided the choice of outcome measures for this intervention research study. 
However, the first step towards addressing the need for improving the science and delivery of 
psychosocial intervention, was identifying gaps in the existing literature pertaining to 
psychosocial interventions for patients with cancer.  
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Chapter II. Literature review 
Cancer is a significant global public health problem, which has caused 7.6 million deaths 
world-wide, as estimated by the World Health Organization (WHO) in 200856. In the United 
States, the Surveillance, Epidemiology and End Results (SEER) for cancer, published by the 
National Cancer Institute (NCI), reports that 41% of Americans face a chance of being diagnosed 
with cancer in their lifetime.57 Cancer remains the second most common cause of death in the 
United States and this year alone, iSEER estimates 1,638,910 men and women (848,170 men and 
790,740 women) will be diagnosed with cancer (of all sites) and there will be 577,190 deaths due 
to cancer. This corresponds to 4,490 new diagnoses and a loss of more than 1,500 lives, every 
day58. The estimated cost of cancer care amounted to $124 billion in 2010 and is projected to 
reach around $158 billion by the year 202059. These data illustrate the public health burden posed 
by cancer, related to morbidity, mortality and healthcare costs. However, cancer affects every 
aspect of the health and well-being of individuals, i.e. physical, mental and social well-being.  
Patients with cancer experience significant psychosocial-emotional trauma that act as 
chronic stress stimuli, which negatively impact physical well-being   (e.g. immune suppression) 
as well as psychosocial well-being (e.g. poor coping with cancer), and poses a major public 
health problem 3. In every stage of their disease course, patients with cancer are faced with a 
complex set of psychosocial problems. Researchers have highlighted a deficiency of research 
evidence related to interventions designed to improve mental and social well-being, i.e. 
psychosocial well-being, in patients with cancer. In order to address the psychosocial problems 
in cancer patients, researchers and health practitioners have developed a wide range of therapies 
and interventions. The first step of this dissertation study was to conduct a comprehensive 
critical review of the literature to identify the types of psychosocial interventions that have 
13 
 
studied in the cancer population and determine how these interventions have influenced 
particular health outcomes (specifically PNI-based outcomes) in patients with cancer. 
PNI-Based Psychosocial Interventions 
Although studies supporting a relationship between psychosocial stress and adverse 
health outcomes have been published since the 1940s, substantial progress in PNI research 
occurred only after 198042. A study published by Spiegel et al60. (1989) drew considerable 
attention to psychosocial intervention research, as it reported an increased survival rate in breast 
cancer patients who participated in a group-therapy psychosocial intervention60. The effects of 
group therapy on increased survival rate were later attributed to neuroendocrine-immune 
mechanisms described in the PNI framework61. Though Spiegel et al.’s study was controversial 
and replication studies of their group-therapy intervention failed to demonstrate increased 
survival62,63, researchers became interested to explore the neuroendocrine-immune effects of a 
variety of psychosocial therapies64, such as Cognitive-Behavioral-Stress-Management (CBSM) 
and supportive therapy in persons with cancer64. Subsequent systematic reviews of PNI-based 
psychosocial therapies have been conducted64,65, but, these reviews have lacked a comprehensive 
approach towards identifying and appraising eligible studies.   
Gaps in Literature: Lack of Comprehensive Reviews  
Previous reviews have lacked breadth and depth in their approach towards evaluating 
PNI-based psychosocial interventions with regards to a) review methodology, b) limited cancer 
types evaluated, c) limited descriptions of the types of therapies and d) lack of specificity in 
reporting PNI-measures  
a) Review methodology. Although early reviews, published in the 1990s66-68, of  
psychosocial therapies indicated that the PNI framework could be used to explain the benefits 
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(e.g. increased survival) of psychosocial interventions for cancer patients, these reviews did not 
use statistical methods to assess the PNI effects of psychosocial interventions. A systematic 
review published in 200269 used a more rigorous methodology provided by the evidence-based 
medicine (EBM) approach, which involved assessing results of rigorous randomized controlled 
trials69. This review concluded that not a single psychosocial intervention strategy could be 
recommended for improving immune function in cancer patients69. However, the review authors, 
Newell et al. 69, made their conclusion based on a small sample of four qualifying studies that 
measured PNI outcomes70-73. The  National Cancer Policy Board (NCPB) criticized this review 
in a report published in 200474, and determined that, due to very narrow methodological 
specifications, many valuable effects of psychosocial interventions, which includes PNI effects, 
may have been “missed or undervalued”74(p97).Other health researchers have also suggested that 
the EBM methodology may be too restrictive for evaluating psychosocial therapies and have 
advocated for reviewers to ensure methodological diversity (described below) in the inclusion of 
psychosocial interventions75,76.  
b) Cancer population. Reviews of PNI-based psychosocial interventions have most 
commonly reported studies conducted for a specific cancer populations, most often women with 
breast cancer64,77-79. Reviews that adopt this narrow focus eliminate studies conducted in other 
cancer populations and this limits the reach of psychosocial therapies for persons with cancer.  
c) Types of therapies. A wide variety of interventions have been developed for 
addressing the psychosocial aspects of cancer. A meta-review of psychological interventions 
identified 79 distinct modalities of psychosocial therapies80, ranging from education to breathing 
exercises. However, reviewers have not appraised the details of psychosocial interventions in 
terms of their individual components and activities, methods of delivery or duration of the 
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interventions80. Health researchers have been recommended to pay attention to the 
aforementioned details of psychosocial therapies in recently provided recommendations for 
reviewing complex interventions: assessment and trials implementation of services 
(COMPASS)80,81.  
d) PNI measures employed. Reviews of psychosocial interventions that included studies 
which used PNI biomarkers as outcomes, have not detailed the specifics of the PNI biomarkers 
and psychometric scales employed64,79. Also, researchers in this field have noted that many 
psychosocial interventions claiming to work through PNI mechanisms have not measured actual 
PNI biomarkers68,77,82. For example, even though the landmark study  by  Spiegel et al. (1989)60 
alluded to PNI mechanisms61, it has been noted that biomarkers associated with PNI systems 
were not obtained as outcome measures in the original study64.  Recent reviews of research 
studies designed to determine relationships between psychosocial factors and survival outcomes 
of patients with cancer continue to suggest psychoneuroimmunologic mechanisms of actions83,84. 
However, these reviews83,84 have included research that did not use PNI-based biomarkers as 
outcome measures, and thus calling into question the validity of the claims regarding PNI effects 
of therapies targeting psychosocial variables in persons with cancer.  
Comprehensive Approach to Literature Review   
Thus, a comprehensive approach to conducting a review of the current literature was 
undertaken. To this end the directives for conducting evidence reviews of psychosocial 
interventions provided by the IOM3,74, the World Health Organization76 and the COMPASS 
checklist proposed by Hodges et al80. were followed. These directives were operationalized for 
the current review by a) having methodological diversity in study designs, b) including all cancer 
populations, c) examining details of the types of psychosocial therapies and d) identifying the 
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specific PNI outcome measures employed. The aim of the literature review was to assess the 
current state-of-the-science (studies published after 2001) for PNI-based psychosocial therapies 
to answer the following questions (Qs): 
Q1) Population: In which cancer populations, in terms of type and stage of cancer, have 
psychosocial interventions using PNI-based measures been conducted?  
Q2) Types of interventions: What types of psychosocial interventions (that used PNI-based 
outcomes measures) have been delivered for cancer patients? Particularly,    
a) What activities (e.g., relaxation training) did the therapies employ?   
b) What were the method(s) of delivery (e.g., individual/group-based) and personnel 
involved? 
c) What were the durations of the interventions (including length of each session)?    
Q3) PNI measures: Which specific measures of PNI subsystems were used as outcomes for 
psychosocial interventions in the cancer population?  
Review Methodology  
Methodology for the review process was based on guidelines provided in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement85. Authors 
also reviewed methodological recommendations for conducting literature reviews put forth by 
the Cochrane collaboration86, the IOM committee on standards for systematic reviews of 
comparative effectiveness research87, and the assessment of multiple systematic reviews 
(AMSTAR) checklist88. Methods involved developing a systematic a) search strategy and b) 
selection criteria, along with c) screening and identification procedures to eliminate irrelevant 
studies, which were followed by d) data extraction procedures.   
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a) Search Strategy 
The following electronic databases were searched online during November and 
December of 2013 to identify the studies: PubMed/Medline, EMBASE, PSYCINFO, CINAHL, 
and Google Scholar. Studies were considered if they were published from January, 2001 to 
November Week 4, 2013. The search terms (keywords) from a previous systematic review69 and 
a meta-analysis89 of psychological interventions were included in our search strategy.  
There were three categories of keywords (described in italics) used in combinations to 
identify relevant studies related to i) cancer: cancer, neoplas*, oncolog*; ii) psychosocial 
intervention: psych*,  psychosoc*, interven*, psychotherapy, psycholog*,  cognitive therapy, 
behav* therapy, self-help-groups, support group*, relax*, hypno*, meditat*, imagery, stress, 
psychological, counsel*, group therap*,  family therapy, depressive disorder therapy, 
treatment(s), therapy/therapies; and (iii) PNI measures: leukocyte, lymphocyte, natural killer 
cell, interferon, interleukin, tumor necrosis factor, cortisol, neuroendocrine, hormonal, 
psychoneuroimmunology, immune function, where * represents wildcard characters. 
Additionally, the reference sections of all relevant papers were examined to identify any 
additional relevant studies. This electronic search strategy yielded 403 research records, from 
which 112 duplicate records were eliminated. The remaining 291 records were screened based on 
our selection criteria to find eligible studies.  
b) Selection Criteria  
A set of five independent selection criteria related to 1) time-frame and language, 2) 
study design, 3) cancer population, 4) types of therapies, and 5) PNI-based measures, were used 
to identify, screen and select eligible studies corresponding with the aims of this review.    
1) Time-frame and language. Only studies published in peer-reviewed journals after 
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January, 2001 until November, 2013 were included in our literature review. For a comprehensive 
review of psychosocial therapies for cancer patients that used PNI-based measures published 
before 2001, refer to Andersen, 200290. The searches were conducted in English and all the 
studies included in this review were either published in English or translated into English 
language by the publishers of the journal.   
2) Study design. True experimental designs, i.e. randomized controlled trials (RCTs), as 
well as studies with rigorous quasi-experimental designs91, such as non-randomized controlled 
trials (NRCTs) and pretest-posttest measurement designs were included. RCTs had to include the 
number of cancer patients included in the intervention group and in the control group. Non-
experimental designs, such as correlational research studies, were excluded.  
Selection criteria relevant to the specific research questions of this review were:  
3) Cancer population. Interventions conducted with participants diagnosed with cancer 
at any stage beyond initial diagnosis were included. Since this review aimed to evaluate the 
impact of psychosocial therapies on the health of patients actually diagnosed with cancer; 
interventions conducted exclusively with family members or caregivers of cancer patients were 
excluded.  
4) Types of interventions. To guide the inclusion of psychosocial therapies, the IOM’s 
definition of psychosocial health interventions, which involved therapies that help patients “to 
optimize biomedical health care and to manage the psychological/behavioral and social aspects 
of illness and its consequences so as to promote better health”3(p69) was adopted. This IOM 
definition inherently encompasses therapies employing cognitive and behavioral therapeutic 
activities, such as coping skills training. However, therapies that emphasized integrative concepts 
of healing body, mind and spirit, which were classified under complementary medical therapies 
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by the National Cancer Institute92,93 were also included. Interventions that exclusively involved 
behavioral regimens, such as physical exercise, were excluded because the IOM definition 
required psychosocial therapies to address psychological and or social problems related to 
illness. Interventions delivered by any health professional, and in any setting, using any method 
of delivery or duration were included.  
5) PNI-based measures. Only those psychosocial intervention studies that reported results of 
at least one neuroendocrine or immune outcome measure, as well as described the PNI 
framework in the paper’s background section were included. Studies that merely referred to the 
PNI framework but only measured psychological constructs (e.g., depression) or global 
outcomes (e.g., survival) were excluded.  
c) Screening and Identification Procedures 
The 291 research records obtained from the search strategy underwent two stages of 
screening. Details of the screening and identification process are outlined in Figure 3. In the first 
stage of screening, the title and abstracts of the research records were evaluated according to the 
five criteria. In this stage 246/291 records were eliminated leaving us with 45 records. These 45 
records entered the second stage of screening, where full text papers were further evaluated for 
final eligibility. The second screening stage eliminated an additional 23/45 studies leaving 22 
studies (Figure 3 below). However, review of the reference lists of full-text research papers 
obtained during second screening, revealed 4 additional studies found eligible for review. 
Therefore, finally 26 papers were identified and included for review procedures. Of note in this 
sample of 26 papers, there were two pairs of manuscripts (2 RCTs94,95 and 2 pretest-posttest 
studies47,52) that had reported results during different phases of the same larger intervention. 
These 2 pairs of papers were collapsed and considered to be single studies; which led to 24 
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original studies (reported in 26 manuscripts) obtained at the end of the search and selection 
process. For the review procedures, information was extracted from all 26 manuscripts.   
 
 
d) Data Extraction Procedures   
The reviewers prepared a detailed data extraction manual. This manual was applied to the 
sample of 26 papers. Data were extracted and entered into an Excel spreadsheet. Studies were 
categorized based on the strength of their study design as suggested by the evidence-based 
approach for therapeutic interventions previously suggested by some health scientists96,97. This 
Figure 3: Flowchart of literature review 
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categorization involved placing RCTs first, followed by NRCTs and finally pretest-posttest 
studies (Table 1). One RCT that reported results from only their intervention group participants 
was included in the pretest-posttest study group for review procedures98. Data from the 
manuscripts of the 2 RCTs94,95 and 2 pretest-posttest studies 47,52 which reported findings from 
the same intervention, were pooled and reported collectively in their respective study groups.  
 The following data were obtained from the research papers: a) first author, year of 
publication; b) stage and type of cancer; c) number of participants in the intervention group; d) 
the type of control condition and number of participants in control group; e) the type and 
duration of intervention and length of each session, f) psychosocial measure(s) used, g) 
neuroendocrine  measure(s) used and h) immunological  measure(s) used. Other noteworthy 
points (e.g. adequacy of sample size, analysis of mediators) were included as i) additional 
remarks. Since this review aimed to appraise studies with regards to the specific research 
questions (stated above), methodological quality scores were not assigned to the studies.  
Review Results 
This literature review included results from 19 RCTs, 1 NRCT and 4 pretest-posttest 
studies of PNI-based psychosocial interventions conducted in the cancer population. Table 1 
gives an outline of the type and duration of the interventions and their effects on the respective 
psychosocial, neuroendocrine and immunological measures used.  Specific findings related to the 
research questions posed by this review are presented below. 
Q1) Cancer population. Most studies consisted exclusively of women diagnosed with 
breast cancer (18/24, 75%). The studies of women with breast cancer consisted of 9 studies that 
had patients with early stage breast cancer (stage I or II),99-107 and 7 studies that included patients 
with stage III breast cancer94,98,108-112. Only 1 study included patients with metastatic breast 
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cancer (stage IV)113 and 2 studies included breast cancer survivors114,115. The next most common 
type of cancer population was patients with prostate cancer (4/24, 16.7%). In terms of prostate 
cancer staging, 3 studies included patients with early-stage localized prostate cancer 
patients99,100,116, while 1 study had prostate cancer survivors116,117. In the aforementioned studies, 
2 studies used a mixed population of patients with early-stage breast and prostate cancer99,100. 
Only 8.3% (2/24) of PNI-based psychosocial therapies included persons with cancers other than 
breast and or prostate cancer. These studies consisted of one study of cervical cancer 
survivors118; and another study involving mixed cancer populations including persons with lung 
and colorectal cancers, as well as person with prostate and breast cancers in the entire range of 
cancer stages, including cancer survivors119.  
Q2) Types of psychosocial interventions. The two major types of interventions 
identified were i) cognitive-behavioral therapies (15/24, 62.5%) and ii) complementary medical 
therapies (9/24, 37.5%). Each study was assessed for the types of therapeutic activities employed 
in the psychosocial intervention.  
Q2. A) What activities did the interventions employ? All studies used more than one 
therapeutic activity during the delivery of their intervention. Table 2 presents a complete list of 
activities employed in each study. The two most common activities, used by more than half of all 
psychosocial therapies reviewed, were relaxation training and education (Table 2). Descriptions 
of the kinds of activities used by psychosocial interventions for cancer patients elucidated by the 
IOM3 and National Institutes of Health (NIH)92,120 were reviewed to guide categorization of 
interventions. Studies were either classified as a cognitive-behavioral therapy or a 
complementary medical therapy based on the activities involved in the intervention.  
i) Cognitive-behavioral therapies consisted of interventions that emphasized cognitive 
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and behavioral activities and approaches such as cognitive restructuring, psycho-education and 
coping skills training (Table 2). Some studies delivered highly structured cognitive-behavioral 
programs, such as CBSM, that were specifically designed to meet the psychosocial needs of 
breast cancer patients104,108,113. Few studies used supportive care activities such as individual 
supportive care, home care and group social-support (Table 2). Several studies also included 
progressive muscle relaxations, meditation, abdominal breathing, and guided imagery (Table 2). 
There were 3 cognitive-behavioral studies that particularly emphasized visualizations. Of these, 
2 studies asked patients to mentally visualize personal and metaphorical images of their immune 
systems effectively removing cancer cells from their bodies103,107, while the third study employed 
hypnosis to guide visualizations107. Another intervention included cognitive-behavioral activities 
specifically tailored for insomnia and sleep management, e.g., stimulus control121. One study 
utilized an expressive writing  intervention that asked patients to write about their experience 
with prostate cancer and its treatment and other traumatic and upsetting experiences in their 
lives117. Finally, a cognitive-behavioral study also included counseling for relationship and 
sexual problems faced by their participants118. 
ii) Complementary medical therapies involved activities such as yoga, meditation, 
qigong, mindfulness-based stress reduction (MBSR) and massage (Table 2). In this group of 
therapies, 5 studies emphasized stress-management through meditation. One yoga  study 
combined activities including breathing exercises, meditations, a set of yoga postures (asanas), 
along with relaxation and mental imagery109. Another study delivered an integrated yoga 
program at the bedside before and after a surgical operation and provided patients with 
audiotapes of instruction for yoga exercises to be practiced at home111. The other 3 studies 
delivered a structured MBSR program99-101,122 previously developed by another researcher123. 
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MBSR consisted of teaching participants to achieve mindfulness, defined as a “non-elaborative, 
non-judgmental present-centered awareness”124(p232) and help participants enhance the acceptance 
of their life experiences123. Participants learned MBSR through the use of breath awareness, 
sitting and walking meditations and yoga techniques and were also provided with educational 
materials and workbooks to help them with cognitive reappraisals and in practicing mindfulness 
in daily life.  
There were 3 complementary therapies that encouraged stress-reduction through either 
active behavioral practices, such as body movements, or passive behavioral techniques such as 
massage. One yoga intervention consisted exclusively of performing poses from the “Iyengar 
yoga” tradition, that were executed slowly with the help of props to maintain proper orientation 
and posture114. One study of medical qigong consisted of body movements during specific 
standing postures along with meditation training, visualization and a range of breathing exercises 
including chest and abdominal breathing119. One massage intervention employed a protocol that 
consisted of a combination of massage and acupressure techniques that promoted relaxation106. 
Finally, one study emphasized a body-mind-spirit connection and combined yoga and massage 
techniques with psychosocial approaches such as forgiveness therapy115. 
Q2. B) What were the method(s) of delivery? Studies delivered their respective 
psychosocial therapies to participants either within a group-setting (15/24, 62.5%) or on an 
individual basis (9/24. 37.5%).  On average 7 participants were included in the group-based 
therapies, but group-size ranged between 3 and 15 participants. Most studies involved in-person 
interactive (21/24, 87.5%) sessions with participants. There were 3 studies that did not involve 
any personal interactions with participants (3/24, 12.5%).  Of these, 2 studies delivered their 
intervention exclusively through phone-conversations105,118 and one study delivered an 
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expressive writing therapy through oral and written instructions given to the patients and 
followed-up with patients through a phone call46. The interventions delivered entirely through 
phone conversations consisted of one study that used a telephone conference call to deliver 
group-therapy105, and another study that conducted individual telephone-counseling sessions 
with participants118. It was noteworthy that two studies provided therapy sessions on the morning 
of scheduled surgery to mentally prepare patients for surgical procedures111,116, and one 
supportive therapy intervention was provided to participants on a residential basis102.  
Who delivered the therapies? Half the psychosocial therapies were delivered by clinical 
psychologists, while 3 therapies were delivered by nurses, and 2 therapies involved physicians 
(Table 1). Supportive care services were delivered by a variety of health professionals including 
group therapists, social workers, art therapists and visualization specialists102,105. The 
complementary medical therapies, also employed a variety of allied health professionals, such as 
clinical massage therapists and instructors trained in yoga and qigong techniques102,106,109,114.  
Q2. C) What were the durations of the interventions? The average duration of 
interventions using PNI-based psychosocial therapies (taken over all 24 studies) was roughly a 
total of 10 hours (600 minutes). The 10 hours of psychosocial intervention were delivered over 
an average period of 8 weeks consisting of approximately 8 therapy sessions, with each session 
lasting for about 70-75 minutes. However, the duration of interventions, including the time 
required for each session varied considerably among the studies. The briefest intervention was 
expressive writing, which lasted for a total of 1.3 hours (80 minutes) over a single week, with 4 
sessions taking 20 minutes per session over 4 consecutive days117. In contrast, the lengthiest 
intervention was 20 times greater in duration, and consisted of a cognitive-behavioral therapy 
intervention of 27 hours (1620 minutes) over 18 consecutive weeks, with 18 therapy sessions 
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that lasted about 90 minutes per session108.  
Q3) PsychoNeuroImmunologic (PNI) outcome measures. Only a third of studies 
(8/24) in this review collected outcome measures for all three PNI subsystems. All studies, 
except one (23/24) used at least one psychosocial measure. With regards to PNI biomarkers, less 
than half (11/24) the studies, employed biomarkers of the neuroendocrine system, as opposed to 
the majority (22/24) of studies that used some type of immune biomarker.  
Psychosocial measures (P). All studies used self-report scales to measure participants’ 
psychosocial profiles, except 1 study that did not report measures of any psychosocial 
construct98. The most commonly employed measure of psychosocial outcomes was the profile of 
mood states, POMS (11/24, 45.8%) scale. Most studies measured negative psychological states 
such as depression, negative mood, distress and anxiety102,104,105,108,109,114. Even though most 
interventions aimed to reduce stress in patients, only three studies actually used psychometric 
measures of stress103,109,112. Studies also assessed psychosocial well-being and function by 
measuring of quality of life and functional assessments related to cancer treatments and living 
with cancer100,105,119. Some studies were interested in the psychological coping response of 
participants and measured constructs such as benefit finding104 (i.e., perceived benefits arising 
from the experience of being diagnosed and treated for breast cancer), and coping with 
illness101,117. Finally, 3 studies used measures that were closely related to the constructs 
emphasized in the therapies; for example, the cognitive-behavioral intervention aimed at 
improving sleep behavior measured the severity of insomnia121, one CBSM intervention 
measured the specific psychosocial skills that were targeted by the CBSM program95 and one 
MBSR study measured mindfulness attention and awareness101.   
Neuroendocrine measures (N). The glucocorticoid stress hormone, cortisol, was the 
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most common neuroendocrine measure, used in all 11/24 research studies that had 
neuroendocrine parameters (45.8%). Studies measured cortisol levels in the participants’ blood 
using radioimmunoassay techniques95,101 or in saliva using enzyme linked immunosorbent assay 
(ELISA) techniques99,109,114,122. Other neuroendocrine parameters measured included a) 
catecholamine stress hormones, including epinephrine, norepinephrine in urine106; b) 
neurotransmitters, including urinary dopamine and serotonin106 and salivary melatonin122; and c) 
serum levels of the corticosteroid hormone, dehydroepiandrosterone-sulphate (DHEA-S) 122.  
Immunological measures (I). The 22/24 studies that reported immunological measures 
(91.7%) obtained blood samples for immune analysis. The most commonly measured immune 
outcome was the cytotoxic function of natural killer cells (9/24, 37.5%). Most studies typically 
evaluated both types of immune measures89, including enumeration of immune cells, e.g. T 
lymphocyte counts, and functional measures of the immune system89, e.g. cytokine levels (15/24, 
62.55%). However, 6 studies exclusively used functional immune measures (6/24, 25%) and 1 
study measured only certain immune cell counts (4.2%),%), namely CD4+ and CD8+ T 
lymphocytes and NK cells105. Only a couple of studies did not use any type of immune outcome 
measure (2/24, 8.3%). We noted that only one study measured the inflammatory biomarker, C-
reactive protein (CRP)119 and another study measured serum immunoglobulin (Ig) levels (IgG, 
IgM and IgA) 111.  
Efficacy of Psychosocial Therapies for Patients with Cancer   
Due to the wide diversity of interventions and PNI measures reported, statistical 
comparisons required for a meta-analysis were not possible. Hence, limited comment could be 
made about the statistical evidence for the efficacy of psychosocial interventions on PNI-based 
outcome measures in the cancer population. However, we do deliberate over studies that reported 
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significant changes in PNI outcome measures. Firstly, with respect to psychosocial measures, 20 
studies that included 13 RCTs, one NRCT and 3 pretest-posttest studies reported significant 
effects on at least one psychosocial measure (Table 1). Secondly, in terms of neuroendocrine 
outcomes, 6 studies reported significant results for changes in at least one neuroendocrine 
measure, including 4 RCTs, one NRCT and one pretest-posttest study (Table 1). Finally, 
regarding immune measures, 16 studies reported effects on at least one immune measure, which 
included 11 RCTs, one NRCT and 4 pretest-posttest studies (Table 1).  
Effectiveness with respect to types of interventions indicated that more than half the 
studies using cognitive-behavioral therapies (10/15, including 8 RCTs) reported significant 
findings for at least one neuroendocrine or immune outcome measure. One cognitive-behavioral 
intervention reported a significant effect on an immune outcome up to twelve months after 
initiating the intervention110. Some cognitive-behavioral therapies statistically modeled the 
variables in the PNI framework and demonstrated that psychosocial constructs had an influence 
on immune outcomes. For example, one study reported that benefit finding was correlated with 
an increase in the T lymphocyte proliferative response to anti-CD3,104 and another study showed 
that anxiety and depression mediated the increase in blood levels of the cytokine, interferon-γ121. 
Thus, several studies of cognitive-behavioral therapies reported significant effects on 
neuroendocrine-immune function through PNI interactions in patients with cancer.   
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Table1. Summary of psychosocial interventions for cancer patients using psychoneuroimmunology (PNI) - based outcome measures 
No First author, 
year citation 
Stage & type 
of cancer 
Intervention (n)  
Control condition (n) 
Type of therapy b and 
duration of intervention 
Psychosocial 
measure(s) ab 
Neuroendocrine  
measure(s) ab 
Immunological  
measure(s) ab 
RANDOMIZED CONTROLLED TRIALS (RCTs) 
        
1 Rosenbergc, 
2002117 
Prostate 
cancer 
survivors  
Intervention (n=15) 
Assessment only 
control (n=15) 
Individual expressive writing 
intervention. 20 minutes of 
continuous writing over four 
consecutive days.   
(↓) BPI 
(X) MOS-SF-36 
(X) SCL-90-R 
(X) POMS 
(X) Ruminationd 
(X) WOC-CA 
(X) FACT-P  
 (X) TNFα 
(X) IL-4 
(X) IL-10 
(X) CD4+ T cells  
(X) CD8+ T cells 
 
2 Heiney, 
2003105 
Stage I or II 
breast cancer.  
Intervention (n=33) 
Standard of care  
control (n=33) 
Therapeutic group intervention 
through a telephone conference 
call. 6 weekly sessions lasting 
90 minutes each. 
(↑) POMS total  
POMS subscale  
  (↑) tension 
  (↑) anger 
(X) QOL-BCV  
 (X) CD4+ T cells 
(X) CD8+ T cells 
(X) NK cells 
3 Andersen, 
2004108 
Stage II or III 
breast cancer.  
Intervention (n=114) 
Assessment only  
control (n=113) 
CBT sessions with trained 
psychologists in small patient 
groups.18 weekly sessions 
lasting 90 minutes each. 
(↑) PSS-Family 
(↓) POMS total  
POMS subscale 
  (↓) anxiety  
(X) IES  
 No (↓) LPR to PHA  
(↑) LPR to Con A  
(X) T lymphocytes 
(X) NK Cell count  
(X) NK Cell lysis 
4 McGregor, 
2004104 
Stage I or II 
breast cancer.  
Intervention (n = 18)  
1 day seminar  
control (n = 11) 
Group-based CBSM program. 
10 weekly meetings lasting 120 
minutes each.  
(↑) BFS   
(X) Distresse 
 
 (↑) LPR to anti CD3 
(X) Lymphocytes  
5 Hernandez-
Reif,  
2004106 
Stage I or II 
breast cancer. 
Intervention (n = 18) 
Wait list  
control (n = 16) 
Individual massage sessions. 
3 massages a week for 5 weeks 
with every massage session 
(↓) POMS  
STAI subscale 
  (↓) Anxiety  
(↑) Dopamine 
(↑) Serotonin 
No (↑) in Nor-
(↑) NK Cells 
(X) NKCC 
(X) Lymphocytes  
                                                          
a  (↑) Significantly higher in: intervention group compared to control group in RCTs; & post-intervention compared to pre-intervention in  pretest-posttest studies    
    (↓) Significantly lower: in intervention group compared to control group in RCTs; & post-intervention compared to pre-intervention in  pretest-posttest studies    
    (X) No differences between: intervention and control groups in RCTs; & post-intervention compared to pre-intervention in  pretest-posttest studies    
b Note: Full forms of all abbreviations used  in Table 1  are provided in Annexure for Table 1  
c Only a smaller subset of the sample completed immune measures 
d Rumination measured using 10 items from a study assessing moderating effects of goal beliefs that influence rumination, depression and physical complaints 
e A distress index was developed using descriptive adjectives from scales developed in a previous research published by Carver et al. 
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No First author, 
year citation 
Stage & type 
of cancer 
Intervention (n)  
Control condition (n) 
Type of therapy b and 
duration of intervention 
Psychosocial 
measure(s) ab 
Neuroendocrine  
measure(s) ab 
Immunological  
measure(s) ab 
lasting 30 minutes each. SCL-90-R subscale 
   (↓) Depression 
   (↓) Hostility  
 
epinephrine 
(X) Epinephrine 
(X) Cortisol 
6 Savard,  
2005121 
Chronic 
insomnia 
secondary to 
breast cancer  
Intervention (n = 27)  
Wait list  
control (n = 30) 
Group-based CBT for insomnia 
management. 8 weekly sessions 
with psychologists lasting 90 
minutes each.   
(X) POMS 
(X) ISIf 
(X) MFI  
(X) HADSg 
 (↑) IFNγ  
(↓) Lymphocytes  
(X) WBC 
(X) Monocytes 
(X) CD3+ T cells 
(X) CD4+ T cells  
(X) CD8+ T cells  
(X) NK Cells 
(X) IL-1β  
(X) NK cell activity  
7 Savard, 
2006113  
Metastatic 
breast cancer 
patients with 
depression 
Intervention (n=25) 
Wait list control 
(n=20) 
Individually-based CT 
intervention. 8 weekly sessions 
with psychologists lasting 60 to 
90 minutes each.  
(↓) HDRS 
(X) BDI 
(X) HADS 
(X) MFI 
(X) ISI 
(X) EORTC- 
       QLQ-C33 
 (X) CD3+ T cells  
(X) CD4+ T cells  
(X) CD8+ T cells  
(X) CD16+ T cells 
(X) Lymphocytes  
(X) WBC 
(X) Monocytes 
(X) IFNγ  
(X) IL-1β  
(X) NK cell activity 
8 Andersen, 
2007110 
Stage II or III 
breast cancer.  
Intervention (n=114) 
Assessment only  
control (n=113) 
8-month maintenance phase 
group CBT intervention which 
followed-up patients from the 
Andersen, 2004 study.108 
8 monthly CBT sessions with 
trained clinical psychologists 
lasting 90 minutes each.  
(↓) POMS 
(X) IES 
 
 No (↓) LPR to PHA  
(X) LPR to Con A  
 
                                                          
f (↓) ISI mediated : (↑) IFNγ, (↑) WBC and (↑) Lymphocytes  
g (↓) HADS mediated : (↑) IFNγ, (↑) WBC and (↑)  Lymphocytes 
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No First author, 
year citation 
Stage & type 
of cancer 
Intervention (n)  
Control condition (n) 
Type of therapy b and 
duration of intervention 
Psychosocial 
measure(s) ab 
Neuroendocrine  
measure(s) ab 
Immunological  
measure(s) ab 
9 Nunes,  
2007103 
Stage I or II 
breast cancer 
Intervention (n=20) 
Assessment only  
control (n=14) 
Relaxation and visualization in 
groups with psychologists. 30 
minute sessions delivered daily 
over 24 consecutive days 
(↓) ISSL 
(↓) STAI 
(↓) BAI 
(↓) BDI 
(X) Cortisol (X) LPR to PHA 
(X) LPR to DEX 
(X) LPR to CORT 
10 Nelson,  
2008118 
Cervical 
cancer 
survivors  
Intervention (n=17) 
Standard of care  
control (n=19) 
Psychosocial telephone 
counseling therapy. 6 sessions 
with psychologists lasting 45-
50 min each. 
(↑) FACT-Cx (X) Cortisol 
(X) DHEA 
(↓) IL-10 
(X) PBMC  
(X) IFN- γ 
(X) IL-5 
 
11 Lindemalm, 
2008102 
Early stage 
breast cancer 
patients 
undergoing 
radio/chemo-
therapy.  
 
Intervention (n= 21) 
Assessment only 
control (n=20) 
Support group consisting of 
oncologists, art therapists, 
masseuses and person trained in 
qigong and mental imagery was 
offered on a residential basis. 
Week long program with a 4 
day follow-up 2 months later. 
No information about duration 
of sessions.   
(X) HADS 
(X) NFQ 
  (X) NK cells 
(X) NKCC 
(X) Lymphocytes 
(X) IFN-γ 
(X) IL-2 
(X) IL-4 
12 Phillips, 
200895  
    & 
Antoni, 
200994 
Stage I, II and 
III breast 
cancer 
Intervention (n=63)    
1-day education  
seminar control  
(n=65) 
Group-based CBSM program. 
10 weekly meetings with 
psychologists lasting 2 hours 
each. 
MOCS subscale 
   (↑) Relaxationh  
IES subscale 
   (↓) Intrusion 
(↓) HAM-Anxiety 
(X) ABS  
(↓) Cortisol  (↑) IL-2 
(↑) IFN-γ 
(↑) IL2:IL4 ratio 
(X) IL-4 
(X) IFN-γ: IL4 ratio 
(X) CD4+ T Cells 
(X) CD8+ T Cells 
(X) CD56 + T Cells 
13 Rao,  
2008111 
Stage II and 
III breast 
cancer 
Intervention (n=45) 
Supportive therapy 
control (n=53) 
Integrated yoga program. 
4 individual sessions with yoga 
instructor at bedside lasting 60 
minutes. 
(↓) STAI 
(↓) BDI 
(↑) FLIC 
 (↑) CD56 + T Cells 
(↓) IgA  
(X) CD4+ T Cells 
(X) CD8+ T Cells 
(X) IgG 
(X) IgM 
 
 
                                                          
h (↑) Relaxation did not mediate (↓) Cortisol 
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No First author, 
year citation 
Stage & type 
of cancer 
Intervention (n)  
Control condition (n) 
Type of therapy b and 
duration of intervention 
Psychosocial 
measure(s) ab 
Neuroendocrine  
measure(s) ab 
Immunological  
measure(s) ab 
14 Raghaven-
dra, 2009109 
Stage II and 
III breast 
cancer  
Intervention (n = 44)  
Supportive therapy 
control (n = 44)  
Yoga education and training 
program. 6 weeks program with 
3 sessions per week (total 18 
sessions) lasting 1 hour each.  
 
(↓) HADS 
(↓) PSS 
(↓) Cortisol   
15 Oh,  
2010119 
Range of 
cancers (and 
stages) 
including 
breast, lung, 
prostate 
cancers  
Intervention (n=79) 
Assessment only 
control (n=83) 
Medical Qigong (MQ) group 
therapy. 10 week MQ program 
with Qigong instructor 
consisting of two sessions per 
week lasting 90 minutes each.  
(↑) FACT-G 
(↑) FACT-F 
(↓) POMS 
 
 (↓) CRP 
        
16 Cohen, 
2011116 
Prostate 
cancer 
Intervention (n=38) 
Standard of care  
control (n=44)  
Individual sessions consisting 
of CBT with a clinical 
psychologist and stress 
management information.  
Two sessions lasting 60 to 90 
minutes each. 
(X) POMS  (↑) NKCC 
(↑) IL-1β 
(X) IL-12p70 
(X) TNF-α 
(X) IFN-γ 
(X) IL-6 
(X) IL-8 
(X) IL-10  
17 Banasik, 
2011114 
Breast cancer 
survivors 
Intervention (n=9)i  
Wait list  
control (n = 9) 
Iyengar yoga practice 
consisting of different poses. 
Group yoga practice sessions 
twice a week for 8 weeks 
lasting 90 minutes each.  
FACT-B subscale 
   (↓) Fatigue 
(X) FACT-B Total 
 
(X) Cortisol   
18 Hsiao,  
2012115 
Breast cancer 
survivors 
Intervention (n=26) 
1-session education- 
seminar 
control  (n=22) 
Body-mind-spirit (BMS) group 
therapy. Weekly sessions over 
8 weeks lasting 2 hours each.  
MLQ subscale 
   (↑) Search 
(X) BDI-ii 
 
(↓) Cortisol  
                                                          
i Considerably underpowered study 
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No First author, 
year citation 
Stage & type 
of cancer 
Intervention (n)  
Control condition (n) 
Type of therapy b and 
duration of intervention 
Psychosocial 
measure(s) ab 
Neuroendocrine  
measure(s) ab 
Immunological  
measure(s) ab 
19 Baker,  
2012112 
Stage I, II & 
III breast 
cancer 
Intervention (n=6)i 
Standard of care  
control (n=6) 
Integrated support program 
consisting of 2 day support 
workshop with a maximum 12 
hours consultation with 
therapist. Exact duration of 
intervention not described.    
(↑) SOSI  
MFI subscale 
   (↓) mental fatigue 
(X) FACT-G total 
FACT-G subscale 
   (↓) endocrine- 
        specific  
        symptoms 
(X) POMS 
(X) Cortisol No (↓) NKCA 
No (↓) PBMC-
Arginase 
(X) CD4+ T Cells 
(X) CD8+ T Cells 
(X) NK Cells 
NON-RANDOMIZED CONTROLLED TRIAL (NRCT)j 
 
20 Witek-
Janusek, 
2008101 
Early stage 
breast cancer.  
Intervention (n=38) 
Assessment only  
control (n=28)  
Group-based MBSR training. 
8-weekly (2.5 hours/week) 
sessions plus one full day 
session held after the 5th week 
(↑) QOL- CVIII 
JCS subscales 
  (↑) Supportant & 
  (↑) Optimistic   
      effectiveness 
(X) MAAS 
(↓) Cortisol (↑) NKCA 
(↑) IFNγ  
(↓) IL-4  
(↓) IL-6 
(↓) IL-10 
PRETEST-POSTEST STUDY DESIGNS 
        
21 Bakke, 
2002107 
Stage I and II 
breast cancer  
Total N= 25 
No control  
Individual hypnotic-guided 
imagery delivered by medical 
doctor. 8 weekly sessions 
lasting 60 minutes each  
POMS subscale 
   (↓) Depression 
(X) WCC 
 
 (↑) NK Cells  
(X) NKCC 
 
22 Carlson, 
200332 
   & 
Carlson, 
2004122  
Early stage 
breast and 
prostate 
cancer 
Total N=42  
No control 
Group-based MBSR delivered 
by psychologists. 8 weekly 
sessions lasting 90 minutes 
each and a 3 hour silent retreat 
between weeks 6 and 7. 
(↓) SOSI 
EORTC-QLQ-C30   
    subscales 
   (↑) Global QOL 
   (↑) Appetite  
(X) POMS 
(X) Cortisol 
(X) Melatonin 
(X) DHEAS 
(X) Cortisol/ 
DHEAS Ratio 
 
(↑) IFNγ 
(↑) IL-4T 
(↑) Eosinophils 
(↓) Monocytes  
(X) NK Cells 
                                                          
j Participants self-selected either treatment or control group 
 
b Note: Full forms of all abbreviations used in Table 1 are provided below in the Annexure for Table 1.  
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No First author, 
year citation 
Stage & type 
of cancer 
Intervention (n)  
Control condition (n) 
Type of therapy b and 
duration of intervention 
Psychosocial 
measure(s) ab 
Neuroendocrine  
measure(s) ab 
Immunological  
measure(s) ab 
23 Carlson, 
200799 
 
Early stage 
breast and 
prostate 
cancer 
Total N=51  
No control 
Group-based MBSR delivered 
by psychologists. 8 weekly 
sessions lasting 90 minutes 
each and a 3 hour silent retreat 
between weeks 6 and 7. 
(↓) SOSI 
(X) POMS   
(X) EORTC-QLQ- 
       C30 
(↓) Cortisol  (↑) Eosinophils 
(↓) Monocytes 
(↓) IFNγ T cell 
production  
24 Kang,  
201198 
Stage I, II and 
III breast 
cancer 
Intervention (N=49) 
Data from control 
group not presented 
Group-based CBSM 
intervention. 8 weekly sessions 
lasting 90 minutes each 
  (↑) NKCC 
(↑) LPR to PHA 
(↑) IL-4 
(↑) IL-10 
(X) IL-2 
(X) IL-6 
(X) IFN-γ 
Annexure for Table 1: Abbreviations = Full Form 
Interventions CBSM = Cognitive Behavioral Stress Management, CBT = Cognitive Behavioral Therapy, CT = Cognitive Therapy, RVT = Relaxation 
and Visualization Therapy, BMS = Body-Mind-Spirit, MBSR = Mindfulness Based Stress Reduction. 
 
Psychosocial 
Measures 
BFS = Benefit Finding Scale, POMS = Profile of Mood States, DES-IV = Differential Emotions Scale-IV,  CES-D = Center for 
Epidemiological Studies Depression Scale, IES = Impact of Events Scale, LOT = Life Orientation Test, MOS-SF36 = Medical Outcomes 
Study—Short Form—36, SCL-90-R = Symptom Checklist—90 Revised, BPI = Brief Pain Inventory,  WOC-CA = Ways of Coping 
Inventory – Cancer Version, FACT-P = Functional Assessment of Cancer Therapy – Prostate, QOL = Quality of Life,  BCV = Breast 
Cancer Version, ISSL = Inventory of Stress Symptoms  Lipp (for adults), PSS-Family = Perceived Social Support from Family, BAI = 
Beck Anxiety Inventory, STAI = State-Trait Anxiety Inventory, ISI = Insomnia Severity Index, MFI = Multidimensional Fatigue Inventory, 
HADS = Hospital Anxiety and Depression Scale, HDRS = Hamilton Depression Rating Scale, HAM-anxiety = Hamilton Rating Scale for 
Anxiety, ABS = Affects Balance Scale, BDI = Beck Depression Inventory, FLIC = Functional Living Index of Cancer, MLQ = Meaning in 
Life Questionnaire, EORTC-QLQ = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, NFQ = 
Norwegian Fatigue Questionnaire, MOCS = Measure of Current Status, PSS = Perceived Stress Scale, FACT-B = Functional Assessment of 
Cancer Therapy – Breast, QOL-CVIII = Quality of Life Index –Cancer Version III, MAAS = Mindfulness Attention Awareness Scale, JCS 
= Jaloweic Coping Scale, WCC = Ways of Coping Checklist, SOSI = Symptoms of Stress Inventory.  
 
Neuroendocrine 
Measures 
DHEAS = Dehydroepiandrosterone-sulphate  
 
Immunological 
Measures 
NK = Natural Killer, IFN = Interferon, TNF = Tumor Necrosis Factor, IL = Interleukin, CD = Cluster of Differentiation, LPR = 
Lymphocyte Proliferative Response, NKCC = Natural Killer Cell Cytotoxicity, WBC = White Blood Cells, PHA = Phytohaemagglutinin, 
ConA = Concavalin A, DEX = Dexamethasone, CORT = Corticosterone. 
 
35 
 
Table 2: Activities involved in PNI-based psychosocial interventionsk 
Name of activity  Study No.l (Type of therapies) using specified activities % of studiesm 
Study No. l (Cognitive-behavioral) Study No. l (Complementary medical ) 
    
Relaxation training  3, 4, 8, 9, 11, 12, 16, 19, 21, 24, 13, 14, 15, 17, 18, 20, 22, 23 75% (18/24) 
      - Breathing exercises/techniques (e.g. deep breathing)   - 4, 8, 9, 12, 16, 19, 21, 24,    - 13, 14, 15, 17, 18, 20, 22, 23   - 67% (16/24) 
      - Imagery/guided imagery and visualizations   - 4, 8,  9, 12, 16, 21, 24,     - 14, 18, 20, 22, 23   - 50% (12/24) 
      - Progressive muscle relaxation   - 3, 4, 8, 9, 12, 16, 21, 24    - 33% (8/24) 
Psycho-Education  2, 3, 4, 6, 8, 9, 11, 12, 16, 19, 21, 24  15, 18, 20, 22, 23 71% (17/24)   
Coping skills training (e.g. problem solving, setting goals)  2, 3, 4, 7, 8,  10, 12, 16, 24,  13, 14, 18, 50% (12/24) 
Cognitive restructuring  4, 6, 7,  8, 12, 16, 24 20, 22, 23 42% (10/24) 
Yoga training (e.g. asanas) 19 13, 14, 15, 17, 20, 22, 23 33% (8/24) 
Group social-support   2, 3, 4,  8, 12, 24,  20, 22, 23 38% (9/24) 
Personal stress awareness   2, 3, 7, 12, 16  20, 22, 23, 33% (8/24) 
Expressing emotions and feelings 1, 2, 4, 8,  12, 24 18, 29% (7/24) 
Meditation  4,  8, 9, 12,  13, 14, 15, 29% (7/24)  
Physical Exercise  3, 11, 19, 24 17, 21% (5/24) 
Emphasizing the mind-body connection  17, 18, 20, 22, 23, 21% (5/24)  
Qigong training  11, 19 15, 18, 8% (4/24) 
Mindfulness meditation training  18, 20, 22, 23, 8% (4/24) 
Conflict resolution and  anger management 12, 4, 8,  12  8% (4/24) 
Assertiveness training  3, 4, 8,  12  8% (4/24) 
Individual supportive care 16, 19  8% (2/24) 
Massage   5, 18 8% (2/24) 
Diet/nutritional advice  3, 19  8% (2/24) 
Art therapy  11, 19  8% (2/24)  
Counseling for relationship and sexual problems  10  4%(1/24) 
Forgiveness therapy   18  4% (1/24) 
Stimulus control  6  4% (1/24) 
Expressive writing  1  4% (1/24) 
Insomnia management (Sleep restriction) 6  4% (1/24) 
Hypnosis/hypnotherapy  21  4% (1/24) 
Communication skills training  3  4% (1/24) 
Specialized homecare and leisure activities 11  4% (1/24)  
                                                          
k Activities listed in Table 2 are based on the types of psychosocial treatments identified in a previous meta-review of psychological interventions in cancer patients41 
l Study no.’s are referenced in the first column of Table 1  
m Numbers for percentages reported are rounded off to next integer 
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With regards to complementary medical therapies, two-thirds of the studies (6/9) showed 
significant effects on at least one neuroendocrine or immune outcome measure. Though therapies 
involving yoga, qigong, and massage were evaluated using RCT designs, only two RCTs that 
included the aforementioned therapeutic activities reported significant effects on functional 
immune measures111,119. MBSR was not evaluated using a RCT study design; however, all three 
studies that used MBSR, involving one NRCT101 and 2 pretest-posttest studies, had significant 
impacts on PNI biomarkers99,100. This suggests that complementary medical therapies are 
emerging psychosocial therapies which require more investigation regarding their impact on 
PNI-based outcomes in patients with cancer. We found a few brief and inexpensive psychosocial 
interventions appealing for further investigation in this study.    
A Brief and Inexpensive Psychosocial Intervention for Cancer Patients  
A significant finding in our review regarding the implementation of psychosocial 
interventions was that most interventions were delivered over 60-90 minute sessions conducted 
by health professionals over a span of several weeks (commonly 6-8 weeks), thereby, making 
most psychosocial interventions expensive and resource intensive. One intervention that emerged 
in this review was the expressive writing (EW) intervention, which is a brief (total of 80 minutes 
over 4 days) and inexpensive (does not need trained health professionals) psychosocial 
intervention which can be technologically adapted (computer-based format using the internet) for 
greater access and appeal. EW interventions in cancer patients have demonstrated improvements 
in self-reported physical symptoms of cancer patients and other self-reported psychological 
outcomes such quality of life125. Only one study was identified that employed EW in CS and 
used PNI measures117, which was found to be problematic, since only a smaller subset (N=20) of 
the sample completed actual PNI measures. Researchers have proposed that a proactive approach 
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to the psychosocial care of CS can help prevent or mitigate stress during re-entry as well as lead 
to positively adaptive survivorship14. Therefore, empirically testing the effect of EW on CS 
psychological state and neuro-hormonal indices will provide significant advancement in the 
science of psychosocial health services for the cancer population, specifically for CS. Previous 
research conducted in other populations has demonstrated that EW has an effect on PNI-based 
outcome measures. 
The Influence of EW on PNI Interactions  
Disclosing emotional and stressful experiences through writing has been studied as an 
intervention to improve health outcomes in healthy as well as clinical populations. Three meta-
analyses published in 1998, 2004 and 2006 have concluded that expressive writing has a 
significant positive impact on a variety of health outcomes126-128. EW has shown to impact a 
variety of neuroendocrine and immunologic variables. Scientific studies of EW that have used 
neuroendocrine measures (i.e. cortisol) have shown that expressive writing decreases cortisol 
secretion129. In the landmark study conducted by Pennebaker, Kiecolt-Glaser and Glaser 
(1988)130, EW improved the response of two mitogens—phytohemagglutinin (PHA) and 
concanavalin A (ConA)–which are proteins that increase the proliferation of T lymphocytes that 
are important components of the immune system. Anti-body production was increased by EW 
for individuals injected with Hepatitis B vaccine131 as well as those having chronic Epstein Barr 
Virus (EBV)132 infection. In HIV infected population, an EW intervention demonstrated a 
significant increase in levels of CD4+ T Cells133. EW has demonstrated an improvement in 
immune function for healthy individuals as well as certain clinical populations such as post-
traumatic stress disorder 129, fibromyalgia 134 and HIV+ patients133. However, researchers are still 
working on a robust theory that can explain the psychological and physiological effects of EW.   
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How does EW regulate psychosocial stress and impact PNI outcomes? Initially, EW 
was considered to work through the expression of inhibited thoughts and feelings (disinhibition 
theory) which are disclosed during the process of writing135. Subsequently, further studies of EW 
revealed the importance of cognitive processing, wherein EW was thought to help individuals 
make sense of or gain insight into stressful  events that affected them, as well as organize and 
integrate their stressful experiences135. However, there is no consensus among researchers on a 
singular theory that adequately explains or predicts the diverse psychobiological effects of EW. 
In fact, the pioneer of EW, Dr. James Pennebaker, suggests that a single theory of EW is 
unlikely, since EW “affects people on multiple levels—cognitive, emotional, social, and 
biological.”136 (p.138) Therefore, decisions on choosing a theory for EW intervention should be 
based on the outcomes (that are economically valuable to the population), and the issues faced by 
the population of interest135,136. The emotion-regulation of theory of EW137 provides a sound 
framework for evaluating the effect of EW on psychosocial as well as PNI outcomes in CS.  
Expressive writing helps regulate stress through emotion-regulation. Emotion-
regulation theory suggests that emotional responses in individuals have three components. The 
first is the experiential, which involves positive (e.g. pleasure) or negative (e.g. pain) valence 
states, and includes the subjective cognitions and feelings of the individual. The second is the 
physiological component, which is involved with the regulation of stress hormone secretions 
(e.g. adrenaline and cortisol) through the HPA axis or the SNS. The third is the behavioral 
component, which include verbal and bodily responses137. Therefore, unresolved emotional 
responses (e.g. fear of cancer recurrence in CS) act as chronic stressors which deregulate stress 
hormone secretions and lead poor health behaviors (e.g. smoking). Psychosocial interventions 
such as EW help regulate these emotional responses and improve health outcomes.  
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Some evidence exists to support the emotion-regulation effects of EW on experiential 
(cognitive and affective) and physiological (PNI) outcomes, however, in general EW has had 
very low effects on behavioral outcomes128. The EW intervention allows individuals to see their 
stressful experiences at a distance and helps them give those experience structure and 
meaning137,138. This helps in generating positive coping responses to the stressors and cognitive 
reappraisal of negative emotional experiences139 and a reduction in perceived psychological 
stress140. Also, the process of observing oneself expressing and controlling emotions during EW, 
gives the participant a newfound or greater sense of self-efficacy for regulating emotions128 and 
coping with cancer. Emotional self-efficacy makes stressful experiences and emotions more 
controllable, and hence reduces negative affect. Regulation of psychological and emotional 
stressors reduces the chronic stress stimuli that are acting on the HPA axis and SNS, which 
regulate hormonal secretions, and in turn will help in bolstering immune function, as described in 
the PNI framework77,141, see Table 3. However, no study of EW in the cancer population has 
empirically demonstrated the emotional regulation effects of EW and elicited the pattern of 
changes in secretion of neuro-endocrine hormone levels over time.   
Cancer survivors are known to have changes in the rhythms of their neuro-hormonal 
secretions39,142. Therefore, it is essential to collect data over multiple time points, in order to 
empirically demonstrate how EW leads to reduced stress and improves PNI outcomes. The 
current study was designed  to determine the psychoneuroimmunologic processes that occur over 
time, when CS write expressively about their stressful experiences related to cancer, by 
collecting repeated measures of neuroendocrine function and psychological status over a 6 week 
period. In order to provide increased accessibility and comfort to CS participating in EW, this 
study used technology to adapt the traditional pen-paper writing format to a computer-based one. 
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Table 3:  Theoretical framework of PNI for our expressive writing intervention 
 
 Psychosocial 
Intervention 
 
Theoretical framework of Psychoneuroimmunology (PNI) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psychosocial (P) Neuroendocrine (N) Immune (I)  
  
 
 
Respective Outcome Measures  
i ) Percieved Stress 
ii) Fear of cancer    
     recurrence  
iii) Self-efficacy for     
      coping with cancer 
Response from  
i) Hypothalamo-pituitary  
adrenal (HPA) axis: Cortisol 
ii) Sympathetic nervous system 
(SNS): α-Amylase  
Inflammatory response  of immune 
system: 
i) C-Reactive Protein (CRP)  
 
Possible Mechanisms of Action 
 
Emotion Regulation 
 
Regulation of neuro-hormonal 
response from HPA and SNS axes 
 
 
Regulation in secretion of  
inflammatory molecules of the immune 
system  
 
 
 
Psychosocia
l Stress 
Expressive 
Writing Psychosocial Stress 
Immune system 
Neuroendocrine system 
Habituation/ 
Desensitization 
Become less 
bothered by 
intrusive 
thoughts about 
the stress they 
are experiencing 
Insight  
Develop 
new 
insights 
about their 
self or the 
stressful 
experience
. 
Emotion Regulation:          
Greater working memory 
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Chapter III. Specific Aims 
For this study, a 20 minute EW intervention for cancer survivors (who have completed 
radiation treatment) was implemented over 4 consecutive days delivered using an online 
computer-based format. Neuro-hormonal response from the HPA axis as a result of EW was the 
primary outcome of interest and was measured by salivary cortisol levels. Secondary outcome 
measures of physiological (α-amylase  and c-reactive protein; CRP) and psychological function 
(perceived psychological stress, negative emotion, and efficacy for coping with cancer) were also 
included. Using a two-arm (EW and control-writing) randomized-controlled trial (RCT) study 
design, the specific aims and hypotheses of this study were: 
Specific Aims and Hypotheses  
• Aim 1: Determine the efficacy of EW to impact the HPA axis in CS as measured by 
salivary cortisol levels, i.e. the primary outcome of interest.  
H1: CS participating in EW (treatment arm) will have lower levels of salivary cortisol 
compared to CS participating in control-writing (control arm), 6 weeks post-intervention. 
• Aim 2: Determine the efficacy of EW to impact the SNS in CS as measured by salivary 
α-amylase levels, i.e. a secondary physiological outcome of interest.  
H2: CS participating in EW (treatment arm) will have lower levels of salivary α-amylase 
compared to CS participating in control-writing (control arm), 6 weeks post-intervention. 
• Aim 3: Determine the efficacy of EW to impact the immune system in CS as measured 
by salivary CRP levels, i.e. a secondary physiological outcome of interest.  
H3: CS participating in EW (treatment arm) will have lower levels of salivary CRP 
compared to CS participating in control-writing (control arm), 6 weeks post-intervention 
• Aim 4: Determine the efficacy of EW to impact psychosocial functioning in CS as 
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measured by scores on self-report questionnaires: a) PSS (perceived psychological stress), b) 
FCRI-S (negative emotion), and c) CBI-B (efficacy for coping with cancer), i.e. secondary 
psychosocial outcomes of interest. 
H4: CS participating in EW (treatment arm) will have lower scores on the PSS compared 
to CS participating in control-writing (control arm), 6 weeks post-intervention.  
H5: CS participating in EW (treatment arm) will have lower scores on the FCRI-S 
compared to CS participating in control-writing (control arm), 6 weeks post-intervention. 
H6: CS participating in EW (treatment arm) will have higher scores on the CBI-B 
compared to CS participating in control-writing (control arm), 6 weeks post-intervention 
• Aim 5: Determine the effect of EW on the primary and secondary (physiological and 
psychosocial) outcomes of interest immediately after the intervention.  
H7: CS participating in EW (treatment arm) will have higher levels of salivary cortisol, 
compared to CS participating in control-writing (control arm), 24 hours post-intervention.  
H8a: CS participating in EW (treatment arm) will have higher levels of salivary α-
amylase and CRP (secondary physiological outcomes), compared to CS participating in control-
writing (control arm), 24 hours post-intervention. 
H8b: CS participating in EW (treatment arm) will have higher scores on the PSS and 
FCRI-S and lower CBI-B scores (secondary psychosocial outcomes), compared to CS 
participating in control-writing (control arm), 24 hours post-intervention 
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Chapter IV. Significance and Innovation 
Delivering the Expressive Writing Intervention in an Internet-Based Format  
One of the most significant changes in individual lifestyles and societies in the modern 
world has been the use of computer technology and the internet. Recent statistics indicate that 
more than half the adults in the United States own a computer device that can access the internet, 
and 58% own a desktop computer, 61% have a laptop, and 18% own a tablet computer143. 
Smartphones are a recent technological innovation that offer a small computer interface and 
internet access, in addition to cellular phone use, and 45% of Americans own a smartphone, and 
the number goes up to 66% in age group 18-29144. In terms of access to the internet, recent data 
indicates that 82% of American adults can access the internet and 66% have a high-speed 
broadband connection at home145. In August of 2012, data reveals that 215 million Americans 
were active online and spent an average of 29 hours on the Internet that month146.  
The above data demonstrate the accessibility and popularity of computer-use and the 
internet amongst Americans and suggests it is a suitable medium for delivering psychosocial 
interventions such as EW. The computer-based format of EW also provides the participant to 
undertake their writing task at their own convenience, comfort and privacy, and the meta-
analytic review of EW indicates that the settings in which EW is delivered moderates the 
outcome of EW128. Some studies have demonstrated an effective response for a computer-based 
and online EW intervention147,148. However, no study of EW has been done using an online 
computer-based format in cancer populations. A review of internet interventions in the oncology 
setting has suggested that cancer patients find internet based interventions to be highly 
acceptable and feasible, and psycho-oncology researchers have suggested that more psychosocial 
interventions should be delivered using the internet in the cancer population149.  
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Study Innovation 
The current EW study was a pioneering research effort designed to move the field of 
psychosocial interventions for cancer patients forward in terms of science, technology and 
service delivery. This was the first known study to collect repeated PNI based outcome measures 
for an EW intervention in CS. This research approach allows scientists to make inferences about 
the changes in neuroendocrine hormone secretions and immune parameters caused due to a 
psychosocial intervention (EW in this case) over time. Research shows that patterns of cortisol 
rhythms are indicators of survival rates in cancer patients142. Therefore, generating evidence to 
understand changes in the patterns of hormone secretion resulting from psychosocial 
interventions is crucial to our understanding of psycho-emotional effects on the biological 
function of CS. This knowledge will provide a significant contribution to the science of 
psychosocial health interventions for the CS population.  
The NCI and IOM, in their 2008 report3, Cancer Care for the Whole Patient have 
encouraged researchers and health practitioners to include psychosocial health of cancer patients 
and CS as part of routine cancer care. This study was the first to specifically target CS in the 
post-radiation re-entry phase of survivorship. This population (post-radiation CS) was 
deliberately chosen at a particular phase (re-entry) in the cancer-care trajectory, since research 
indicates an urgent need for psychosocial interventions for these individuals. Results from this 
study will contribute to the scientific understanding of patient outcomes from psychosocial 
interventions for re-entry phase CS that have completed radiation therapy. Lastly, this was the 
first study that takes the EW intervention to the medium of the internet and computers for the CS 
population. If online computer-based EW is shown to be effective in improving CS physical and 
psychosocial health (measured by PNI based outcomes), this health intervention has the potential 
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to reach millions of CS all over the US and the world over through the medium of computers and 
the internet. Therefore, this study also contributes to the knowledge base related to the 
technology and delivery of psychosocial health interventions for the cancer population.  
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Chapter V. Methods 
The ultimate aim of this study was to determine the efficacy of a brief and inexpensive 
psychosocial intervention (called expressive writing; EW) for the supportive care of CS after 
completion of radiation therapy. In view of this aim, a randomized controlled trial (RCT) 
provided an appropriate and rigorous study design that eliminates selection bias and group 
differences by way of random allocation of participants. Also, this study constituted an 
explanatory trial150, since we aimed to contribute to the scientific understanding of PNI-based 
psychosocial interventions for CS. The research team for this study consisted of 1) the first 
author and chief research coordinator, Utkarsh B. Subnis (UBS), 2) study mentor and adviser Dr. 
Richard F. Brown (RFB), 3) study statistician, Dr. Maureen Wilson-Genderson (MWG), 4) 
nursing scientist and nurse practitioner, Dr. Angela R. Starkweather (ARS) and licensed clinical 
social worker (LCSW), Connie Macaluso-Dickerson (CMD).  
Randomized Controlled Trial (RCT) Study Design   
A RCT study design is the gold standard design for determining therapeutic efficacy of a 
health intervention. The participants in this study were randomly allocated to either the treatment 
condition, or the control group through a randomization protocol to ensure that every participant 
had equal chance of getting either the treatment or the control condition. The unit of 
randomization in this study was the individual cancer patient.    
Randomization protocol. Randomization of participants was performed through a 
computerized random numbers generator program. Two sets of random numbers were generated 
by the statistical software program SPSS for each group. The list of random numbers in each 
group was maintained in a secure location by UBS. These random numbers were then written on 
a piece of paper (5cm X 5cm) along with the group to which the random number belonged, for 
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example, “33 – Control group”. The random number also served as the participant ID number. 
These pieces of papers were folded twice and placed inside opaque envelopes. These opaque 
envelopes were then sealed and sequentially numbered. Each participant's name and email was 
entered on the front of the envelop (after study enrollment), and the research team was informed 
about the participant’s ID number, study group, name and email. The name and emails were de-
identified from the participant ID number at the end of the study. There was no alteration in 
treatment allocation once random allocation procedures were completed. Measures to ensure 
adherence to protocol were taken, and are presented below.   
     Intervention condition (EW group). The intervention condition consisted of a 
prompt that encouraged patients to disclose their deepest possible emotions and feelings about 
their experience with cancer. Participants wrote about their stressful experiences over 4 
consecutive days. The intervention protocol used in this study had been shown to be efficacious 
in improving stress related self-report and immune parameters as reported by previous meta-
analyses126-128. Participants were instructed to, “Write your very deepest thoughts and feelings 
about your cancer experience.” Participants in the EW group were instructed to write 
continuously for between 20 - 30 minutes, and told to not worry about spelling, grammar or 
sentence structure. Please refer to Appendix N for the EW prompts. 
     Control condition (Control group). This study had a control writing condition, 
equivalent to a placebo condition in RCTs for drug trials. The participants in the control 
condition also performed a writing task over four consecutive days. However, the control 
participants were asked to write about more mundane matters, i.e. how they spent their time, and 
were encouraged to approach the writing task in a more distanced and objective manner. The 
protocol used for the control writing had been developed and used in previous studies151,152. The 
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time allotted for writing the control condition was similar to the intervention condition, i.e. 20-30 
minutes, over 4 consecutive days. Please refer to Appendix N for the control writing prompts.  
Delivery of intervention. Participants in the treatment group and the control group 
received the writing prompt through an online link created using the web-based survey delivery 
software Qualtrics153 and was delivered via email. Qualtrics is a HIPPA compliant survey 
delivery software, and participant’s email addresses were entered in the program to directly 
deliver the surveys and writing prompts. Qualitrics generates a unique link for the survey which 
prevents spamming. By default, the anonymous survey link collects the user’s IP address to help 
detect potential spam responses. However, the setting in Qualtrics was set to “anonymize 
responses” from participants; this prevented Qualtrics from obtaining any identifying 
information such as the IP address of participants.  
Manipulation check. The intervention group was instructed to write about stressful and 
emotional experiences and the control group about mundane matters. However, it was important 
to determine if experimental manipulation of the intervention and control condition (by giving 
different directives for the two groups) was in fact successful. The EW literature suggests that 
data obtained from an EW writing intervention differ from data obtained from other writing tasks 
in language use. Therefore pronouns, cognitive terms, as well words denoting positive and 
negative affect are different. A software program that analyzes text for sentence and word use 
that is indicative of emotional expression, called the Linguistic Inquiry and Word Count (LIWC), 
has been developed by the pioneering EW researcher, James Pennebaker154. This LIWC software 
is able to detect and differentiate words and phrases routinely used when people write 
expressively as opposed to other writing tasks155. The LIWC software is updated on a regular 
basis and EW researchers have found it a reliable way of performing manipulation checks. 
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Therefore in order to check our manipulation, we submitted our participant’s writing responses 
to a series of linguistic analyses performed through LIWC154 to assess for use of positive and 
negative emotion words. The LIWC software application was available for download from the 
developer’s website, http://www.liwc.net/index.php. All writing responses were deleted and 
destroyed after completing the text analysis procedures to maintain participant confidentiality.  
Trial Outcomes Measures 
The outcome measures for this study were chosen to help explain the psychosocial (P), 
neuro-endocrine (N) and immune (I) effects of EW. Each measure was carefully selected based 
on the scientific evidence regarding the reliability and validity of the measure, its role in the PNI 
interactions framework, and its relevance and importance for public health research, health care 
professionals and stakeholders, i.e. CS. The physiological measures were selected to provide 
information regarding activity of the HPA axis, SNS and immune system. The psychosocial 
measures were self-reported and were selected to provide information regarding the 
psychological processes influenced by EW and psychosocial functioning of the participant CS. 
To determine if EW was indeed helpful in managing stress for CS, we measured levels of 
perceived stress and severity of negative emotion. In addition, to determine if EW helped CS 
regulate emotions and improve their coping skills, we measured coping self-efficacy. 
Primary and secondary outcome measures. Considering the specific aims and study 
design, it was appropriate to choose a “single main measure of clinical outcome,” 156 p. 1075 that 
constituted the primary end point157 of the RCT, referred to as the primary outcome measure 
henceforth. The primary outcome measure for this study was salivary cortisol levels (which 
described the activity of the HPA axis). A number of secondary outcomes that indicate both 
physiological and psychosocial functioning were also employed to help explain the multi-system 
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and PNI effects of psychosocial interventions. Salivary α-amylase levels (marker of SNS 
activity), and salivary levels of C- reactive protein—CRP (a parameter for the immune system), 
were used as secondary physiological outcome measures. In terms of secondary psychosocial 
outcome measures, reliable and valid self-reported psychometric scales were used which 
included the: a) Perceived Stress Scale (PSS) for levels of perceived psychological stress; b) Fear 
of Cancer Recurrence Inventory – Severity subscale (FCRI-S) for severity of negative emotion 
experienced by CS; and c) Cancer Behavior Inventory-Brief Version (CBI-B) for self-efficacy 
for coping with cancer.  
All measures (primary and secondary) were obtained from each participant in the 
intervention and control groups at three time points, 1) 24 hours pre-intervention, i.e. baseline 
measure, 2) 24 hours post-intervention, i.e. immediate post-intervention measure and 3) 6 weeks 
post intervention, i.e. delayed post-intervention measure, see Table 4 below.  
Table 4. Outcome measures used and the timing of their collection 
Outcome Measures Pre Intervention  Post Intervention 
 24 hours 
(Baseline) 
 24 hours 6 weeks 
Primary Outcome (Salivary Specimen)     
      Cortisol  ×  × × 
Secondary Outcomes – Physiological (Salivary Specimens)     
      α-Amylase ×  × × 
      C-reactive protein – CRP ×  × × 
Secondary Outcomes – Psychosocial  
(Self-reported questionnaires)   
    
      Perceived Stress Scale, PSS (14 items)        ×  × × 
      Fear of Cancer Recurrence Inventory-Severity,  
      FCRI-S (9 items) 
×  × × 
      Cancer Behavior Inventory-Brief Version,  
      CBI-B (12 items) 
×  × × 
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Figure 4: Diurnal Cortisol Rhythm 
Primary outcome: salivary cortisol. Salivary cortisol was an appropriate primary 
outcome for this study, since levels of salivary cortisol have been demonstrated to be highly 
correlated with serum cortisol levels (r=0.91)158and is a reliable measure of HPA axis activity. 
Also, substantial evidence implicates a direct 
relationship between salivary cortisol levels and 
immune function159,160. These factors make cortisol 
levels a clinically relevant outcome measure  for 
health researchers and professionals, and for our 
population, i.e. CS.  Measuring levels of salivary 
cortisol has gained popularity in the social-behavioral 
sciences due the non-invasiveness of the procedure. However, it is important to take account the 
biological variations in cortisol secretion. Research indicates that there is a diurnal variation in 
cortisol level, which means there were considerable difference in a measure of cortisol level 
based on what time during the day the measure was collected161. Human beings experience a 
large spike in cortisol secretion 45-60 min after waking up from sleep, called the Cortisol 
Awakening Response (CAR)162. This initial spike during CAR reaches the peak cortisol release 
and is followed by a rapid decline and a gradual decrease and plateauing towards bedtime see 
Figure 4. CAR and the diurnal variation (from awakening to bedtime) of cortisol secretion have 
been associated with levels of psychosocial stress162.  
Therefore, in order to account for these patterns, bio-behavioral researchers recommend 
obtaining multiple measures of salivary cortisol during different times of the day163. Participants 
were asked to give their saliva samples by drooling into salivette tubes 3 times per day on every 
day of data collection, i.e. once at baseline (BOM), which is 24 hours before the intervention, 
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and twice after the intervention, specifically, 24 hours (POM1) and 6 weeks (POM2) post-
intervention, see Table 4. Participants were requested to provide their saliva in their saliva 
containers at the following times: 1) immediately after waking up, for the waking response (W), 
2) within 30 min after waking, for the peak response (P), and 3) immediately before going to 
sleep, for the bedtime response (B).  
Secondary physiological outcomes: salivary α-amylase and CRP. Other elements of 
the PNI interactions such as the SNS/ANS and the immune system were assessed using two 
secondary physiological outcome measures. The procedures for collecting, storage and data 
analysis were identical to the salivary cortisol measures and are described below. 
1) Salivary α-Amylase. Biomarkers for the activity of the SNS/ANS in saliva have only 
recently investigated by researchers. Alpha (α) –amylase is an enzyme produced in the salivary 
glands that helps to degrade starch and aid digestion. Studies have shown that production of α-
amylase in saliva increases in response to psychological stress (e.g., written examinations) and 
physical stress (e.g. exercise, heat and cold)164. Some research indicates that the secretion pattern 
of α-amylase does often correlate with cortisol levels during stress, suggesting a physiological 
stress response separate from the HPA axis165,166. A recent study found that α-Amylase was 
significantly correlated with blood levels of norepinephrine (r = 0.33)167. α- Amylase is now 
considered a reliable correlate of sympathetic activity under conditions of stress166. Some 
research suggests a diurnal rhythm in α-amylase secretion, with pronounced decrease in the first 
hour after awakening and a steady increase during the rest of the day.  
2) C-Reactive Protein. C-reactive protein (CRP) was used as a secondary physiological 
outcome measure of the immune system since it provides information regarding the general level 
of inflammation in the body. CRP is a protein synthesized by the liver during inflammation and 
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the acute-phase response, and has been is widely used as a bio-marker of inflammation for a 
variety of conditions ranging from cardiovascular disease88,168 (e.g. in myocardial infarction) to 
cancer169,170. CRP plays an important role in immune function and increases in levels during the 
body’s response to physical stressors (e.g. infection, physical trauma, or malignancy). This 
involves a process of inflammation, which starts with recruitment of certain immune cells in the 
blood, i.e. white blood cells, WBCs, e.g. neutrophils. These WBCs secrete a number of signaling 
molecules called cytokines (e.g. Interleukins, IL) into the bloodstream. IL-6 induces increased 
production of CRP in the liver to assist with inflammatory processes171. CRP enhances the 
capacity of immune cells to produce more inflammatory cytokines168,172 along with facilitating 
production of opsonin, that helps in destruction of pathogens and dead or dying cells171,172.  
CRP is also implicated in activation of other immune pathways (the classical complement 
pathway) and enhancing tumor-cell killing activity of immune cells (macrophages)172. Evidence 
also links psychosocial (chronic stress) and behavioral (exercise) factors with increased levels of 
CRP, which lends support to CRP’s role in the PNI framework173,174. The ability to detect CRP 
levels in saliva has been a recent scientific development and data regarding correlation between 
blood and salivary levels is being established. However psychosocial interventions have found 
significant changes in CRP levels after improving participant’s psychosocial functioning174. 
Hence, the saliva collected from CS was used to determine levels of CRP.   
Procedures for the collection and storage of saliva from participants. Salivette tubes 
provided by the Center for Biobehavioral Clinical Research at the VCU School of Nursing were 
used for obtaining saliva samples from the participants in this study. This procedure needed a 
high level of adherence to protocols; therefore detailed training material was provided to 
potential participants to demonstrate how they would collect their saliva by drooling into the 
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salivette tube. An information booklet along with a link to a video demonstration of saliva 
collection was mailed to the participants prior to the study, see Appendix K. The study staff were 
also available to answer any questions participants had over the phone or voice/video chat as 
well. Salimetrics Inc.175 Labs, which provide the assay kits for the analytes, recommend 
collecting a total volume of approximately 500 micro-liters (μl), when testing for three analytes. 
In their instruction and training booklet and video (please see Appendix K), participants were 
shown the marking on the salivette tube (Eppendorf tube) which would indicate that an adequate 
sample of saliva had been collected (i.e. at least 500 μl) for the purpose of this study.  
Salimetrics reports their kits to be highly sensitive, reliable and valid ways to measure 
salivary cortisol, α-amylase and C - reactive protein, with a detection range of 0.012 – 3.0 
μg/dl176. Also, past studies that have used these kits have reported that the intra-assay coefficient 
ranged from 3.35% to 3.65% and inter-assay coefficient ranged from 3.75% to 6.41%177,178. 
Participants were mailed the saliva collection kits (salivettes) for all three measures and for all 
three days of data collection at least one week before the intervention. The salivette tubes had a 
sticker pasted on the surface of the tube (see Appendix L), containing only the participant ID 
number along with a box to mark which type of sample it was based on the criteria for the timing 
of the sample described below.  
Timing of saliva collection on Day 2 (BOM), Day 7 (POM1) and Day 49 (POM 2). 
Participants were asked to provide three samples at the following times on the day of outcome 
measures data collection:  
1) Immediately after waking up, for the waking response (W),  
2) Within 30 min after waking, for the peak response (P), and  
3) Immediately before going to sleep, for the bedtime response (B).  
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Note: Saliva samples given at random times during the day (i.e. that do not meet with  
timing requirements of W, P or B) were also be marked as Other (O).   
After giving their saliva sample, the participants were instructed to note the timing of their saliva 
sample by and checking a box on the labels on the salivette tubes and indicate whether the 
sample was W, P, B, or O, please see Table 5 below.  
Table 5: Timing of saliva samples and marking of samples   
Sample 
number 
What time during the day to collect your saliva 
sample?    
Which box to check on saliva 
tube label?   
 
1. 
 
Please provide your first saliva sample immediately 
after you wake up. This is when you have opened 
your eyes and are ready to get up for the day.  
 
(Note: You may keep the saliva collection tubes beside 
you the night before. This way you can collect your 
saliva before you get out of bed. You can also collect this 
sample immediately after getting out of bed.) 
 
Please check box marked “W” 
 
 
 
 
 
2. 
 
Please collect the second saliva sample at about 30 
minutes after you have woken up for the day. The 
timing of this sample is particularly important, so 
please make attempt to collect exactly 30 minutes 
after Sample 1. 
 
Please check box marked “P” 
 
 
 
 
3. 
 
Please collect the third and last saliva sample at 
bedtime. The timing for this sample is ideally right 
before you get into bed.  
 
Please check box marked “B” 
 
 
 
   O 
 
In case you miss the timing for the samples or are 
unable to give a sample at any of the above 3 times, 
you can still provide your saliva sample at any time 
of the day.  
 
Please check box marked “O”  
 
 
 
Participants were also provided with Ziploc freezer bags marked for each day of data 
collection, namely, Day 2, Day 7 and Day 49. Participants were instructed to store the saliva 
samples in the freezer compartment of their refrigerator. Researchers have indicated that saliva 
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O  
PID No. _______ 
W  P  B  O 
PID No. ______ 
W   P  B  O 
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samples for testing all three of our measures (cortisol, amylase and CRP) can be frozen for long-
term storage (beyond 8 weeks), at negative (–) 20 degrees Celsius in whole, un-centrifuged 
salivettes, without loss of substances. Most home freezer compartments provide a temperature 
very close to the recommended freezing temperature. Therefore, I collected all samples from the 
participant after the entire study protocol was completed, i.e. six to seven weeks after the 
intervention. Samples were immediately transported, from the participant’s location to the bio-
behavioral clinical research laboratory at the School of Nursing at VCU, using temperature 
controlled kits. Once they arrived at the laboratory, the samples were centrifuged in order to 
remove mucous from the salivary specimens, and were subsequently stored and frozen at –70° F.   
Monitoring adherence to protocol of salivary data collection. The following 
procedures were employed to ensure adherence to the study protocol:  
1) Participants were educated about the timing for each of the three samples (W, P, B)  
2) The salivette tubes had a sticker where participants were instructed to write down the time of 
the collection and check a box to identify whether the sample was W, P, B, or O.  
3) It was emphasized to the participants that the Peak sample (P) must specifically be collected 
within 30 minutes of waking up. In case they give the sample beyond 30 minutes of waking 
up, they were asked to mark the sample as Other (O). Saliva samples given at random times 
during the day (i.e. that do not meet with timing requirements of W, P or B) were also 
requested to be marked as Other (O)   
4)  Participants were provided with an opportunity to enroll in an interactive reminder system. 
This involved participants listing their preferred method of communication (e.g. cell-phone 
number, email, instant-messaging-IM or landline) for being reminded on the days of data 
collection. Participants were also asked to provide the approximate time they wake-up, and 
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the time they would prefer a reminder message. On the day of day collection (i.e. baseline 
and 2 times post-intervention), participants were sent a text-message (or IM/e-mail) through 
a chat engine (e.g. GChat) reminding them about the timing for their salivary sample. 
Participants were sent a follow-up text-message asking them if they had given the sample at 
the required time point (i.e. W/P/ B/O). They were also sent a message inquiring if they had 
placed their samples in their freezer at the end of the day of data collection. Participants had 
the opportunity to respond as Yes or No, to this text-message (or IM) through their cell-
phone (or other technological device). These responses were maintained as a record of 
participant’s adherence to protocol. Participants were thanked for their participation at the 
end of each communication.   
5) Participants were provided a detailed spreadsheet with dates and times for study activities 
such as when they would be filling out the online surveys, writing online.  
6) Decision for excluding samples: As explained above, the O samples were to be included in 
our estimation of average cortisol secretion (Area Under the Curve), but excluded in our 
estimation of Cortisol Awakening Response and Diurnal Cortisol Secretion.   
7) The survey program time stamped each writing entry (treatment and control) in order to 
monitor adherence to writing intervention protocol   
8) Participants were informed that they could contact UBS or RFB at any time during the 
sample collection if there were any problems or clarifications.  
Secondary outcomes: Self-reported psychometric measures. This study also employed 
self-report survey items that were administered through an online survey link (Qualtrics) at the 
same time points as the biological measures, i.e. Day 2 (Baseline Outcome Measure), Day 7 
(Post intervention outcome measure 1), and Day 49 (Post intervention outcome measure 2) 
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Previously validated measures were used to detect changes related to reduction in psychological 
and emotional stress and quality of life.  
1) Perceived Stress Scale (PSS). The levels of perceived psychological stress levels were 
assessed using the Perceived Stress Scale (PSS). The PSS is one of the most frequently used 
scales in stress research, and scores on the PSS have been correlated with physiological stress 
measures (salivary cortisol)179. The scores on the PSS provide information related to the amount 
of psychosocial stress as perceived by CS, which would help us determine if EW is indeed 
successful in reducing stress. The PSS is designed to detect the degree to which participants 
appraise stress in their daily life, and consists of dimensions such as unpredictability, loss of 
control, and overwhelm180. This psychometric instrument has 14 items (see Appendix N) that 
were answered by the participants on a 5-point Likert scale. This scale has a demonstrated good 
reliability in healthy and clinical populations, and has a Chronbach’s alpha value of 0.86180.   
2) Fear of cancer recurrence inventory– Severity subscale (FCRI-S). The fear of cancer 
recurrence is the most salient emotional stressor faced by CS during survivorship24. Therefore, 
the severity of fear of cancer recurrence (FCR) is a good indicator for the level of negative 
emotional stress experienced by CS. Interventions designed to regulate psycho-emotional stress 
in CS should be able to reduce FCR. Hence, in order to determine whether EW is actually able to 
help CS regulate their emotional stress, we used the 9 item severity subscale of the FCRI, the 
FCRI-S (see Appendix N). The FCRI is a 42 item multi-dimensional measure of FCR, which has 
been recently developed and validated and good reliability has been established181. The FCRI-S 
specifically describes the amount of emotional stress experienced by CS due to FCR and is a 
suitable instrument to detect the clinical response to psychosocial interventions such as EW24. 
FCRI-Severity-Subscale is strongly correlated with the total FCRI score (r = 0.84), and has high 
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internal consistency and adequate 1-month test–retest reliability181,182.  
 3) Cancer Behavior Inventory-Brief Version (CBI-B). The CBI-B, a 12 item self-
reported instrument was used to measures the level of self-efficacy among CS for their capacity 
to cope with cancer183. The CBI-B has been shortened from its original 33 item long version, the 
CBI-L184, to reduce patient burden. This psychometric measure assesses cancer patient’s ability 
to cope effectively with cancer, and includes dimensions such (a) beliefs about maintaining 
independence and a positive attitude, (b) ability to participate in medical care, (c) coping and 
stress management skills, and (d) capacity to manage emotions/affect in stressful situations.  
A major advantage of the CBI-B is that it is relevant to the specific psychosocial 
problems faced by patient with cancer. The CBI-B scores was chosen to help us determine if EW 
can improve coping and emotion regulation in CS. Since this measure was designed primarily for 
cancer patients undergoing treatment, we modified one item (i.e. item 7) to relate to cancer 
survivorship. All 12 items are rated on a 9-point likert scale that ranges from 1 (“not all 
confident”) to 9 (“totally confident”). Reliability evidence for the CBI-B is strong and three large 
scale studies in oncology populations have provided a minimum internal consistency value of α 
= .84183. The CBI-B is also highly correlated (r=0.95) with the CBI-L183. Table 6 summarizes the 
all information that was collected (i.e. cancer information and demographics) and the measures 
collected (primary and secondary) along with the timing of collecting those measures with 
respect to the intervention.  
Statistical Power and Estimation of Sample Size 
Since the study used a repeated measures RCT design the statistical test used to analyze 
study data needed to account for the correlation between repeated measures (e.g. Day 2 CRP 
correlates with Day 7 CRP and Day 49 CRP). Also, since this study used a balanced two-arm 
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RCT design, there was an equal number of participants randomized to the treatment or control 
condition. Thus, we used GPower statistical program to estimate sample size for our study for a 
multivariate analysis of variance (MANOVA) statistical test. The first step in the sample size 
calculations was to decide the on the parameters of statistical significance. This study’s sample 
size calculation used 80% power (β=0.2) in order to estimate the number of subjects needed to 
show significant differences between the intervention and control groups with 95% confidence 
(α=0.05). The next step in the power analysis was to determine the expected effect size for the 
intervention on the primary outcome measure.   
         An older meta-analysis of previous EW studies estimated a standardized effect size 
for the EW intervention in mixed populations58 and reported a Cohen’s d = 0.47. A more recent 
meta-analysis60 reported a smaller standardized effect size, Cohen’s d = 0.15. However, 
standardized effect sizes do not take into account variations in treatment effect based on the 
population and outcome measures. A standardized effect size for EW interventions within cancer 
population has not been estimated, although past studies have reported large effects, such as d = 
0.89656. A meta-analysis of EW interventions in clinical populations59 yielded a d = 0.21 for 
physical health outcomes, which included cortisol levels. Studies assessing the psychological 
determinants of the cortisol stress response116, 117 suggest a standardized effect size of d = 0.3 for 
salivary cortisol. Therefore, the initial power analysis considered the primary outcome of interest 
(salivary cortisol) to detect a more conservative effect size (between d = .21 and .896) of d = .33  
The a priori power analysis conducted by GPower statistical program based on the effect 
size for EW chosen (d = .33) indicated that a MANOVA could detect significant effects between 
two groups with 80% power in a total sample size of N=52 participants. However, oversampling 
was recommended due to the possibility of missing data which is common problem in 
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longitudinal RCT designs. Past studies and meta-analyses of EW indicate that an overall 20% of 
the study population has attrition and or missing data. This 20% of the population translated into 
10 additional participants, which were added to the initial calculation of 52 participants. Thereby 
the total sample size estimated a priori for this study was N=62, participants, which translated to 
the recruitment and enrollment of 24 participants in each arm, i.e. n=31 in treatment arm (EW 
intervention) and n=31 in the control arm (control writing task). During the process of 
recruitment and enrollment, the study faced low accrual rates which is commonly encountered in 
psychosocial trials in the cancer population185. A preliminary report was conducted to determine 
the adequacy of participant completion of the study protocol. Finding that N=40 participants had 
completed the study protocol, it was decided to forego oversampling and continue with the 
analysis based on 20 participants in each arm.  
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Table 6: Study protocol (activities, measures and data sources)  
Prior to enrollment Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 49 
Provide study 
information 
+ 
Screening 
+ 
Informed consent 
Confounds 
+ 
Cancer-
related 
information 
Baseline 
outcome 
measures 
(BOM) 
 
Writing 
 
Writing 
 
Writing 
 
Writing 
 
Post-
intervention 
outcome 
measures 
(POM1) 
Post-
intervention 
outcome 
measures 
(POM2) 
                                  Expressive writing                            
     Intervention  
                                    Control writing 
20 – 30 
minutes 
20 – 30 
minutes 
20 – 30 
minutes 
20 – 30 
minutes 
20 – 30 
minutes 
20 – 30 
minutes 
20 – 30 
minutes 
20 – 30 
minutes 
20 – 30 
minutes 
Screening – 5 questions 
(Telephone-based) 
 Cognitive dysfunction (Brief Screen for Cognitive Impairment: 3 items )  
 Depression (Patient Health Questionnaire-2: 2 items) 
 
Confounds – 28 questions 
(Online survey)   
 Social support and Perceived social status  
 Smoking, Alcohol consumption, Sleep, Oral health – gum disease  
 Use of complementary and alternative medicine (CAM)  
 Comfort with using computers and internet technology  
 Demographics: Health insurance status; Employment status; Household income; Education 
level; Marital status; Age ; Gender ; Race/Ethnicity  
Cancer-related information – 9 
questions 
(Online survey)   
 Cancer Diagnosis information (primary site, tumor stage) 
 Cancer Treatment regimen information (date, toxicity, late and long term effects)   
 Medication use  
BOM, POM1 and POM2 
(Salivary Specimens) 
 Cortisol,   α-Amylase and C-reactive protein – CRP  
BOM, POM1 and POM2  – 33 
questions 
(Online survey)   
 Perceived Stress Scale  
 Fear of Cancer Recurrence Inventory-Severity subscale  
 Cancer Behavior Inventory-Brief version  
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Identification of Eligible Patients      
Potential participants were identified by using a defined set of inclusion criteria for 
patients with cancer at sites that were available for recruitment to this study. Participants 
identified through the inclusion criteria could have some characteristics that would be 
problematic with the study protocol. For example, participants with radiation treatment to the 
face region may be unable to produce adequate saliva (due to damaged salivary glands), and 
hence will not be able to complete the primary outcome measure. Therefore, exclusion criteria 
were used to help exclude certain participants that were initially eligible.   
Inclusion criteria. Patients with cancer having the following characteristics were 
considered eligible to participate in our study; patients who: a) had completed their cancer 
radiation treatment (intent to cure), b) were cancer free, i.e. not having any diagnosis of 
primary/secondary cancer or any recurrence/relapse of cancer, c) were in the re-entry phase of 
cancer survivorship, i.e. 2-12 months post-treatment completion, d) had access to a computer and 
internet in a private setting, e.g. at home, e) were above the age of 21 years, f) were fluent in 
English, and g) were able to provide informed consent. The participants had received radiation as 
their final cancer treatment, and could have received other cancer treatments before radiation, 
such as surgery or chemotherapy. Participants were provided the option to discontinue their 
participation in the study due to any reason at any time during our intervention protocol. 
Participants had access to UBS and RFB for any assistance regarding contacting supportive care 
services provided to the patients.  
Exclusion criteria. Eligible participants were excluded from the study if they met any 
one or more of the following criteria: a) scheduled to undergo any type of cancer treatment 
(intent to cure/palliative) in the future (e.g. surgery after completing radiation), b) on any kind of 
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corticosteroid medication (e.g. long-term prednisone therapy), c) having any condition that 
affects function of the adrenal glands (e.g. adrenal hyperplasia), d) limited ability to produce 
saliva, e.g. patients that received radiation (or surgery) on the face region or on salivary glands; 
or patient’ssuffering from dry mouth (e.g. Sjögren's syndrome), and e) suffering from 
inflammation of the oral cavity (e.g. gingivitis). Individuals on corticosteroid medication or those 
with diseases of the adrenal glands have irregularities in cortisol secretion that can interfere with 
data collection for the primary outcome measure, and hence were excluded from the study. 
Patients with limitations in salivary production would be unable to complete the primary 
outcome measure and were hence excluded. It was important to exclude patients with oral 
inflammation because their salivary measures may erroneously indicate increased inflammation, 
resulting from local inflammation in oral cavity, and not from systemic immune processes.  
To take into account typing skills, potential participants were also asked if they would be 
comfortable typing on a computer for 20 -30 minutes over 4 consecutive days. Only patients that 
confirmed they were comfortable typing for that amount of time were included in the study. 
Patients were also screened for cognitive impairment and depressive symptoms (Brief Screen for 
Cognitive Impairment and Patient Health Questionnaire-2).    
Identification procedures. The human subjects involved in this study were cancer 
patients who have finished their radiation treatment (intent to cure) and were in the re-entry 
phase of cancer survivorship (2-12 months post-radiation treatment completion).  Eligible 
patients were identified based on the aforementioned set of inclusion and exclusion criteria. 
Medical records at the VCU Health system was accessed only for the purpose of identification of 
potential participants, no information from the medical records was used for research purposes. 
Once potential participants were identified, an initial letter regarding the study was mailed to the 
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patient that provided information about the study and contained the full contact information of 
the study mentor and UBS, see Appendix D. Subsequently, the potential participant was 
contacted by phone. If the potential participant’s voicemail was reached during any phone 
interaction, no details about the study were mentioned. A voice message consisting of the name 
of the first author (Utkarsh B. Subnis, UBS) and affiliated institution (i.e. VCU), along with a 
call back number was left, see Appendix G. UBS was in communication with potential 
participants through email or their preferred method of communication (phone or mail) after the 
initial call. 
Recruitment Plan  
Firstly, we obtained permission from the Chair of the Dept. of Radiation Oncology at 
Massey Cancer Center (MCC), Dr. Mitch Anscher, to recruit patients from MCC. Support was 
also obtained from Clinical Research Nurses (CRN) at Virginia Cancer Institute (VCI), and Bon 
Secours Health System, Richmond, VA, to assist with recruitment. The research team identified 
potential participants, by working collaboratively with oncologists, nursing staff and CRNs at the 
Radiation Oncology Department at MCC and VCI and Bon Secours. Active and passive 
strategies (described in detail below) were used to recruit patients to this study.  
Active recruitment: Electronic health records. Active recruitment was conducted by 
identifying eligible patients using the electronic records of the Virginia Commonwealth 
University Health System (VCUHS), which is a HIPPA compliant electronic medical 
information database as well as working with oncologists and research nurse personnel. The 
research team identified all potentially eligible cancer patients who had completed their primary 
radiation treatment through the VCUHS electronic health record database. The research team 
worked with the administrators at the VCUHS to organize access for to the relevant VCUHS 
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systems, Cerner and IDX. Access to these systems was obtained on a weekly basis to identify 
patients who were scheduled for follow up radiation therapy appointments, assess the time since 
last appointment and identify those patients whose last appointment was between 2 months and 
12 months prior to the access date. This process involved creating patient lists of those who were 
discharged after radiation in the last 10 months. For example, if the VCUHS scheduling data 
base IDX was accessed on July 1, 2013, patients were identified whose last radiation therapy 
appointment was between June 1, 2013 and August 1, 2012, see Appendix C.  
The radiation oncologist/nurse at the clinic from where the patients were discharged were 
contacted to inquire if the patients were eligible for the study. If patients were considered eligible 
by the oncologist, the patient’s contact information, which included their name, phone number 
and mailing address was collected. Patient medical records were not accessed once eligibility 
was determined. An initial letter regarding the study was mailed to the patient containing the full 
contact information of UBS and RFB, see Appendix D. A “do not contact” return-addressed 
postage paid opt-out mail-card was sent along with the initial letter, see Appendix E. Two weeks 
after the recruitment letter was mailed, UBS attempted to reach the eligible participants by 
phone. In the first phone call, UBS asked the potential participant about the letter regarding the 
study. In case the participant mentioned that s/he did not receive the letter, UBS informed the 
potential participant that the letter would be mailed to them again, and that UBS would contact 
them again. If the potential participant acknowledged receiving the letter, UBS then explained 
the study in some more detail, conducted screening procedures (i.e. the BSCI and PHQ-2), 
answered any questions the participant may have, and requested for the participant’s preferred 
email address. 
Subsequently, UBS confirmed if the potential participant was interested in taking part in 
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the study on the phone and a hard copy of the informed consent document was mailed to the 
participant, see Appendix I. The participants were requested to mail the informed consent form 
back to UBS after signing it. An extra copy of the informed consent form was mailed along with 
the consent form. Also, a returned addressed postage-paid mail envelope was provided for 
participants to mail the consent form back, see Appendix I. Participants were enrolled once the 
signed consent forms were received. Potential study participants were in communication with 
UBS through email or the patient's preferred method of communication (phone or mail) after the 
initial call. UBS also offered a home visit or visit at a convenient location to the participants for 
explaining the study more in detail and having personal contact with the participant. UBS 
provided the participants with his full contact information, and the participants were able to 
contact UBS at any time for any doubts or reservations.  
Passive recruitment: Flyers. A recruitment flyer containing some basic information 
about the study and with UBS’s contact information was prepared. Also, UBS informed the 
nursing staff at MCC, VCI and Bon Secours about the details, inclusion and exclusion criteria for 
the study and provide the staff with the flyers, see Appendix A. The nurses handed out the 
recruitment flyers at the radiotherapy consultation departments to potential patients. UBS also 
visited and presented the study’s flyer to community support groups for cancer patients in 
Richmond, VA, such as support groups at the VCU Massey Cancer Center; and bulletin boards 
of community health centers, such as the VCU community health education center. The 
information from the flyers was also posted on the VCU e-listserv for ongoing studies. CS 
interested in this study had the necessary information to contact UBS. If patient’s contacted UBS 
regarding the study, UBS then explained the study in some more detail and conducted identical 
recruitment procedures (as described above), and answered any questions that potential 
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participants may have and request for contact details such as email and mailing address. UBS 
verbally ascertained interest in study participation on the phone and participants were mailed the 
informed consent form. Participants were kept informed about the study through their preferred 
mode of communication (i.e. email/phone/postal mail).  UBS offered a home visit or visit at a 
convenient location to the participants for explaining the study more in detail and having 
personal contact with the participant. UBS also provided the participants with his contact 
information, and the participants were able to contact him for any doubts or reservations 
regarding the study. 
Recruitment at non-VCU sites. Virginia Cancer Institute and Bon Secours Health 
System, both have radiation oncology units for treating patients in Richmond and surrounding 
counties.  These Non-VCU centers were used only for passive recruitment of participants, and 
hence were considered not engaged. They only performed the following activities as described in 
OHRP’s guidelines:  
The Clinical Research Nurses and related health professionals at non-VCU sites:  
a. informed prospective subjects about the availability of this research study; 
b. provided prospective subjects with information about the research (which included a copy of 
IRB approved recruitment flyer) but did not obtain subjects’ consent for the research or act 
as representatives of the investigators; 
c. provided prospective subjects with information about contacting investigators for 
information or enrollment; and/or 
d. sought or obtained the prospective subjects’ permission for investigators to contact them. 
UBS undertook liaising efforts with clinical research nurses and health professionals to 
identify patients based on inclusion and exclusion criteria. The identified potential participants 
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were handed flyers with information about the study. Those participants who were interested in 
the study contacted UBS. No medical records were accessed at Non-VCU institutions. The same 
precautions for the safety and protection of participants and their data (described above) were 
used for participants from Non-VCU institutions. Participants were informed that the study is 
primarily through VCU, being conducted by UBS. 
Screening patients before recruitment. Potential participants were screened for 
cognitive dysfunction using the Brief Screen for Cognitive Impairment and depression using the 
Patient Health Questionnaire-2, before inviting patients to participate in the study. Screening for 
cognitive impairment and depression took place over the phone during the initial recruitment 
call. Potential participants having moderate to severe cognitive dysfunction were excluded from 
the study. Patients were also screened for depressive symptoms prior to consent using a validated 
depression screening questionnaire (Patient Health Questionnaire –PHQ –2). Using the PHQ-2 
has been described in the literature as a suitable "first step" approach to screen for depressive 
symptoms and is not used for diagnosis and monitoring of depressive symptoms.   
Screening for cognitive dysfunction. Cognitive impairment can impact the ability of 
patients to provide informed consent, as well as this intervention requires a certain degree of 
cognitive effort and cognitive ability. Therefore excluded patients with cognitive dysfunction, 
and screened for cognitive impairment. Screening for cognitive dysfunction was performed 
before obtaining verbal assent from the eligible participants during the initial telephone 
conversation. The Brief Screen for Cognitive Impairment (BSCI), a previously validated (Hill et 
al., 2005) three item screening instrument for administration during a telephone conversation, 
was used for screening out cancer survivors with significant cognitive impairment. The time 
required to administer the BSCI is approximately 80 sec.  
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The first item on the BSCI consists of memory recall question is: 1) the participants were 
told three unrelated words (dog, apple, and house) after describing the purpose of the 
conversation to the participants. Then the participants were asked to repeat those three words 
after the details of the study were described to them. The responses from the participants were 
scored from a perfect score of 0 (no mistakes in recalling the three words correctly) to the worst 
score of 3 (none of the three words correctly recalled).  
The other two items on BSCI included the following:  2) how frequently do you need 
help with planning trips for errands?; and 3) How frequently do you need help for remembering 
to take medications? Both these items were scored from 0 (never needs help) to 4 (frequently 
needs help). Finally, the scores were weighted and summed to arrive at the final BSCI score 
(scores from delayed recall and frequency of help with remembering to take medications was 
assigned a weight of 2.0 and the score from frequency of help with a trip for errands was 
assigned a weight of 1.0.). Patients with a score of >6 on the BSCI were considered to have 
significant cognitive impairment and were excluded from the study. The scores on BSCI have 
shown to be significantly correlated with scores for other tests of cognitive function such as the 
Mini Mental State Examination (r= −0.83) and the Alzheimer’s Disease Assessment Scale 
(r=0.65).  
Screening for depression. Patients were also screened prior to enrollment for depressive 
symptoms using validated depression screening questionnaire (Patient Health Questionnaire –
PHQ –2). The 2 items PHQ-2 depression scale is a very brief and extensively researched 
instrument for screening of depression. The PHQ 2 has 2 items and is rated from 0 – 6.  The 
recommended cut off score for screening is  3. During the initial recruitment call, UBS scored 
potential participants on the PHQ-2 questionnaire in real-time on the phone after completing the 
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cognitive dysfunction questions.  The actual questionnaire and scoring sheet is provided below in 
Table 7 and the psychometric properties of the PHQ-2 are described below in Table 8. 
 
We did not expect to be contacting clinically depressed patients, or receiving responses from 
depressed patients. However the PHQ-2 enabled us to screen out patients who were in need of 
intensive mental health care.   
Table 8: Psychometric Properties of the Patient Health Questionnaire –PHQ –2a 
Major Depressive Disorder (7% prevalence) Any Depressive Disorder (18% prevalence) 
PHQ-2 
score 
Sensitivity Specificity Positive 
Predictive  
Value (PPV*) 
PHQ-2 
score 
Sensitivity Specificity Positive 
Predictive 
Value (PPV*) 
1  97.6  59.2  15.4  1  90.6  65.4  36.9  
2  92.7  73.7  21.1  2  82. 1  80.4  48.3  
3  82.9  90.0  38.4  3  62.3  95.4  75.0  
4  73.2  93.3  45.5  4  50.9  97.9  81.2  
5  53.7  96.8  56.4  5  31.1  98.7  84.6  
6  26.8  99.4  78.6  6  12.3  99.8  92.9  
* Because the PPV varies with the prevalence of depression, the PPV will be higher in settings with a higher 
prevalence of depression and lower in settings with a lower prevalence. 
a Kroenke K, Spitzer RL, Williams LB. The Patient Health Questionnaire-2: Validity of a Two Item Depression 
Screener. Medical Care. 2003; (41) 1284-1294. 
 
Patients that were found to have PHQ2  3 were not included in this study. These participants 
were advised to not participate in the study at that time and were provided information about 
supportive care services. UBS also offered a referral plan for these patients (see below) and were 
asked  if they would like to be contacted at a later time regarding their psychosocial needs.  
Table 7: Patient Health Questionnaire -2 Telephone Screening tool for Depression  
Over the past 2 weeks, how often have you been bothered by any of the following problems? 
 Not at 
all 
Several 
days 
More than half 
the days 
Nearly 
every day 
Little interest or pleasure in doing things 0 1 2 3 
Feeling down, depressed or hopeless 0 1 2 3 
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Referral plan after screening procedures. Scores on the BSCI and PHQ-2 
questionnaire were estimated by UBS in real time during the phone conversation. Based on 
standards provided for using the PHQ-2, patients with PHQ-2 scores above 3 are recommended 
to be further evaluated for a depressive disorder. Participants that had PHQ-2 scores 3 were 
advised to not participate in the study and were provided information about supportive care 
services. During the call, UBS offered to immediately conference call Connie Macaluso, for 
further evaluation. Connie Macaluso is a licensed clinical social worker (LCSW) and trained in 
dealing with mental health issues of cancer patients. In case the patient refused to be conference 
called to Connie Macaluso, UBS asked the participants if he could refer them to Ms. Macaluso 
for additional evaluation. The participant’s response regarding this matter was honored and their 
right to refuse further assistance was respected. No further contact with the participant occurred. 
Since this was a student research project, limitations in resources precluded us from employing a 
trained neuropsychiatry health professional.  Also, since UBS did not have training required for 
clinical management of mental health issues in patients, referring patients to a trained and 
licensed clinical social worker was considered an appropriate approach. For patients who were 
eligible after screening, UBS proceeded with assessing their interest in participating in the study.    
Assessing interest in study participation. UBS again asked if there were any 
unanswered questions, as well as provided more details of the study as needed. Then UBS asked 
the patient if they would be interested in participating in the study. If the patient expressed 
interest in the study, UBS requested for their preferred email address (and other preferred modes 
of communication). The potential participant was then told that s/he would need to sign the 
informed consent form for this study before s/he could be enrolled in the study. After the initial 
call, UBS was in communication with potential participants who expressed interest in the study 
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through email or their preferred method of communication (phone or mail). Patients who 
declined participation were thanked for their time, and participants who wanted more time to 
think about the study, were contacted again at their convenience. 
Informed Consent Procedures 
A paper copy of the informed consent document was mailed to the participant along with 
additional copy of the consent document and a return addressed postage-paid envelope, see 
Appendices H and I. The participant then signed the consent document and mailed it back to 
UBS. Up to 3 reminders were sent to patients about their potential participation. The reminders 
informed patients that, a) UBS was following up about potential participation in this research 
study focusing on stress management or cancer survivors after radiation therapy using expressive 
writing, b) a consent form was mailed to the participant but UBS had not heard back from him or 
her yet, c) if the patient is interested in participating, they should please return the signed consent 
form in the reply envelope provided, and d) if the patient has any questions, please feel free to 
contact study staff. The contact information for UBS and RFB was provided on the consent 
document and UBS was available to further clarify any details of the study.  
Enrolment in study. After receiving the signed informed consent document from the 
participant, the participant was enrolled in the study and mailed the salivette kits and study 
materials, see Appendix J and K. UBS offered home visits to the participants to personally 
deliver the salivary kits and go over the study procedures. Participants who provided written 
consent were enrolled in the study, and a Participant ID number was generated for them, using a 
random number generator computer program. The participants were requested to indicate 4 days 
in their upcoming time schedule for the writing intervention. Based on their preferred days, a 
schedule with specific dates and activities (including data collection) using the protocol (Table 6) 
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was prepared, see Appendix M. Participants were offered to enroll in the interactive reminder 
system. All data obtained from the participants was connected with the Participant ID number. 
The salivette kits and information booklets were subsequently mailed to the participant’s home 
address. A web-link for the instructional video showing how to collect saliva in the salivette 
tubes was emailed to participants. The salivettes had the participant ID number printed on the 
labels; no identifying information was present on these salivette kits. The salivette kits were 
recovered from the participant’s home at the end of the study.  
Data Sources  
The sources of data for this study were all from the participant’s in the form of 1) self-
report questionnaires, 2) responses from the writing prompts and 3) salivary specimens, see 
Table 9.  
Compensation of Participants  
Since this was a student dissertation project, limited funds were available for this 
research. Participants were thanked in appreciation for their time and effort devoted to this study. 
Table 9: Data sources and research material  
1) Self-report questionnaires (administered online) 
Health-related symptoms and behaviors: Social support, Perceived social status,  Smoking, Alcohol 
consumption, Sleep, Oral health – gum disease, Use of complementary and alternative medicine 
(CAM), Comfort with using computers and internet technology 
Demographics: Health insurance status; Employment status; Household income; Education level; 
Marital status; Age; Gender; Race/Ethnicity  
Cancer-related information: Cancer Diagnosis information (primary site, tumor stage); Cancer 
Treatment regimen information   (date, toxicity, late and long term effects); Medication use 
Outcome Measures (BOM, POM1 and POM2): PSS, FCRI-S and CBI-B 
2) Responses from the writing prompts (administered online): 
Responses to expressive writing prompt 
Responses to control writing prompt 
3) Salivary specimens (provided at home, collected at the end of study)  
Outcome Measures (BOM, POM1 and POM2):  Cortisol,  α-amylase and  C-reactive protein – CRP 
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Participants also had an opportunity to indicate if they would be interested in periodic updates 
about the study results, progress and publication. Participants did not receive any monetary 
compensation for their participation. The participants had the opportunity to join a listserv that 
updates participants about the study results, publication and dissemination activities.  
Minimizing Potential Risks for Participants 
     In the unlikely event that participants got distressed to the point of needing an 
intervention during their expressive writing activity, we ensured that adequate measures were 
taken to reduce risk for participants. The following measures were taken during the intervention 
process.  
1. Phone contact with participants during the intervention. UBS contacted all 
participants on Day 2 and Day 7 to check if they were doing well during the intervention. 
If participants report requiring any additional support services, these were provided by 
actively referring these patients to Connie Macaluso, LCSW. UBS was available to the 
participants at any time, and UBS informed the participants that he would be available for 
phone contact or home visits at any point during the intervention. Patients with 
depression were not included in the study.  
2. Monitoring the participants writing responses for concerning depressive symptoms. 
The participants writing responses were read as soon as they submitted them through the 
Qualtrics survey link. UBS was sent a notification whenever a participant submitted a 
response to their writing prompts. UBS then read the content for any statements that 
would be concerning, such as threat to harm themselves or others. Additionally, we also 
monitored the participants writing responses using the Linguistic Inquiry and Word 
Count (LIWC) software. The LIWC is composed of almost 4,500 words in different 
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categories. Below is an excerpt from the LIWC manual which gives details of the word 
categories of affective processes. The essays were monitored for negative emotion words. 
This helped us identify any concerning writing responses that may have been in the initial 
reading and monitoring.  Participants with writing responses containing several negative 
emotion words identified by the LIWC were read again. Any participant with concerning 
symptoms was referred to the research clinical social worker, who is part of this study, to 
assess if they were in need of any psychosocial support services.   
LIWC software word categories  
Process Abbrev Word examples No. of words Validity 
 
 
3. Information about support services.  Participants were provided with information 
about supportive care services from the start of the intervention (provided on the consent 
form) as well as they had the contact information available on their computer screens 
while writing. The following information was available on the screen of the participants 
on the survey link while they were performing their writing tasks.  
i) The screen of the writing task prompt had a hyperlink to the National Cancer Institute’s 
Support Services Locator, http://supportorgs.cancer.gov/ . The Toll-free phone 
number for NCI cancer support information was also be provided, 1-800-4-CANCER (1-
800-422-6237).  The NCI provides this service in English and Spanish, Monday through 
Friday, 8:00 a.m. to 8:00 p.m. ET. The NCI provides a comprehensive list of 
psychosocial and other supportive care services to meet the supportive care needs of 
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patients with cancer.  
ii) Additionally, the writing prompt screen also contained the toll-free phone number for the 
Cancer Information and Counseling Line, 1-800-525-3777. The Cancer Information 
and Counseling Line (CICL) is a free nationally recognized telephone counseling service 
that provides a range of psychosocial supportive services to patients anywhere along the 
cancer continuum, Monday – Friday, 8:30 a.m - 5 p.m. MT. CICL services range from 
providing emotional support to resource referrals and medical information for patients 
and caregivers affected by cancer. CICL counselors are master’s-level psychosocial 
professionals that offer brief, personalized and professional counseling over the phone. 
They can support and assist with managing feelings, resolving challenges related to 
having cancer and communicating with doctors and loved ones.  
iii) In case participants needed information at odd hours, the American Cancer Society 
(ACS) hotline was also provided to them, 1-800-227-2345, http://www.cancer.org/ . 
The ACS provides information and referral on various issues related to cancer treatment, 
services, literature, transportation, equipment, encouragement and support, 24 hours a 
day seven days a week at 1-800-227-2345.  
4. Referral plan in case of depressive symptoms. Although steps were put in place to 
prevent contacting clinically depressed patients, or receiving responses from depressed 
patients, the PHQ-2 was used to screen out patients who were in need of intensive mental 
health. All phone calls to the participants were made during regular business hours. 
Referral to Connie Macaluso, LCSW occurred in case the following scenarios take place.  
i) Participants at initial eligibility screening had scores 3 on the PHQ-2.   
 UBS offered to immediately conference call Connie Macaluso, LCSW at support 
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services at Massey Cancer center. Ms. Macaluso is trained in managing psychosocial 
needs of cancer patients and survivors. Ms. Macaluso is also trained in connecting 
patients with appropriate mental health services. UBS also offered to conference call 
Ms. Macaluso or intake and referral the VCU psychiatric services, to patients at any 
time during the intervention or course of the study. Contact information for VCU 
Department of psychiatry was made available to the participants along contact 
information with other supportive care services. (The Dept. of Psychiatry at VCU 
School of Medicine is available at (804) 828-2000 or (800) 232-0901 (Select option 2 
for appointments or Option 3 for admissions; and has a system of Intake and Referral 
Service that expeditiously screen, evaluate and admit clinically appropriate patients to 
the various inpatient teams.  
i) Participants who experienced depressive symptoms or needed any mental health services 
or support services during the intervention 
 UBS contacted the participants on Day 2 and Day 7 of the intervention to inquire how 
participants were doing in the intervention. The referral plan in case patients need 
additional support services were identical to that described above, and involved follow-
up by Connie Macaluso, LCSW. Participants were also informed about the possible 
support services they can use if they need assistance with any mental health problem. 
The participants were provided UBS’s contact information if any assistance is needed 
for them for using any supportive care services.  
A list of all support services provided by the NCI were given to the participants along 
with the informed consent forms, see Appendix I. Participants could make use of these services 
during as well as after the intervention. At the end of the intervention, i.e. at 6 weeks post-
  
79 
 
intervention, participants were asked if they used any of the support services they were informed 
about. Finally, participants had the contact information of UBS at all times and could contact 
him at any point during the intervention. Participants were informed of their choice of 
withdrawing from the study at any point in time. Participants were assured that no contact would 
be made with their employer, insurance provider or health care provider. Hence, several 
measures were taken to minimize potential risks to the participants in this study. The research 
team used rigorous procedures for assuring subject anonymity as described above and in the 
training of research staff. The risks to subjects were minimal compared to the benefits of the 
research. Participants were free to withdraw at any time. The study protocol is scheduled as per 
participants’ convenience.  By using computers and the internet, the participants could complete 
the writing tasks and provide data at their own comfort and convenience.  
Protection of Patient Privacy  
The following steps were taken to ensure the privacy of participants.  
1. UBS conducted all patient phone interactions, including recruitment and follow up 
calls, in a designated private office space.  Participants were reminded that their privacy would 
be maintained at all times. If we reached the participant’s voicemail during any phone 
interaction, no details about the study were mentioned. A voice message consisting of the name 
of RC and affiliated institution (i.e. VCU), along with a call back number was left.  
2. Participants were informed that their writing responses and data were stored in secured 
HIPPA compliant servers at all time. Participants were also assured that no communication 
would occur with their employer, insurance provider, or health care professional. All participants 
were informed about their privacy and confidentiality and their right to discontinue the study at 
any time. 
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3.  The surveys and writing responses were sent using Qualtrics. Qualtrics is web-based 
survey application that uses secure web authentication, data logging, and Secure Sockets Layer 
(SSL) encryption which ensures security and confidentiality. Qualtrics has SAS 70 Certification 
and meets the rigorous privacy standards imposed on health care records by the Health Insurance 
Portability and Accountability Act (HIPAA). All Qualtrics accounts are hidden behind 
passwords and all data is protected with real-time data replication. Qualtrics service meets the 
standards for security required by CFR 45.46 (Federal Guidelines for Human Research) and by 
VITA (Virginia Information Technology Agency).  
4. All salivette kits and mailing materials were affixed with the randomly generated 
participant ID number. This ensured that no salivary specimen could be linked back to the 
participant. Even the transportation containers for the salivary specimens had only the Participant 
ID numbers, and no other identifying information, in case of misplaced salivette tubes or 
containers.  
5. All email communication was conducted through UBS’s VCU email account that is 
secured by VCU Central Authentication Service, which is a centralized login system for Web 
applications at Virginia Commonwealth University. All data were stored in computers having 
firewalls and virus protection. The email communications were archived and downloaded and 
stored along with the study data. All these data will be destroyed within 3 years. 
6. The temperature controlled transportation container for the salivette kits was labeled 
with Participant ID number, no other identifying information was present on the transportation 
container, in case it is misplaced or damaged due to any unforeseen circumstances.  
7. A physical lock was placed on the Central Processing Unit (CPU) of the computers 
used for storing and accessing data, which secured the CPU to the physical location of the office, 
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and thus prevent loss due to theft or other circumstances. All stored data will be destroyed within 
3 years of completing the study.    
Data Safety and Monitoring Plan  
The data and safety monitoring plan included: i) data security procedures, ii) 
identification of adverse effects, iii) quality assurance activities and iv) investigator-initiated 
procedures for data and safety monitoring. 
Security Procedures for Transfer, Implementation and Storage of Data.  All computers 
used to collect and send data during implementation of the study or to receive or store data at the 
central location were password protected. Patient surveys and expressive writing were web-based 
and stored within a secure, dedicated server with appropriate firewalls. Servers were routinely 
scanned for viruses and systems were in-place to detect attempts at unauthorized entry. All 
phone interactions and online surveys were conducted from a central location therefore data 
transfer were not be necessary. 
Identification of Adverse Effects. The study staff  monitored all adverse events identified 
during implementation of the trial. Adverse effects were monitored through 1) reading the 
writing prompts after participants complete their writing task online, and 2) phone interactions 
with the patient on Day 2 and Day 7 of the protocol. UBS documented any adverse effects 
reported to them by the patient. The research team also met weekly as a team to discuss any 
potential for an adverse event. In addition, patients were given UBS’s direct telephone number so 
that any adverse events could be reported spontaneously by the subject.  Participants were also 
provided with contact information for a variety of supportive care services, which included a 
telephone counseling service for cancer patients and survivors.  
Quality Assurance Activities. UBS was available for questions on weekends and during 
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the evenings. If problems arose, the research team were instructed to call Utkarsh Subnis (UBS) 
or study mentor, Dr. Richard Brown (RFB). UBS was evaluated by the study mentor in areas 
such as the time management, inter-personal skills, participant recruitment procedures and how 
closely he adhered to set procedures such as checking call attempts. Booster training session 
were held as needed based on the quality assessment. Weekly meetings were held between the 
study mentor and UBS to address UBS’s concerns and give project updates, as well as role-play 
different possible scenarios. UBS was given memos on any new procedures or protocols when 
necessary. Private one-to-one meetings were held with the research team as needed. 
Investigator-Initiated Data and Safety Monitoring Plan. The research team for this study 
were responsible for oversight of the quality of the RCT. All violations of protocols were noted. 
If any adverse effects were reported or detected from the interventions, the study mentor was 
notified immediately. The study mentor and the study statistician determined if any portion of 
the protocol was violated and why and how such a violation may be related to the adverse event. 
A referral plan was is place in case of any inadvertent emotional harm due to study involvement 
was noted and the LCSW who was part of the research team had arranged to contact the study 
participant to determine safety of continuing in the study.   
Accrual to Study  
Study recruitment using both active and passive strategies was undertaken after receiving 
approval from the Institutional Review Board (IRB) of VCU. UBS and study mentor first 
contacted all the radiation oncologists at MCC by email. Most psychosocial interventions have 
been targeted towards surgical and chemotherapy patients, most commonly breast cancer. 
Therefore, we received acceptance and approval from all health professionals working in 
radiation therapy at MCC as anticipated. We identified N=372 patients in the cancer registries 
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through the VCUHS by mining data regarding cancer patients who have completed radiation 
treatments. We sent these 372 patients an initial contact letter and followed-up with them by 
phone. From these 372 patients, n=20 patients agreed to participate in our study, see figure 5. 
Reasons for the high refusal rates included 1) collection and provision of salivary data, 2) 
commitment of time since the study protocol involved four days of writing and three days of 
salivary data collection (three times a day), 3) mistrust with the government and collection of 
biological specimens, 4) disinterest in the study and 5) commitments to other research studies.  
   
After encountering low accrual from contacting participants by mail and following-up by 
phone, the research team decided to modify recruitment efforts. UBS liaised with multiple health 
professionals at the MCC, and VCI radiation oncology centers to advertise our study. UBS began 
following up with patients in the waiting rooms and follow-up consultations at MCC, downtown 
and Stony point cancer-care centers with patients who have completed their radiation treatments. 
This approach yielded another n=20 patients who agreed to participate in our study, see figure 5 
Figure 5: Recruitment procedures 
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of recruitment procedures. The EW meta-analysis described that 75% of EW studies reported 
less than 20% attrition rates128. Continued engagement with participants during and after the 4 
day writing tasks was maintained to retain participants in this study. During the study, frequent 
contact was made with study participants to determine if they were encountering any problems 
with the study protocol, salivary data collection or had any general questions.   
Data Analysis Plan 
      The unit of analysis in this study was the individual cancer survivor. Data were 
analyzed using the statistical software packages, SPSS186 and JMP187. The first step for analyzing 
the study data was examining the distribution of the data for normality and for descriptive 
statistics, which included measures of central tendency and dispersion, e.g. mean, standard 
deviation, standard error, for each variable measured in this study. To assess if the randomization 
was successful, initial analyses were conducted to detect any significant differences in the EW 
and control groups based on the data obtained at baseline, i.e. demographics, confounds and 
primary and secondary outcome measures. This consisted of t-tests for continuous variables (e.g. 
treatment dosage) and χ2 analyses for categorical variables (e.g. sex). Any variable significantly 
different in the two groups would be used as a covariate for further analytic procedures. 
Hypothesis testing was planned using the Multivariate Analysis of Variance 
(MANOVA), statistical test to determine differences between the EW and control writing groups 
based on the outcomes measures collected on Days 2, 7 and 49. Since this study design involves 
repeated measures, this type of data violates the analysis of variance’s (ANOVA) assumption of 
independence of measures, due to the correlations that occur among subsequent repeated 
measures. Therefore, a multivariate repeated measures analysis of variance (MANOVA) can 
model each of the mean stress measures over time separately for each group, and was considered 
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an appropriate statistical approach. 
Intent to Treat Analysis. Data related to recruitment, participation and drop-out rates 
were reported according to the guidelines given by the Consolidated Standards of Reporting 
Trials (CONSORT) statement188.  All participants that entered our study were included in our 
analyses and were retained in the arm (treatment or control) to which they were originally 
randomly allocated. Participants were included in our analyses, regardless of their alignment 
with the inclusion criteria, the treatment they received, and if they withdrew from the 
intervention protocol (attrition) completely or deviated from the protocol (non-adherence). 
Therefore this study had an intent to treat (ITT) analysis design188,189. However, RCTs 
commonly have participants who were non-adherent to the protocol, which must be accounted 
for, since non-adherence interferes with the integrity of the design and determining the efficacy 
of the intervention.    
Therefore this study also employed a modified intent-to-treat (MITT) approach, in which 
we included participants that received a minimum amount of the intervention and provided a 
minimum number of measures. The most recent meta-analysis of EW describes that participants 
who completed a minimum of two days of emotional disclosure were more likely to experience 
the effects of EW128. Also, previous studies of EW have excluded participant if they failed to 
give less than one post-intervention measure. Therefore, our MITT sample consisted of 
participants that completed at least two days of EW writing, and provided at least one post-
intervention measure (i.e. either at 24 hours or six weeks, post-intervention). Statistical analyses 
from both, the ITT and MITT samples were presented and described in our results. A plan for 
handling missing data was also essential due to the repeated-measures design of this study.  
    Management of missing data. A meticulous record of all missing data was kept, and 
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reported in the results as per suggested guidelines. The CONSORT statement states that no 
universally accepted strategies exist for dealing with missing data188; however there are some 
suggested guidelines. We adopted the systematic approach to manage missing data in trials190, 
which started with assessing the nature and mechanism of missingness. This involved 
determining if data were missing completely at random (MCAR), missing at random (MAR), or 
missing not at random (MNAR). Data were considered MCAR if data were missing for reasons 
that were not related to any inferences about intervention effects, e.g. saliva collection tube is 
lost for a measure, and is as likely to occur for every participant. MAR data is dependent on 
other variables in the study and the possibility of an association variable linking the probability 
of patient drop-out and the missing value, e.g. patients with a particular staging of cancer (e.g. 
Stage III) may not have responded well to EW and withdraw. The assumption for data 
considered MCAR and MAR is that missing cases were independent of the value of the 
unobserved (missing) data point.  
     Finally, data that were MNAR indicate a probabilistic relationship between the 
missing value and the time point at which it is missing, e.g. participants with lower levels of 
perceived stress (or negative emotion) at baseline may not experience the benefits of EW and not 
give the six month follow-up measure. Therefore, in data MNAR missing cases were dependent 
on the value of the unobserved (missing) data point, and cannot be ignored. To account for 
missing values, and approach called multiple imputations has gained considerable support from 
statisticians191. This approach allows for the uncertainty about the missing values by generating 
several different, plausible, imputed data sets (that replace the missing values with predicted or 
imputed values), and can appropriately combine results obtained from each data set191. In the 
systematic approach to managing missing data, all the investigators of this study first discussed 
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the possible mechanisms for missingness in the observed data set and rank their plausibility. 
Statistical models were generated based on the plausibility of missingness: 1) the most plausible 
missingness model, 2) similar missingness models and 3) least plausible missigness models. 
Statistical analyses were performed on data sets generated under the aforementioned categories 
and the investigators reconvened to discuss conclusions from the analyses and arrived at a valid 
interpretation of the data obtained for this study.     
    Manipulation check. In order to determine if our experimental manipulation of 
participants to the expressive writing and control writing conditions was successful, we analyzed 
participants writing responses for use of emotion words. The literature suggests that since EW 
encourages people to write their deepest thoughts and feelings, so EW participants typically use 
strong emotion words in their writing128. In this study, we expected to find that the EW group 
would use significantly more positive and negative emotion words in their writing tasks when 
compared to the control writing group. The Linguistic Inquiry and Word Count (LIWC) was 
used to analyze writing responses from both the EW group and control writing group on all 4 
days of the writing tasks. The LIWC estimates the level to which people use different types of 
words in a given text. The text from the writing responses of all participants was analyzed using 
the LIWC to assess the use of positive and negative emotion words. We used one-way analysis 
of variance (ANOVA) tests to assess for differences with regards to usage of positive emotion 
words (POS_EMO)  and negative emotion words (NEG_EMO) between the intervention and 
control groups for all fours days of the writing tasks (Days 3, 4, 5 and 6) during the intervention.  
Preparing salivary data for assay procedures. The salivary data collection process 
yielded a total of 357 saliva samples, with the exception of one participant (from a total N=40) 
on one day of data collection, each participant providing a total of 9 samples over three days of 
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data collection (Days 2, 7 and 49). However, resource constraints allowed for the assay testing of 
all three salivary analytes, namely cortisol, α-amylase and CRP for 120 (out of 357) salivary 
samples. We decided to use our limited resources parsimoniously and chose to analyze specific 
sets of saliva samples from our data. The primary end outcome for our study was salivary 
cortisol levels at Day 49 ( six weeks post-intervention). Cortisol is known to have changes in 
secretion patterns based on time of the day. Research has shown that different biological 
mechanisms may determine the cortisol response within the first 30 minutes of awakening, 
referred to as the cortisol awakening response (CAR) as opposed to average cortisol secretion 
over the entire day, determined by calculating area under the curve (AUC)162,192. Thus, all three 
salivary samples (W, P, B, or O) obtained on Day 49 were essential for statistical modeling of 
CAR and AUC of salivary cortisol, and were selected for assay procedures, see Table 10 below.  
Table 10: Salivary samples selected for assay procedures  
Assay Day 2 samples  Day 7 samples Day 49 samples 
Cortisol      
a-Amylase     
C-Reactive Protein     
Determining diurnal variations in secretion of salivary α-amylase and CRP were not 
critical to answer the study’s primary aim. Also, there is some research evidence indicating that 
levels of salivary α-amylase and salivary cortisol are correlated193,194. Thus we assumed that 
values of salivary α-amylase estimated at baseline and immediately post-intervention could serve 
as surrogate values for salivary cortisol as well. Therefore, only one salivary sample each (W) 
was assayed for secondary physiological outcome measures (salivary α-amylase and CRP) on all 
three days of data collection (Days, 2, 7 and 49), see Table 10.     
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O 
PID No. _______ 
W  P  B  O 
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  Assay procedure. All assay procedures were conducted in the Center for Biobehavioral 
Clinical Research laboratory in the VCU School of Nursing building located at 1100 East Leigh 
Street, Richmond, VA 23059-0567. The director of this laboratory,  Dr. Jamie Sturgill had been 
informed about this study and supervised the assay procedures. The first step for the assay 
procedure involved thawing the frozen samples and centrifuging them at 2500 rpm for 15 
minutes. The supernatant fluid available after thawing was used for assessment of cortisol and α-
amylase levels. The levels were assessed using an enzyme linked immune sorbent assay (ELISA) 
method for cortisol, α-amylase and CRP. At the conclusion of the assay procedures, the assay 
kits were disposed of using protocols currently in place and utilized by the Center for 
Biobehavioral Clinical Research Laboratory. Data values from the assay procedures were 
provided in excel sheets for every participant and were entered into the statistical software 
programs JMP and SPSS for statistical modeling and analyses.  
Transforming Physiological Data for Statistical Analysis 
    Determining AUC. Calculating AUC  is a regularly used method in endocrinology 
research for data obtained from repeated measurement of a hormone during the same day195. It 
allows for making meaningful comparisons of data between groups, and collapses data for 
physiological measures by giving a single average value for each day of measurement.  
Therefore, AUC also limits the number of statistical comparisons that need to be done between 
groups. AUC allows researchers to determine the intensity or magnitude of the physiological 
response (i.e. distance from the ground) to a stimulus or intervention, and also assess the 
sensitivity of that response (i.e. called change over time). The formula employed commonly in 
PNI research were used, called area under the curve with respect to ground (AUCg). The AUCg 
values for both groups were estimated using the trapezoidal formula195, see Figure 6. This is a 
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Figure 6: Trapezoidal formula for determining                            
AUCg and CAR of salivary cortisol 
trapezoidal formulas that breaks down cortisol secretion as areas of triangles and rectangles in 
the area under the curve for the 
measures taken at W, P and B on Day 
49. The AUCg accounts for all 
measures (W, P and B) i.e. the total 
area under the curve, and describes 
the magnitude of the average cortisol 
response over the entire day and was 
determined by summing all areas in 
the trapezoid (a1 + a2 + a3), see 
Figure 6. AUCg was calculated for 
Day 49 of data collection, and the 
AUCg values for the Day 49 measure were the primary end outcome measure for the analysis.   
Modeling CAR and diurnal cortisol slope. The CAR is the difference between the peak 
cortisol measure collected 30-45 min after waking up (P) and the measure collected immediately 
after waking up (W), i.e. P-W. Thus CAR is estimated in the similar way as AUC by estimating 
the triangle under the curve between the W and P measure (only a1), see Figure 6. CAR is 
considered to be mediated by different neurobiological mechanisms and is known to be relatively 
stable across time196. Next, the diurnal cortisol slope was determined which consisted of the rate 
of decline in cortisol levels across the day, i.e. wakeup to bedtime. Therefore slope for the simple 
regression equation that was anchored on the waking cortisol measure (W) and the end point is 
the bedtime measure (B) provided the diurnal cortisol slope (DCS) values for both groups. The 
CAR and diurnal cortisol slope for the 6 week measure (Day 49) were the end outcome. Next, all 
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three cortisol variables AUC, CAR and DCS were tested for normality of distribution. 
Hypothesis Testing 
We planned for using the multivariate analysis of variance (MANOVA) statistical test for 
testing all hypotheses since it accommodates the effects of repeated measurements. The 
MANOVA statistical formula used the variances of the groups (and not just the mean values, as 
in the case of t-tests) and provided F values within the degrees of freedom to determine if the 
hypotheses were significant, i.e. p<.05. Specific data analytic plan for each hypothesis is 
described below.  
Hypothesis one (H1). Neuro-hormonal response from the HPA axis to EW was the 
primary outcome of interest, and cortisol levels at 6 weeks post-intervention was the primary end 
outcome measure. Data included for testing the hypothesis were AUCg, CAR and DCS for 
cortisol at 6 weeks after the 4 day intervention. Since, baseline and immediate post-intervention 
data were not available for cortisol, analytic plan was modified to use independent sample t-test 
and one-way analysis of variance to test differences between the EW group and control writing 
group with respect to average values of AUCg, CAR and DCS on Day 49. Group differences for 
all cortisol values at Day 49 were planned to be reported with p-values.  
Hypothesis two (H2) and Hypothesis three (H3). Hypotheses 2 and 3 were regarding 
the values for secondary physiological outcomes (salivary α-amylase and CRP) at six weeks 
post-intervention. For H2 and H3, the MANOVA model had two predictor variables 
(intervention and control group) and three levels of the outcome variables (salivary α-amylase 
and CRP), namely 1) at baseline (Day 2), 2) immediate post-intervention outcomes (Day 7), and 
3) delayed post-intervention outcomes (Day 49). The MANOVA estimated differences between 
factors (the EW group and control writing group) based on all three levels of the secondary 
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physiological outcome variables (baseline, Day 7 and Day 49), with a significance level of α < 
0.05 that were reported with the F-value within the degrees of freedom and respective p-values. 
The MANOVA model also tested for differences within factors for the repeated outcome 
measures at all three time points (baseline, Day 7 and Day 49) to determine changes over time 
for salivary α-amylase and CRP.   
Hypothesis four (H4), Hypothesis five (H5), and Hypothesis six (H6). Hypotheses 4, 5 
and 6 were pertaining to the values for secondary psychosocial outcome measures (scores on the 
PSS, FCRI-S and CBI-B) at six weeks post-intervention. For H4, H5 and H6, the MANOVA 
model had two predictor variables (intervention and control group) and three levels of the 
outcome variables (PSS, FCRI-S and CBI-B), namely scores at 1) baseline (Day 2), 2) 
immediate post-intervention outcomes (Day 7), and 3) delayed post-intervention outcomes (Day 
49). The MANOVA estimated differences between factors (the EW group and control writing 
group) based on all three levels of the secondary psychosocial outcome variables (baseline, Day 
7 and Day 49), with a significance level of α < 0.05, that were reported with the F-value within 
the degrees of freedom and p-values. The MANOVA model also tested for differences within 
factors for the repeated outcome measures at all three time points (baseline, Day 7 and Day 49) 
to determine changes over time for PSS, FCRI-S and CBI-B scores.     
Hypothesis seven (H7). Testing H7 was not possible due to unavailability of baseline 
cortisol data.   
Hypothesis eight (H8). In the last hypothesis, H8, we wanted to assess the immediate 
post-intervention effects of expressive writing. The literature indicates that EW participants 
typically experience increased stress immediately after completing their writing tasks due to 
experiencing pent-up emotions137. Thus we expected to find increased stress in EW participants 
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immediately after the intervention (Day 7) with regards to their secondary physiological 
outcomes (salivary α-amylase and CRP; H8a) as well as their secondary psychosocial outcomes 
(PSS, FCRI-S and CBI-B scores; H8b). For H8, the MANOVA model had two predictor 
variables (intervention and control group) and two levels of the outcome variables (H8a: salivary 
α-amylase and CRP; H8b: PSS, FCRI-S and CBI-B scores), at 1) baseline (Day 2) and 2) 
immediate post-intervention outcomes (Day 7). The MANOVA estimated differences between 
factors (the EW group and control writing group) based on two levels of the secondary outcome 
variables (baseline and Day 7), with a significance level of α < 0.05, that were reported with the 
F-value within the degrees of freedom and p-values. The MANOVA model also tested for 
differences within factors for the repeated outcome measures at two time points (baseline and 
Day 7) to determine changes over time for all the secondary outcome measures.     
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Chapter VI. Results 
Results of this study are reported under two major sections, namely descriptive analyses 
and hypothesis testing. The measured variables for this study are reported under four categories 
which include 1) sample characteristics, 2) disease and treatment characteristics, 3) health related 
symptoms and behaviors and 4) outcome variables (primary and secondary).  
Descriptive Analyses  
Sample characteristics. The participants in this study had a mean age of 52.1 years 
(S.D., 14.74; range, 28 to 80 years) and were mostly white (29/40, 72.5%) women (25/40, 
62.5%) that were married (22/40, 55%), see Table 11. Most participants were privately insured 
(25/40, 62.5%), employed full time (24/40, 60%) with a four year college education or post-
graduate education (30/40, 75%) and were in the income range of $50,000 to $100,000 and 
above (20/40, 50%), see Table 11 for details of all sample characteristics.  
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Table 11: Sample characteristics 
Variable Name [Results of bivariate t-tests/ and chi-square 
test (2 ) between the EW and control groups]  
Intervention Grp (n=20) 
Count (% of Total) 
Control Grp (n=20) 
Count (% of Total) 
Total 
(% of Total) 
Gender [2 (1, N=40) = 0.107, p = .74]    
 Male 8 (20%) 7 (17.5%) 15 (37.5%) 
 Female 12 (30%) 13 (32.5%) 25 (62.5%) 
Marital Status [2 (3, N=40) = 5.82, p = .12]    
 Single 5 (12.5%) 1 (2.5%) 6 (15 %) 
 Divorced/separated 1 (2.5%) 5 (12.5%) 6 (15 %) 
 Married 11 (27.5%) 11 (27.5%) 22 (55%) 
 Living together with a partner 3 (7.5%) 3 (7.5%) 6 (15%) 
Race [2 (3, N=40)  = 3.534, p = .2]    
 White 14 (35%) 15 (37.5%) 29 (72.5%) 
 Black or African American 3 (7.5%) 5 (12.5%) 8 (20%) 
 Asian or Native Hawaiian or Pacific Islander 2 (5%) 0 2 (5%) 
Insurance type [2 (6, N=40) = 9.04, p = .06]     
 Private Health Insurance 12 (30%) 13 (32.5%) 25 (62.5%) 
 Medicare/Medicaid/ State-Sponsored Health Plan  6 (15%) 4 (10%) 10 (25%) 
 No Coverage of Any Type 2 (5%) 0 (0%) 2 (5%) 
Employment type [2 (5, N=40) = 1.8, p = .9]    
 Employed Full time 13 (32.5%) 11 (27.5%) 24 (60%) 
 Employed Part time / Self-employed 3 (7.5%) 5 (12.5%) 8 (20%) 
 Retired / Unable to work 3 (7.5%) 3 (7.5%) 6 (15%) 
Income [2 (4, N=40)  =  6.75, p = .1]    
 Up to $50,000 10 (25%) 8 (20%)  18 (45%) 
 $50,000 and above  10 25(%) 12 (30%) 22 (55%) 
Education [2 (3, N=40)  = 4.2, p = .24]    
 Grade 12 or GED  4 (10%) 1 (2.5%) 5 (12.5%) 
 College 1 year to 3 years 2 (5%) 3 (7.5%) 5 (12.5%) 
 College 4 years or more  14 (35%) 16 (40%) 30 (75%) 
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Disease and treatment characteristics. With regards to cancer site, about half the 
participants were diagnosed with breast cancer (21/40, 52.5%), and other cancer diagnoses 
included, prostate, lung, brain and bone cancer, see Table 12. In terms of cancer stage, majority 
participants reported having a Stage II diagnosis (20/40, 50%), see Table 12, and had completed 
their last radiation treatment about 6-8 months (22/40, 55%) prior to study enrollment.  
Table 12: Cancer Site, Stage and Treatment 
Variable Name [Results of bivariate chi-square 
tests (2 ) between EW and control groups] 
Intervention Grp 
(n=20) 
Count (% of Total) 
Control Grp 
(n=20) 
Count (% of Total) 
Total 
 
(% of Total) 
Cancer Site [2 (3, N=40) = 3.83, p = .43]    
 Breast 12  (30%) 9 (22.5%) 21 (52.5%) 
 Prostate 3 (7.5%) 2 (5 %) 5 (12.5%) 
 Lung 2 (5%) 1 (2.50%) 3 (7.5%) 
 Brain 1 (2.5%) 5 (12.50%) 6 (15%) 
 Other (Bone) 2 (5 %) 3 (7.50%) 5 (12.5%) 
Cancer Stage [2 (3, N=40) = 2.67, p = .26]    
 Stage I 6 (15%) 2 (5%) 8 (20%)  
 Stage II 10 (25%)  14 (35%) 24 (60%) 
 Stage III 4 (10%)  4 (10%) 8 (20%) 
Cancer Treatments     
 Radiation [2 (3, N=40) = 0] 20 (100%) 20 (100%) 40 (100%)  
 Chemotherapy [2 (3, N=40) = 0.17, p 
= .68]  
4 (10%) 3 (7.5%)  
 Surgery [2 (3, N=40) = 0.5, p = .49 7 (17.5%) 5 (12.5%)  
 
Health related symptoms and behaviors. Participants reported having social support 
(e.g. someone to help with daily chores) available to them a little of the time (mean =2.07, S.D. = 
0.75, scores ranging from 1 to 5). The average subjective social status (measured on a scale of 1-
10) of participants in this study was 5. 23 (S.D. = 1.05).  Participants were mainly non-smokers 
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(34/40, 85%) that reported consuming alcohol on a monthly basis or less (12/40, 52.5%). On 
average participants reported sleeping for 7.53 hours (SD=0.96) every day and having sleep 
related problems on some of the days (mean=2.04, SD=0.56). Participants reported being very 
comfortable using a computer (mean=1.18, 0.46), and on average used a computer almost 
weekly (mean=3.8, SD=1.56). Finally, participants reported using at least one type of CAM 
therapy once a month or less than once a month (mean=1.6, SD=0.6), please refer to Table 13.  
Table 13: Health-related symptoms and behaviors 
Variable Name [Results of bivariate t-tests and chi-
square tests (2 ) between the EW and control groups]  
Intervention Grp (n=20) 
Mean (SD) or  
Count (% of Total) 
Control Grp (n=20) 
Mean (SD) 
Count (% of Total) 
Cognitive Impairment (BSCI) [t (38) = -0.35, p = 
.73]  
3.7 (1.34) 3.55 (1.4) 
Depressive symptoms (PHQ2) [t (32.6) = -0.82, p = 
.42] 
1.1 (0.45) 0.95 (0.69) 
Social support (MOSS) [t (37.8) = -1006, p = .0]  2.2 (0.72) 1.95 (0.78) 
Perceived social status [t (38) = 1.056, p = .3]  5.05 (1.05) 5.4 (1.05) 
Smoking behaviors   
         Smoking- frequency  
               Daily [2 (1, N=40) = 1.03, p = .24] 
               Weekly [2 (1, N=40) = 1.03, p = .31] 
 
1 (4.47) 
5 (22.36) 
 
0 
0 
Alcohol consumption    
      Frequency [2 (3, N=40) = 9.11, p = .105]                         
                   Monthly or less 
 ≥2 to 4 times a month  
Prefer not to answer  
 
12 (20%) 
5 (12.5%) 
3 (7.5%) 
 
9 (22.5%) 
9 (22.5%) 
2 (5%) 
Sleep Related Behaviors    
       Sleep Hours [t (30.7) =  -2.65, p = .0125*] 7.9 (0.64) 7.15 (1.1) 
       Sleep Problems [t (38) =  -0.66, p = .514] 6.3 (1.72) 5.95 (1.64) 
Oral health – gum disease [2 (3, N=40) =  3.8, p = 
.3] 
                 Yes 
                  No 
                  Don’t know/PNTA 
 
2 (5%) 
12 (30%) 
6 (15%) 
 
0 (0%) 
10 (25%) 
10 (25%) 
CAM Use [t (37.4) = 1.24, p = .22] 8.85 (3.22) 10.2 (3.64) 
Comfort with using computers [t (36.051) = - 0.45, 
p = .66]  
3.65 (1.14) 3.45 (1.6) 
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Outcome variables (primary and secondary). Baseline data for the primary outcome 
measure cortisol was not available. The means (and S.D.) of measurements for all secondary 
baseline outcome variables is reported in Table 14.  
Table 14: Means of outcome variables (Baseline: Day 2)      
Variable Name [Results of t-tests 
between the EW and control groups]  
Intervention grp (n=20) 
mean (SD) 
Control grp (n= 20) 
mean (SD) 
Cortisol (pg/dl) [Data N/A] Data N/A Data N/A 
a-Amylase (U/ml) [t (38) = -1.58, p = .12] 1.16 (0.73) 0.793 (0.74) 
CRP (pg/dl) [t (36) =  0.16 , p = .87]  994.05 (455.12) 1020.70 (581.84) 
PSS [t (38) = -0.61, p = .55] 31.95 (5.32) 31.05 (3.89) 
FCRI-S [t (38) = 0.33, p = .74] 24.4 (3.62) 24.7500 (3.06) 
CBI-B [t (38) =   1.115, p = .27]  75.45 (6.67) 78.45 (10.013) 
 
Distribution and tests of normality. Study data pertaining to all variables in the study, 
sample characteristics, disease and treatment characteristics, health related symptoms and 
behaviors and outcome variables (primary and secondary) were analyzed for normality and 
outliers by using centered leverages and visual inspection of the data plotted on normal quantile 
plots. Outliers n=2 were found for CRP levels on Day 7 (z = 3.8) and Day 49 (z = 3.6) and were 
replaced with values 3 standard deviation above the mean. The Shapiro-Wilk test was used to 
assess if the data for all variables in the study were normally distributed. The Shapiro-Wilk 
goodness of fit test revealed that with the exception of cortisol, data for all variables in the study 
were normally distributed. All three variables related to salivary cortisol secretion on Day 49 did 
not follow a normal distribution, area under the curve (AUCg), W = 0.39, p<.0001, cortisol 
awakening response (CAR) W = 0.39, p<.0001 and Diurnal cortisol slope (DCS), W=0.81, 
p<.0001,  please see figures of normal quantile plots in Appendix O. Since our study’s primary 
aim was to determine EW’s efficacy to reduce stress in CS as measured by salivary cortisol, we 
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expected to find that cortisol data on Day 49 would be skewed.  
Success of Randomization  
Of the n = 40 participants that were enrolled in the study, n = 20 were randomized to the 
EW group, and n = 20 were randomized to the control writing group. In order to assess if the 
randomization procedures were successful, we tested for group differences between the EW 
group and control group with regards to all four categories of variables, 1) sample characteristics, 
2) disease and treatment characteristics, 3) health-related symptoms and behaviors and 4) 
baseline outcome variables. The first three categories of variables had variables measured as 
categorical as well as continuous, while baseline outcome measures were only continuous 
measures. Statistical comparisons between patients randomized to the expressive writing and 
control writing groups were made using t-tests for continuous measures and chi-square analyses 
for categorical measures. The null hypothesis ( H0 ) for these tests stated that there would be no 
differences between groups with regards to all four categories of variables. Results showed that 
with the exception of one variable related to sleep behaviors, the null hypothesis was retained for 
all variables in the study and there were no significant differences between the EW group and 
control writing groups at baseline, please refer to Tables 11 – 14.  
The only significant group difference at baseline was regarding sleep hours, see Table 13. 
Participants in the intervention group reported sleeping for an average of 7.9 hours (S.D. 0.641, 
SE 0.143, CI, 7.6, 8.2) and control group participants reported an average of 7.15 hours of sleep 
(S.D. 1.089, SE 0.243, CI 6.64, 7.66). Thus, intervention group participants reported sleeping 
approximately 0.75 hours (45 minutes) longer than the control writing group, t (38) = -2.654, p < 
.05. However, when participants were asked specific questions regarding sleep-related problems, 
such as difficulty falling asleep, difficulty staying asleep or problems waking up, no differences 
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emerged between the intervention and control groups. Therefore, the marginal difference in sleep 
hours between the two groups was not used as a covariate for further statistical analyses, and 
randomization was considered successful.  
Manipulation Check 
Experimental manipulation of participants to either the EW or control writing conditions 
was evaluated by assessing participants writing responses for use of positive and negative 
emotion words using the LIWC software. The average (mean and SD) use of positive emotion 
words for each group is described in Table 15, and the average (mean and SD) use of positive 
emotion words for each group is described in Table 16.  
Table 15: Means of LIWC Scores: Positive Emotion Words (POS_EMO)      
Intervention Day   Intervention grp  
mean (SD) 
Control grp  
mean (SD) 
Day 3 4.69 (0.96) 1.75 (0.41) 
Day 4 3.48 (0.97) 2.71 (1.13) 
Day 5 3.47 (1.29) 2.35 (1.09) 
Day 6 4.34 (0.91) 1.86 (0.67) 
 
Table 16: Means of LIWC Scores: Negative Emotion Words (NEG_EMO)     
Intervention Day   Intervention grp  
mean (SD) 
Control grp  
mean (SD) 
Day 3 3.8 (0.92) 1.94 (0.52) 
Day 4 3.44 (0.84) 2.32 (1.3) 
Day 5 3.41 (1.35) 2.2 (0.98) 
Day 6 4.91 (0.79) 1.97 (0.86) 
 
Results of the ANOVAs conducted to test for group differences regarding LIWC scores 
showed that participants in the EW group used significantly more positive emotion words 
compared to the control writing group, on three days of writing Day 3 [F (1, 38) = 157.4, p 
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<.0001], Day 4 [F (1, 37) = 6.4, p <.05] and Day 6 [F (1, 24) = 18.24, p <.0001]. Results also 
revealed that the EW group used  significantly more negative emotion words compared to the 
control writing group on Day 3, [F (1, 38) = 61.4, p <.0001], Day 4 [F (1, 37) = 11.93, p <.05] 
and Day 6. [F (1, 24) = 20.4, p <.0001], see Appendix P for mean difference plots for both 
groups with respect to LIWC scores. Only on one day, Day 5, there were no differences between 
the EW group and control writing group with regards to usage of either positive emotion words 
[F (1, 31) = 2.4, p =.13], or negative emotion words [F (1, 31) = 3.01, p <.1], see Appendix P for 
mean difference plots. Results of the differences in LIWC scores confirmed that the EW group 
overall used significantly more positive and negative emotions in their writing responses 
compared to the control writing group. Thus, we inferred that our experimental manipulation of 
participants was successful.  
Attrition Rates 
Overall participants in the study showed high rates of compliance with regards to 
completing the writing tasks as well as completing the outcome measures which included 
answering online survey questions and providing their saliva in Eppendorf tubes. All participants 
(n=40, 100%) provided information regarding demographics, disease and treatment information, 
health related symptoms and behaviors (Day 1) as well as baseline outcome measures (Day 2), 
see Figure 7. All participants completed their online post-intervention psychosocial outcome 
measures, i.e. immediate (Day 7) as well as the delayed 6 week post-intervention measure (Day 
49). Specific rates of attrition regarding writing tasks and salivary outcomes measures are 
described below.  
Writing tasks. With regards to their writing tasks all participants in both EW and control 
writing groups (N=40) completed the first day of writing. On the second day of writing only one 
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participant (n=1) in the control writing group did not complete their schedule writing task, all 
participants in the EW group completed their writing tasks. On the third day of the writing 
intervention, there were n=4 (10%) participants in the EW group and n=3 (7.5%) participants in 
the control writing who did not complete their writing tasks. Finally on the fourth and last day of 
writing, n=5 participants from the EW group and n=3 participants from the control writing group 
did not complete their writing tasks. Thus, almost all participants (n=39, 97.5%) completed at 
least two writing sessions, and majority of participants (n=33, 82.5%) completed at least three 
days of writing tasks. Thus participants demonstrated a satisfactory compliance with the writing 
interventions and both groups complete the minimum required two days of writing.   
The average time (and SD) that participants in each group took for completing their 
respective writing assignments are described in the Table 17 below. To assess for differences in  
Table 17: Mean time taken for writing tasks by both groups 
Day          n    Intervention grp   min (SD)            n   Control grp   min (SD) 
Day 3 20 28.4 (5.92) 20 29.34 (5.96) 
Day 4  20 33.98 (6.05) 19 31.77 (5.56) 
Day 5 16 32.35 (5.81) 17 29.91 (5.57) 
Day 6 15 33.53 (4.49) 11 31.75 (4.37) 
 
writing time between the EW group and control writing groups, we again used one-way analysis 
of variance (ANOVA) tests for all fours days of the writing tasks (Days 3, 4, 5 and 6) during the 
intervention. Results of the ANOVAs were unable to detect significant difference in the amount 
of time spent writing between participants in the EW group and participants in the control 
writing group on all four days of writing Day 3 [F (1, 38) = 0.25, p =.64], Day 4 [F (1, 37) = 1.4, 
p =.24],  Day 5 [F (1, 31) = 1.52, p=.23],  and Day 6 [F (1, 24) = 1.03, p =.32].  Thus participants 
in both groups of this study, the EW and control writing groups, contributed equal amount of 
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time for their writing tasks. 
Outcome measures: Salivary specimens. With regards to salivary specimens, all 
participants (n=40, 100%) provided baseline (Day 2) and immediate post-intervention (Day 7) 
measures. For the delayed 6 week post-intervention measure (Day 49) only one participant (n=1, 
2.5%) from the intervention group did not provide their salivary specimens. In terms of 
following the schedule for providing the three salivary specimens (waking, peak, bedtime and 
other), most participants (n=36, 90%) followed the instructions and provided samples marked at 
waking (W), peak (P) and bedtime (B). There were n=2 (5%) participants (n=1 from the EW 
group and n=1 from the control group) that provided samples marked as Other (O) for their Day 
7 measure. Finally, n=1 participant from the EW group provided two samples marked as peak 
(P) on their Day 49 measure; one peak (P) sample was considered as Other (O) for data analysis. 
Overall, participants showed very low attrition with regards to completing the salivary outcome 
measures, see Figure 7. 
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Figure 7: Randomization flow chart of activities completed by participants 
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Statistical Tests  
Statistical tests on cortisol levels (AUCg, CAR and DCS) on Day 49 revealed that data 
were not normally distributed. Therefore, in order to compare the EW and control writing groups 
with data having a non-normal distribution, the nonparametric Mann-Whitney statistical test was 
chosen. The Mann-Whitney U test was used to compare mean ranks of AUCg, CAR and DCS 
between the EW and control writing groups and results for hypothesis one are reported under 
each respective cortisol variable. However t-tests were also conducted to compare results of both 
non-parametric (Mann-Whitney) and parametric (t-test) tests.  
Mann-Whitney (U) test. The Mann-Whitney U test is employed when comparing 
differences between two independent groups when the outcome variable is measured as ordinal 
or continuous, but is not normally distributed. The Mann-Whitney U test ranks all the values in 
both groups from low to high, and then compares the mean ranks. Specifically, the Mann-
Whitney U test assesses, what is the likelihood that a randomly selected value from the group 
with the higher mean rank will be greater than a randomly selected value from the other group. 
The null hypothesis (H0) of the Mann-Whitney test posits that there will be no difference in the 
ranks of the two groups. A significant P value indicates that the null hypothesis is rejected and 
the mean rank of the one group is lower than the mean rank of the comparison group (here EW 
group vs control writing group).  
However, there are three assumptions that have to be met when using the Mann-Whitney 
U test. The first assumption is that the outcome variable(s) must be measured at the continuous 
or ordinal level. This assumption is met by the study data, since cortisol concentration was 
measured as a continuous variable in units of pictograms/deciliter (pg/dl) in saliva. The second 
assumption is that the predictor variable must consist of two categorical, independent groups. 
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This assumption is also met by the study data, since this study is a randomized trial, the 
intervention and control groups are the categorical, independent groups operating as predictor 
variables. Finally, the last assumption requires the independence of observations, which means 
that there must be no relationship between the observations of the predictor variables or between 
the groups themselves. This means that the Mann-Whitney U test requires that there must be 
different participants in each group with no participant being in more than one group. Study data 
meet the last assumption as well, as randomization procedures ensured that participants had an 
equal chance of being assigned to either the intervention or control group at the start of the study.  
General Linear Model (GLM).  For hypothesis testing with respect to the secondary 
outcome variables, a General Linear Model accounting for repeated measures was selected. The 
study design for this research project consisted of two predictor variables (EW and control 
writing groups) and five outcome variables (amylase, CRP, PSS, FCRIS and CBIB) that were 
repeatedly measured at three time points (Days 2, 7 and 49). For this multivariate repeated 
measures design, the General Linear Model (GLM) test was selected to compare the two 
predictor variables, the intervention (EW) group and control (control writing) group, on each of 
the five outcome variables measured at baseline (Day 2), immediately after the writing tasks 
(Day 7) and a six weeks after the writing tasks (Day 49). The General Linear Model (GLM) test 
accounts for the variance that occurs in measures that are collected repeatedly over time as well 
as accounts for unequal n in predictor variables. The null hypothesis (H0) of the GLM test posits 
that there will be no difference in the predictor variables with regards to the outcome variables of 
two groups. A significant P value in the GLM indicates that the null hypothesis is rejected and 
the mean of one group is lower than the mean of the comparison group (here EW group vs 
control writing group) with a respective effect size statistic (partial eta squared).  
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The GLM for this study assumed independence of observations data and normal 
distribution of data for all secondary outcome variables, physiological and psychosocial. 
Random allocation ensured that no participant completed both writing tasks and thus provided  
independent observations. The second assumption of the GLM was that the data for observations 
on the outcome variables had a multivariate normal distribution, which can decrease the chances 
of encountering Type I error. The multivariate normal distribution was assessed by reviewing the 
normal quantile plots for each variable, please see Appendix O. The graphs for all five outcome 
variables displayed an elliptical shape that is characteristic of normal distribution for each 
respective variable. Based on the results of these analyses, a multivariate normal distribution was 
assumed. The GLM also allows for groups to be unequal, since our final sample had unequal 
numbers of participants (Intervention (EW) group: n=19; Control (Control writing) group: 
n=20). The GLM allows for testing differences both within and between predictor groups. The 
GLM was used for primarily testing differences between the predictor variables (Intervention 
(EW) group, Control (Control writing) group) with respect to all secondary outcome variables 
involving hypotheses two through eight.   
Hypotheses Testing 
Hypothesis one. Hypothesis one was related to the primary outcome measure for this 
study which was cortisol. Research evidence indicates that salivary cortisol is a reliable measure 
of the HPA axis activity in human physiological stress response. In hypothesis one we expected 
that cancer survivors who participated in the expressive writing (EW group) stress-management 
intervention will have lower levels of salivary cortisol at 6 weeks post-intervention (Day 49) 
when compared with cancer survivors who participated in control-writing (control group). The 
first step in testing hypothesis one was to extrapolate the amount and rate of cortisol secretion 
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from the raw data cortisol data. This step involved determining the area under the curve (AUCg), 
cortisol awakening response (CAR) and diurnal cortisol slope (DCS) as described in the 
methods. The median values for AUCg, CAR and DCS for both groups is reported in Table 18.  
Table 18: Median values of cortisol variables on Day 49  
Day Intervention group (n=19) 
median (IQR) 
Control group (n= 20) 
median (IQR) 
AUCg 0.32 (0.18, 0.91) 0.98 (0.36, 4.58)  
CAR  0.013 (0.01, 0.03) 0.04 (0.02, 0.2)  
DCS 0.001 (-0.004, 0.004) -0.003 (-0.01, 0.005)  
 
Cortisol: Area Under the Curve (AUCg).  The AUCg estimation described that the EW 
group had a median secretion of 0.32 (IQR= 0.18, 0.91) pg/dl of cortisol over the course of a 14 
hour day (Day 49), while the control group secreted a median of 0.98 (IQR = 0.36, 4.58)  pg/dl 
of cortisol over the course of a 14 hour day (Day 49). The Mann-Whitney mean ranks of AUCg 
values for both groups are reported in the Table 19 below.   
Table 19: Mann Whitney Ranks for AUCg (Day 49) 
 Intervention group (n=19) Control group (n=20) 
Mean Rank  14.95 24.80 
Expected Ranks 380 400 
Sum of Ranks 284 496 
 
The results for the Mann-Whitney-Wilcoxon test for AUCg showed a statistically significant 
difference between AUCg values of the EW group and control writing groups for the 6 week 
post-intervention measure and the null hypothesis was rejected. On Day 49 the EW group 
participants had significantly lower AUCg values compared with the control group participants, 
U=94, p=0.006, r=0.432, see Figure 8. A t-test also confirmed that the mean AUCg values of the 
EW group participants were significantly lower than control group participants, t (37) = 2.2, 
p<.05 at Day 49.  
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Cortisol: Cortisol Awakening Response (CAR).  CAR evaluation described that over a 
period of half an hour (from waking to peak) on Day 49, the EW group secreted a median of 
0.013 (IQR = 0.01, 0.03) pg/dl of cortisol and the control writing group had a median secretion 
0.04 (IQR = 0.02, 0.2) pg/dl of cortisol. The Day 49 Mann Whitney mean ranks of CAR values 
for both groups are reported in Table 20 below.  
Table 20: Mann Whitney Ranks for CAR (Day 49) 
 Intervention group (n=19) Control group (n=20) 
Mean Rank  14.79 24.95 
Expected Ranks 380 400 
Sum of Ranks 281 499 
 
Parallel to the results for AUCg, the Mann-Whitney U test for CAR on Day 49 also reported a 
statistically significant difference between the CAR of EW participants and control writing 
participants. On the 6 week post-intervention measure the intervention group participants had 
significantly lower CAR values compared with the control group participants, U=91, p=0.005, 
Figure 8: Group differences for cortisol AUCg values at Day 49 
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r=0.45, see Figure 9 below. Similarly, a t-test confirmed that the mean CAR values of the EW 
group participants were significantly lower than control group participants, t (37) = 2.2, p<.05.  
  
 
Cortisol: Diurnal Cortisol Slope. The median DCS for the treatment arm was 0.001 (IQR 
= -0.004, 0.004) and the control arm median DCS was -0.003 (IQR = -0.01, 0.005). The Day 49 
Mann-Whitney mean ranks of CAR values for both groups are reported in Table 21 below.   
Table 21: Mann Whitney Ranks for DCS (Day 49)  
 Intervention group (n=19) Control group (n=20) 
Mean Rank  21.74 18.35 
Expected Ranks 380 400 
Sum of Ranks 367 413 
 
With regards to DCS the null hypothesis (H0) for the Mann-Whitney U test for CAR on Day 49 
was retained and no statistically significant differences were found between the DCS values of 
EW group participants and control group participants. On the 6 week post-intervention measure 
the EW group participants had similar DCS values compared with the control group participants, 
Figure 9: Group differences for CAR values at Day 49 
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U = 157, p=0.365, r=0.15, please see Figure 10 below. A t-test also confirmed that the mean 
DCS values of the EW group participants were similar to the DCS values of control group 
participants, t (37) = -.7, p=0.5.  
 
 
The lack of baseline outcome measures and immediate post-intervention outcome 
measures for cortisol limits the inferences that can be made from the data for hypothesis one. For 
example, we could not estimate if control group participants had higher levels of cortisol than 
EW group participants at baseline before the intervention. Nevertheless, randomization was 
successful with all other variables in this study, including salivary α-amylase (sAA) and research 
indicates to a correlation between levels of cortisol and sAA in healthy subjects as well as 
clinical populations193,194. Thus we can assume that cortisol levels were not significantly 
different at the start of the study. A post-hoc power analysis using Gpower showed that we had 
89% power (β) to detect differences between intervention and control groups (N=39, α=0.05) 
using the Mann-Whitney U test (effect size of r=0.43; d=0.96).  
Hypothesis two. A novel aspect of this study was that in addition to measuring outcomes 
Figure 10: Group differences for DCS values at Day 49 
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of the HPA axis (salivary cortisol), we also measured the SNS (salivary α-amylase). The second 
hypothesis of this study stated that CS participating in EW (intervention arm) would have lower 
levels of salivary α-amylase (sAA) when compared to CS participating in control-writing 
(control arm) at 6 weeks post-intervention  The mean sAA levels for both groups on all three 
days of data collection are presented in the Table 22 below. 
Table 22: Mean salivary a-Amylase levels (Days 2, 7 and 49) 
Day     n      Intervention group U/ml (SD)     n           Control group U/ml (SD) 
Day 2 20 1.15965 (0.73) 20 0.7928 (0.74) 
Day 7  20 1.52910 (0.75) 20 0.89695 (0.83) 
Day 49 19 1.53242 (0.64) 20 0.9388 (0.82) 
 
The GLM findings for hypothesis two did not support our anticipated results of lower sAA in 
EW group compared to the control group. Instead we found that the EW group had higher levels 
of sAA compared to the control group, F (1, 37) = 8.117, p<0.05, partial eta-squared (ηp2 ) = 
.180, at six weeks post-intervention. However, it is important to note that baseline sAA was 
higher in the EW group compared to the control group. There was a significant effect of time on 
the sAA concentration, with an increase in AA on Day 7 and then a plateauing of sAA 
concentration by Day 49, F (2, 36) = 4.145, p<0.05, ηp2 = .178, please see Figure 11. 
 
 
Figure 11: Changes over time for salivary α-amylase (AA) in both 
groups over the six week intervention 
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Hypothesis three: Another aim of this study was to investigate the effects of EW on 
immune function. CRP was the chosen outcome measure of immune function. The third 
hypothesis of this study stated that at 6 weeks post-intervention CS participating in EW 
(treatment arm) will have lower levels of salivary CRP when compared with CS participating in 
control-writing (control arm). The mean CRP levels for all three days of data collection (Day 2, 7 
and 49 for both groups are presented in the Table 23 below.  
Table 23: Mean salivary CRP levels (Days 2, 7 and 49)  
Day       n     Intervention group pg/dl (SD)      n          Control group pg/dl (SD) 
Day 2 20 994.05 (455.12) 20 1020.70 (581.84) 
Day 7  20 1164.73 (571.38) 20 1049.17 (575.99) 
Day 49 19 986.73 (383.86) 20 1012.59 (383.86) 
 
The GLM for hypothesis three revealed no significant differences in CRP levels between 
intervention and control group participants on Day 49 of the intervention, F (1, 37) = 0.009, p = 
0.927, ηp2 = .0, see Figure 12. The data also indicates that there was no impact of time on CRP 
levels for both groups, F (2, 36) = 1.877, p=0.168, ηp2 = .094, see Figure 12.    
 
 
Hypothesis four.  Hypothesis four was related to the psychosocial outcome measure of 
perceived stress as measured by the perceived stress scale (PSS). The mean PSS scores for both 
Figure 12: Changes over time for salivary CRP in both groups over the 
six week intervention 
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groups on all three days of data collection are presented in the Table 24 below.  
Table 24: Mean PSS scores  (Days 2, 7 and 49) 
Day Intervention group (n=20) 
mean (SD) 
Control group (n= 20) 
mean (SD) 
Day 2 31.95 (5.32) 31.05 (3.89) 
Day 7  36.1 (2.69) 35.65 (2.6) 
Day 49 23.9 (1.97) 24.1 (1.99) 
 
Hypothesis four stated that CS in the EW group will have lower perceived stress indicated by 
lower scores on the PSS at 6 weeks post-intervention compared to CS in the control group. The 
results of the GLM for hypothesis four revealed no statistically significant results for group 
differences in PSS scores on Day 49 F (1, 38) = 0.48, p=0.495, ηp2 = .012 , see Figure 13. 
However the data did reveal a significant effect of time for PSS scores in both groups, F (2, 37) = 
254.74, p<0.0001, ηp2 = .932. There was an increase in perceived stress immediately after the 
intervention (Day 7) and a significant decrease in perceived stress for both groups at 6 weeks 
post-intervention, please see Figure 13 below.  
 
 
 
Hypothesis five. One critical aim of this study was to test if EW is effective in emotion 
regulation by actually measuring levels of a relevant emotion for CS, which was fear of cancer 
Figure 13: Changes over time for PSS scores in both groups over the 
six week intervention 
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recurrence over time. The fear of cancer recurrence inventory – severity (FCRI-S) subscale was 
used to measure fear of cancer recurrence in the participants of this study. The mean FCRI-S 
scores for both groups on all three days of data collection are presented in the Table 25 below. 
Table 25: Mean FCRI-S scores  (Days 2, 7 and 49) 
Day Intervention group (n=20) 
mean (SD) 
Control group (n= 20) 
mean (SD) 
Day 2 24.4 (3.62) 24.7500 (3.06) 
Day 7  31.35 (2.37) 30.85 (3.2) 
Day 49 18.2 (2.4) 24.7 (5.2) 
 
Hypothesis five stated that on Day 49 (6 weeks post-intervention) CS participating in EW will 
have lower scores on the FCRI-S compared to CS participating in control-writing. The GLM test 
for hypothesis five demonstrated that fear of cancer recurrence was significantly reduced in the 
EW participants when compared to the control group participants, F (1, 38) = 9.654, p=0.004, ηp2 
= .993, at six weeks post-intervention (Day 49), see Figure 14 below. The data also showed that 
FCRI-S scores changes significantly with time for both groups, F (2, 37) = 97.06, p<0.0001, ηp2 
= .84, where both groups reported increases in FCRI-S scores immediately after the writing 
intervention (Day 7), followed by a significant decrease on Day 49, which was more pronounced 
for the EW group, please see Figure 14 below.  
 Figure 14: Changes over time for FCRIS scores in both groups over the 
six week intervention  
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Hypothesis six. An important way in which EW benefits participants is by boosting 
participants self-efficacy to cope with stressful experiences and stressful life events. Participants 
in this study completed a measure of their self-efficacy to cope with cancer called the cancer 
behavior inventory – brief version (CBI-B). The mean CBI-B scores for both groups on all three 
days of data collection are presented in the Table 26 below. 
Table 26: Mean CBIB scores  (Days 2, 7 and 49)  
Day Intervention group (n=20) 
mean (SD) 
Control group (n= 20) 
mean (SD) 
Day 2 75.45 (6.67) 78.45 (10.013) 
Day 7  72.2 (3.43) 71.05 (3.17) 
Day 49 96.7 (6.26) 89.4 (8.52) 
 
In hypothesis six we anticipated that CS who participated in EW will have greater self-efficacy 
to cope with cancer measured by higher scores on the CBI-B at 6 weeks post-intervention (Day 
49) when compared to CS participating in control-writing. The GLM test for hypothesis six 
showed no significant overall group differences between the EW group and control group 
participants for CBI-B scores, F (1, 38) =  2.765, p = 0.11, ηp2 = .068 on Day 49., see Figure 15. 
However, there was a significant effect of time on CBI-B scores for both groups, with a decrease 
in CBI-B scores immediately after the intervention (Day 7) and a significant increase in CBI-B 
scores on Day 49, F (2, 37) =118.115, p<0.0001, ηp2 = .865, see Figure 15.   
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Hypothesis seven. Hypothesis seven was related to cortisol levels immediately after the 
intervention. Based on the literature, we expected an increase in stress immediately post-
intervention (Day7). Hypothesis seven posited that CS participating in EW (treatment arm) 
would have higher levels of salivary cortisol, compared to CS participating in control-writing 
(control arm) at 24 hours post-intervention (Day 7). Hypothesis seven was not testable due to 
unavailability of data pertaining to cortisol for Baseline (Day 2) and immediately post-
intervention (Day 7) due to resource constraints.   
Hypothesis eight. An important aspect of this research study was that we wanted to 
establish the differential impact of EW on stress outcomes over time. The research literature 
related to EW suggests that there is an initial increase in stress since individuals to confronting 
pent-up emotions related to the stressful experiences and stressful life events. We wanted to 
demonstrate this by seeing how EW impacts stress outcomes immediately after the intervention. 
In hypothesis eight we expected an increase in stress immediately post-intervention (Day 7) as 
measured by physiological outcomes a-amylase, CRP (Hypothesis 8a) as well as by psychosocial 
outcomes PSS, FCRI-S, CBI-B (Hypothesis 8b) 
Hypothesis 8a: α-amylase. In hypothesis 8a we anticipated that salivary α-amylase  
(sAA) levels measured at 24 hours post-intervention (Day 7) will be higher in the EW group 
Figure 15: Changes over time for CBIB scores in both groups over the six week intervention 
levels 
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participants  compared to CS participating in control-writing (control group). The mean sAA 
levels for both groups on days 2 and 7 of data collection are presented in Table 27 below. 
Table 27: Mean a-Amylase levels  (Days 2 and 7) 
Day Intervention group (n=20) 
mean sAA U/ml (SD) 
Control group (n=20) 
mean sAA U/ml (SD) 
Day 2 1.15965 (0.73) 0.7928 (0.74) 
Day 7  1.52910 (0.75) 0.89695 (0.83) 
 
Data indicated that baseline levels of sAA were higher in the EW group compared to the control 
group. The GLM for hypothesis 8a showed that α-amylase levels were higher in the EW group 
participants at Day 7 compared to the control writing group participants, F (1, 38) = 4.84, 
p=0.034, ηp2 = .113, see Figure 16. However, this result could be attributed to preexisting higher 
levels of sAA in the EW group. A significant effect of time was also detected for α-amylase 
levels in both groups, and α-amylase secretion increased on 24 hours post-intervention (Day 7) 
as compared with their baseline (Day 2) levels, F (1,38)=8.145, p=0.007, ηp2 = .177, refer to 
Figure 16.  
    
Hypothesis 8a: CRP. In hypothesis 8a we also expected that increased stress immediately 
post-intervention would impact immune function by increasing inflammation in CS in the EW 
group and will result in higher levels of salivary CRP at 24 hours post-intervention (Day 7). The 
Figure 16: Immediate post-intervention effects for salivary α-amylase (AA) levels   
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mean CRP levels for both groups on days 2 and 7 of data collection are presented in Table 28.  
Table 28: Mean CRP levels  (Days 2 and 7) 
Day Intervention group (n=20) 
mean CRP pg/dl (SD) 
Intervention group (n=20) 
mean CRP pg/dl (SD) 
Day 2 994.05 (455.12) 1020.70 (581.84) 
Day 7  1164.73 (571.38) 1049.17 (575.99) 
 
Hypothesis 8a postulated that CRP levels at 24 hours post-intervention (Day 7) would be higher 
in EW group participants when compared with CS participating in control-writing (control 
group). The GLM for hypothesis 8a showed no significant difference in CRP levels between the 
EW and control group participants at 24 hours post-intervention Day 7, F (1, 38) = 0.083, 
p=0.775, ηp2 = .002, see Figure 17. Results of the GLM also revealed that there was no impact of 
time on CRP levels for both groups at 24 hours post-intervention (Day 7), F (1, 38) =1.561, 
p=0.22, ηp2 = .039, with both groups remaining close to their baseline CRP levels, see Figure 17.    
 
Hypothesis 8b: PSS. The second aspect of hypothesis eight was related to the 
psychosocial outcome measures. The first of the psychosocial outcomes was perceived stress 
measured by the PSS. The mean PSS scores for both groups on days 2 and 7 of data collection 
are presented in the Table 29 below. 
Figure 17: Immediate post-intervention effects for salivary CRP levels 
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Table 29: Mean PSS scores (Days 2 and 7)  
Day Intervention group (n=20) 
mean (SD) 
Control group (n= 20) 
mean (SD) 
Day 2 31.95 (5.32) 31.05 (3.89) 
Day 7  36.1 (2.69) 35.65 (2.6) 
 
We anticipated an increase in perceived stress measured by the PSS in CS that participated in 
EW (EW group) compared to CS participating in control-writing (control group) at 24 hours 
post-intervention (Day 7). Results of the GLM test indicated no significant differences between 
the two groups with regards to PSS scores on Day 7, 24 hours post-intervention, F (1, 38) = 0.64, 
p=0.43, ηp2 = .017, see Figure 18. However, the GLM did demonstrate that in both groups there 
was a significant increase in PSS scores from baseline (Day 2) to 24 hours post-intervention 
(Day 7), F (1, 38) = 26.56, p<0.0001, ηp2 = .411, please see Figure 18.   
 
Hypothesis 8b: FCRI-S.  The second psychosocial outcome measure in hypothesis eight 
was fear of cancer recurrence. The mean FCRI-S scores for both groups on days 2 and 7 of data 
collection are presented in the Table 30 below. In hypothesis 8b we expected an increase in fear 
of cancer recurrence (measured by FCRI-S) immediately after the expressive writing 
intervention (Day 7). Hypothesis 8b also postulated that FCRI-S scores at 24 hours post-
Figure 18: Immediate post-intervention effects for PSS scores 
  
121 
 
intervention (Day 7) would be higher in EW group participants compared to CS participating in 
control-writing (control group). 
Table 30: Mean FCRI-S scores (Days 2 and 7) 
Day Intervention group (n=20) 
mean (SD) 
Control group (n= 20) 
mean (SD) 
Day 2 24.4 (3.62) 24.7500 (3.06) 
Day 7  31.35 (2.37) 30.85 (3.2) 
 
The GLM for FCRI-S scores at 24 hours post-intervention  (Day 7) also reported that there were 
no significant differences between the two groups, F (1, 38) = 0.011, p=0.92, ηp2  = .92, see 
Figure 19. Though, the GLM did describe that both the EW and control groups reported a 
significant increase in fear of cancer recurrence after the writing tasks, indicated by higher FCRI-
S scores on Day 7 in comparison their baseline FCRI-S scores (Day 2) values, F (1, 38) = 100.1, 
p<0.0001, ηp2 = .725, please see Figure 19 below.     
 
Hypothesis 8b: CBIB.  Finally, the last psychosocial outcome was self-efficacy with 
coping with cancer measured by the CBI-B. In this hypothesis 8b, we expected to find a decrease 
in self-efficacy with coping immediately after the intervention due to the stress-induced from the 
EW. The mean scores for CBI-B for baseline (Day 2 ) and immediate post-intervention (Day 7) 
are reported in the Table 31 below.  
Figure 19: Immediate post-intervention effects for FCRIS scores 
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Table 31: Mean CBIB scores (Days 2 and 7)   
Day Intervention group (n=20) 
mean (SD) 
Control group (n= 20) 
mean (SD) 
Day 2 75.45 (6.67) 78.45 (10.013) 
Day 7  72.2 (3.43) 71.05 (3.17) 
 
In hypothesis 8b we anticipated  that EW participants (EW group) will have lower CBI-B scores 
compared to control-writing participants (control group) at 24 hours post-intervention (Day 7). 
The GLM test for this hypothesis also did not find any significant group differences with regards 
to CBI-B scores immediately after the intervention (Day 7), F (1, 38) = 0.42, p=0.522, ηp2 = 
0.011, see Figure 20. However, both groups showed a significant decrease in CBI-B over time, 
i.e. from baseline to immediately post-intervention, F (1, 38) = 13.42, p=.001, ηp2 = .261, see 
Figure 20 below.  
 
 
Figure 20: Immediate post-intervention effects for CBIB scores  
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Chapter VII. Discussion 
Chronic stress has been implicated in an array of negative impacts on the physical and 
mental health of individuals and is especially relevant to the cancer patients transitioning from 
completing their treatments to reassuming their roles in their family and work environments, 
defined as cancer survivors in this study. We conducted a two-arm randomized controlled trial 
(RCT) to determine the efficacy of expressive writing as a stress-management intervention for 
cancer survivors who were 2-12 months post-radiation treatment completion. The theoretical 
framework for this study was psychoneuroimmunology (PNI), which guided our choice of health 
outcome measures, that included salivary biomarkers of the neuroendocrine and immune systems 
as well as psychometric measures of psychosocial function. The results of this study revealed 
that expressive writing was effective in regulating stress over a period of six weeks in our 
samples of cancer survivors. Expressive writing (EW) is a very brief and inexpensive 
psychosocial intervention that can help manage stress in cancer survivors (CS). Results from this 
study have important implications for theory, practice and future research with regards to PNI-
based psychosocial interventions such as EW in the growing population of CS worldwide.  
Aims and Hypotheses 
This research study had five major aims and eight related hypotheses. The first three aims 
of this study were related to determining the delayed neuroendocrine and immune effects of EW 
for our sample of cancer survivors (CS) which were measured six weeks post-intervention (Day 
49). The fourth aim was to determine the delayed impact of EW on the psychosocial outcomes of 
CS which were measured six weeks post-intervention (Day 49). The last aim of this study was to 
investigate the immediate post-intervention psychobiological effects of EW on CS which were 
measured immediately post-intervention (Day 7).    
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 Aim one: Hypothesis one. The first aim of this study was to determine the effectiveness 
of EW to regulate stress in cancer survivors as measured by salivary cortisol levels which was 
the biomarker chosen to indicate HPA axis activity and the primary outcome for this study. In 
the first hypothesis we expected to find that CS that completed EW would have lower levels of 
salivary cortisol compared with CS that completed control writing when measured six weeks 
after completing the writing intervention. The EW literature indicates that EW’s beneficial health 
impacts take effect after a period of approximately 6-8 weeks post-intervention126. During the 6-
8 week period after completing their EW writing tasks, participants process the negative 
emotions and stressful experiences brought to their attention by EW as well as experience 
desensitization from repeated exposures to their emotions128. This emotion processing helps 
decrease arousal of the HPA axis and subsequent regulation of neuro-hormonal physiological 
stress responses of EW participants137. Results from our study demonstrated that EW 
successfully affected the HPA axis of CS in our sample as shown by significantly lower levels of 
salivary average cortisol secretion (area under the curve, AUC) and cortisol awakening response 
(CAR) in the EW group CS compared to CS in the control writing group at six weeks post-
intervention.  
Furthermore, results from this study report medium to large effect sizes (ES) for our 
online EW intervention with regards to our primary outcome variable, salivary cortisol (r=0.43 
for AUC; r=0.45 for CAR) in a sample of CS post-radiation. The ES obtained in this study are 
equal to and even greater than those reported in the three key meta-analyses of EW interventions 
that we used for our sample size and power calculation (r=0.21 in healthy samples126, r=0.1 in 
clinical samples127 and r=0.075 based on wide ranging group of EW studies128.  Salivary cortisol 
is an objective biomarker of stress and has been extensively studied by researchers163. This study 
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is an important contribution to the literature which demonstrates that EW is a brief and low-cost 
intervention that successfully reduced stress in CS which was objectively measured in saliva and 
which can be made readily accessible to a wide range of cancer patients and survivors through 
the internet. This study also lends support for the evidence-base with regards to the 
neuroendocrine effects of EW’s stress-regulation mechanism of action41. In our literature review 
we noted that several studies of psychosocial interventions,  including EW interventions, only 
mentioned the PNI framework as a mechanism of action without actually measuring 
corresponding PNI biomarkers197. This study will fill an important gap in the literature since this 
is one of the first studies of an online EW intervention in the cancer survivor population to report 
significant effects for neuroendocrine outcomes.   
However, the results for our primary outcome should be viewed with restraint since we 
did not have the measures for baseline and immediate post-intervention for salivary cortisol. 
Thus, data for the six week post-intervention outcome measures does not reflect the correlations 
for repeated measures. Also, with respect to salivary cortisol, only AUC and CAR were 
significantly lower in the EW group compared to the control writing, however cortisol diurnal 
slope (DCS) was not significantly different for both groups. Previous studies have suggested that 
patients with comorbid psychological problems such as depression can have flatter and less 
responsive DCS profiles198. Further research is needed to investigate the DCS profile of the CS 
population and relationships between salivary AUC, CAR and DCS for CS post-radiation. 
Finally, though the delayed stress-regulating effects of EW are well-documented in the 
literature128, however we still do not know how long these effects last. Future EW studies should 
incorporate more delayed post-intervention measures, e.g. 3 and 6 months post-intervention.   
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Aim two: Hypothesis two. In the second aim of this study we wanted to determine the 
effectiveness of EW to regulate stress in CS as measured by salivary α-amylase levels which was 
the biomarker chosen to indicate SNS activity. In the second hypothesis we anticipated that EW 
participants would have lower levels of salivary α-amylase (sAA) compared with participants 
that completed control writing measured at six weeks post- intervention. The rationale for 
hypothesis two was that we expected EW to have a delayed stress- regulating impact on the SNS 
similar to EW’s effect on the HPA axis (hypothesis one) However, results for hypothesis two 
were opposite to what we had anticipated, and CS in the EW group had significantly higher 
levels of sAA compared to control writing participants at 6 weeks post-intervention. However, 
the data indicated that baseline levels of sAA were higher in the EW group compared to the 
control group. Therefore, the difference in sAA between the groups at Day 49 could be attributed 
to higher baseline levels of sAA, which plateaued after the expected increase in stress 
immediately after the EW intervention (Day 7). 
Also, the SNS is a more rapid stress-response pathway responsive to acute stressors in 
contrast to the HPA axis which is involved in a more gradual and delayed stress response166. 
Therefore the SNS is more susceptible to be influenced by a range of stressors in the immediate 
physical and social environment of participants such as temperature or daily stress of commuting 
to and from work. Additionally, SNS reactivity is known to have individual variation in 
individuals with respect to acute and chronic responses. Thus, the higher sAA levels of the CS in 
the EW group at six weeks post-intervention may not be reflective of a response to the writing 
intervention. Also, sAA data with regards to average sAA secretion was not available for all 
three days that salivary data was collected. Future research is needed with regards to the impact 
of stress-regulation interventions on sAA and SNS activity. Researchers also need to examine 
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differential relationships between responsiveness of HPA axis biomarkers and SNS biomarkers 
to acute stress and chronic stress stimuli.   
 Aim three: Hypothesis three. In the third aim of this study, we wanted to determine the 
impact of EW on the immune system of CS as measured by salivary C - reactive protein (CRP) 
levels. CRP is an acute-phase response protein that is a biomarker of inflammation in the 
immune system. We expected to find lower CRP levels in CS that participated in EW compared 
to those participating in control writing at six weeks post-intervention. The rationale for 
hypothesis three was similar to the first and second hypothesis, where we expected EW to 
influence delayed neuroendocrine regulation in CS over six weeks, would in turn decrease 
inflammation in the immune system as measured by lower salivary CRP. The study results 
indicated that there was no impact of EW on CRP levels of CS, and participants in both groups, 
EW and control writing, had similar levels of CRP at six weeks post-intervention. CRP levels are 
also affected by a range of other conditions such as cardiovascular disorders, infections and 
inflammation and shares a complex relationship to glucocorticoids such as cortisol199. Moreover, 
the immune profiles of cancer patients and CS are affected in very complex ways due to 
treatments and the cancer itself.  
The absence of an effect of EW on salivary CRP levels of CS in our sample could be due 
to 1) the CRP levels in the CS were sustained due to post-radiation inflammation, or 2) EW may 
exert a selective impact on the HPA axis activity, which may not have a mediating or moderating 
influence on inflammation in the immune system. This was one of the first EW studies to 
incorporate CRP as an outcome measure in the cancer population. A recent study of a 
psychosocial intervention in a population of youth in foster care showed a significant decrease in 
salivary CRP after the intervention200. Also, research indicates that cortisol exerts a 
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downregulating influence on CRP levels in populations faced with pneumonia and respiratory 
disorders201. Our study found no impact of EW on salivary CRP levels of CS post-radiation over 
six weeks. Thus more psychosocial interventions in the cancer population need to measure 
salivary CRP to assess CRP’s responsiveness as well as determine the correlation of salivary 
CRP levels with levels of CRP in blood and other measures of the immune system that include 
functional  immune measures such as cytokines and immune cell counts such as T lymphocyte 
counts. Future observational studies should also investigate the association between levels of 
glucocorticoids such as cortisol on levels of CRP in cancer patients, as well as in healthy 
individuals.   
Aim four: Hypothesis four. The fourth aim of this study was to determine the efficacy 
of EW to impact psychosocial functioning in CS as measured by scores on self-report 
questionnaires: a) PSS (perceived psychological stress), b) FCRI-S (negative emotion), and c) 
CBI-B (efficacy for coping with cancer). Data for aim four was tested in three hypotheses, for 
each self-report outcome measure, i.e. PSS, FCRI-S, CBI-B. In hypothesis four, we expected to 
find lower PSS scores for the EW group compared to the control group on Day 49. Results were 
contrary to what we predicted, and in hypothesis four we found no significant differences 
between the EW and control writing groups with regards to scores on the perceived stress scale 
(PSS). However, the data showed that that in both groups, there was a significant effect of time 
and PSS scores increased immediately after the intervention followed by a significant decrease at 
six weeks post-intervention. This impact of time on perceived stress in CS could be attribute to 
the PSS scale and the natural impact that time has on stress and coping.  
The PSS is an extensively used measure of stress which assesses the degree to which the 
participants regard their life circumstances to be stressful180. In this study, the PSS assessed more 
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global factors leading to stress such as how unpredictable, or overloaded the CS found their lives 
to be. Research indicates that CS gain coping skills and strategies as they transition through 
survivorship and these are incremental gains across the survivorship phase. Previous studies of 
EW have also demonstrated that EW initially increases perceived stress in participants 
immediately after the intervention which is followed by a delayed decrease (over a period of 6-8 
weeks) in perceived stress128,202. Thus, decrease in PSS scores for both groups at the end of the 
intervention could be attributed to the natural coping strategies that CS adopt over time to cope 
with life stressors while reassuming their roles in their family and workplace. Also, the EW 
literature suggests that EW’s mechanism of action is backed by research evidence with regards to 
only specific dimensions of psychosocial functioning, such as emotion regulation and cognitive 
restructuring, while excluding others such as stress perception and coping137,203. Future studies of 
EW should employing more precise measures of stress as they relate to EW’s mechanism of 
action.  
Aim four: Hypothesis five.  The fifth hypothesis of this study was related to determining 
the efficacy of EW to regulate negative emotions, specifically the fear of cancer recurrence in 
CS. In the fifth hypothesis we aimed to generate evidence for EW’s emotion regulation 
mechanism of action by demonstrating a decrease in the severity of a relevant and specific 
emotion for our sample of CS, which was fear of cancer recurrence (measured by the FCRI-S).  
As anticipated by our study, the EW group reported significantly lowered fear of cancer 
recurrence (FCR) compared to the control writing group at six weeks post-intervention. Results 
for hypothesis five is an important finding as this was one of the first studies of EW in the cancer 
population to measure the severity of a relevant negative emotion, i.e. FCR which particularly 
affects CS, and demonstrate that EW was effective in reducing the severity of that negative 
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emotion. This study will be a significant contribution to the EW and psycho-oncology literature 
since very few psychosocial intervention studies in the cancer survivor population have been 
conducted that have evaluated and assessed severity of FCR.  
The fear of cancer recurrence is one of the most frequently reported problems in CS181. 
The research literature indicates that FCR is currently an important area of unmet psychosocial 
needs for CS1. The American Cancer Society website reports that CS commonly express 
concerns with regards to FCR, especially immediately after completion of treatments204. For 
example, the stress and tension induced by FCR is illustrated in the following story of a CS,  
I feel like if I knew my exact chances of the cancer coming back, I could deal with it. But 
when I ask my doctor, he gives me a range of statistics over a number of years. I can’t 
live like this. I need more specifics205.  
In previous research conducted by the first author,  a CS expressed her fear of cancer recurrence 
metaphorically such as, “Because parathyroid cancer has such a high recurrence, it’s like having 
a Rottweiler on a short leash. Right now, I’m fine, but wary, always wary206 (p.62).” Both these 
narratives from CS describe a constant sense of uncertainty and fear with regards to cancer 
returning, but what both CS truly wished to know was that their cancer would never come back.  
With a growing CS population in the United States and the world over, FCR is an 
important psychosocial stressor that needs to be extensively researched. Further research is 
needed with regards to the dimensions of FCR as well as the management of FCR throughout 
survivorship . Future studies should incorporate measures of FCR and include specific activities 
in psychosocial interventions e.g. FCR management in cognitive behavioral therapies (CBT) and 
coping strategies for CS to manage FCR immediately post-treatment as well as over the rest of 
their lifespan. This study provides evidence for the use of EW, a simple and inexpensive 
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psychosocial intervention, for reducing FCR in the CS population. Another approach for 
managing FCR could be providing CS with regularly updated information with regards to cancer 
survival rates. Finally, epidemiological studies are also needed to provide information with 
regards to the prevalence, severity and impact of FCR in the cancer survivor population.  
Aim four: Hypothesis six. The sixth hypothesis was pertaining to the impact of EW on 
CS self-efficacy for coping with cancer. The EW research literature suggests that writing about 
ones deepest thoughts and emotions over four days gives EW participants repeated exposure to 
stressful stimuli137. During the practice of writing ones thoughts and feelings, participants gain a 
psychological distance from where they can process their thoughts and emotions as well as 
confidence for managing their emotions when they resurface207. Thus, we posited that EW would 
enhance CS self-efficacy for coping with cancer (measured using the CBI-B) over the period of 
six weeks post-intervention. The results from the analyses revealed that there were no significant 
differences between the EW group and control-writing groups with regards to CBI-B scores at 
six weeks post-intervention. However, there was a significant effect of time for CBI-B scores in 
both groups and the data indicated that there was a significant decrease in CBIB-B for both 
groups immediately after the intervention (Day 7) followed by a significant increase in CBI-B 
scores immediately after the intervention. The results for hypothesis six for CS self-efficacy for 
coping with cancer (CBI-B) followed a similar pattern to the results for hypothesis four (PSS).  
Increases in CBI-B scores for both groups at the end of six weeks could be attributed to 
similar mechanisms that resulted in lower PSS scores for both groups at the end of six weeks.  
Majority of participants in both groups (EW and control writing) were CS who had completed 
their final radiation treatment six to eight months prior to being enrolled in this study. This phase 
has been referred to as the re-entry phase of cancer survivorship, since CS must reenter their 
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previously disrupted family and work lives12,15. During this transition phase, cancer survivors are 
known to experience stress with regards to reassuming their life roles and dealing with daily 
stressors1. During this transition period CS must also adopt coping skills and strategies over time 
to handle their daily responsibilities and life roles. The data for this study indicated that both, the 
EW and control writing groups, reported a significant increase in self-efficacy for coping with 
cancer (and significant decrease in perceived stress) six weeks after completing their 
intervention. Therefore, CS in both groups could have acquired coping strategies over the six 
weeks following their writing tasks and experienced increased self-efficacy for coping with 
cancer (CBI-B scores) and lower perceived stress (PSS scores) at the end of the six week period.  
Another possible reason for both groups to have experienced an increase in self-efficacy for 
coping with cancer (and lower perceived stress) could be that the control writing intervention 
inadvertently provided CS with coping skills. The control writing condition asked CS to write 
how they spent their time on four days, this writing task could have provided CS with practice 
with regards to listing their daily chores, activities and stressors. Thus CS in the control writing 
group could unintendedly have learned coping skills during their control writing tasks. Future 
longitudinal studies are required in the CS populations which can determine the specific coping 
strategies and psychosocial approaches that CS adopt over time across the survivorship phase.    
Aim five: Hypothesis seven. The fifth aim of this study was related to eliciting the 
effects of EW on CS stress levels immediately after the intervention. The EW research literature 
consistently indicates that EW increases stress in participants immediately after the writing 
tasks128,208. In hypothesis seven we expected to see higher levels of salivary cortisol in the EW 
group compared to the control-writing group. However, hypothesis seven was not testable due to 
the unavailability of data for baseline and immediate post-intervention salivary cortisol due to 
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resource constraints, and was the only study hypothesis that was not tested.  
 Aim five: Hypothesis eight. In the final hypothesis of this study we wanted to determine 
the effect of EW on the secondary physiological outcomes (α-Amylase and CRP; hypothesis 8a) 
and the secondary psychosocial outcomes (PSS, FCRI-S and CBI-B; hypothesis 8b) of interest 
immediately after the intervention (Day 7). The literature consistently reports that EW increases 
stress during the intervention period128. In the course of completing the EW writing tasks, 
participants re-experience their past stressful events and bring back to attention the negative 
emotions associated with those stressful experiences. Therefore, EW participants are expected to 
have increased psychosocial stress immediately after the EW intervention. This increase in 
psychosocial stress in turn stimulates the HPA axis leading to secretion of stress hormones as 
well as autonomic arousal and increased SNS activity209. Previous meta-analyses of EW have 
reported small to medium effect sizes with regards to its post-intervention impacts on physical 
and psychological outcomes126-128. In this study, we expected that on Day 7, the EW group will 
have higher salivary α-Amylase and CRP levels (physiological outcomes) and higher PSS and 
FCRI-S scores and lower CBI-B scores (psychosocial outcomes) in comparison to the control 
writing group. 
 The results for the physiological outcomes for hypothesis eight showed that α-Amylase 
was found to be significantly higher in the EW group compared to the control group immediately 
after the intervention (Day 7). However, the data showed that α-Amylase was higher in the EW 
group at baseline. Hence the difference in α-Amylase levels between the EW group and control 
groups at Day 7 could be due to the preexisting higher levels of α-Amylase in the EW group. 
Salivary α-amylase is a reflection of the immediate SNS response to stressful stimuli in human 
beings and is correlated with other acute stress hormones such as adrenaline. The bio-behavioral 
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research literature indicates that short-term stressors typically increase salivary α-amylase levels 
in healthy as well as clinical populations164,166. Although, α-Amylase levels rose on Day 7 in the 
EW group compared to the control group, no conclusive statement could be made regarding the 
SNS reactivity of our sample to the EW intervention. Additional data regarding changes to α-
amylase levels during the day (e.g. diurnal variation) would have provided a clearer picture of 
the SNS reactivity of the CS in our sample to EW. Future studies of EW should further 
investigate EW’s impact on SNS reactivity by employing measures similar to salivary α-
amylase, e.g. adrenaline. 
The second physiological outcome in hypothesis eight was salivary CRP. We assumed 
that EW would increase CRP levels in CS immediately after the intervention based on the fact 
that CRP is an acute phase response protein which increases within a couple of hours after the 
onset of inflammation210. The results indicated there was almost no change in CRP levels for 
both groups after completing their intervention. These results indicate that CRP may not be 
responsive to short-term increases in stress. It is noteworthy that both salivary α-amylase and 
CRP are new biomarkers in PNI research and more data are needed with regards to mediators 
and moderators of their salivary secretion patterns. Also, further data are needed with regards to 
the sensitivity and specificity of salivary α-amylase and CRP and their correlation with other 
biomarkers of stress and inflammation. Future research is needed with regards to EW’s influence 
on CRP levels in healthy and clinical populations, e.g. cardiovascular disorders.  
The results for the psychosocial outcomes for hypothesis 8 showed that both groups, EW 
and control writing, experienced a significant increase in perceived stress (higher PSS scores) 
and fear of cancer recurrence (higher FCRI-S scores) immediately after the intervention (Day 7). 
Results also described that both groups, EW and control writing, reported a significant decrease 
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in self-efficacy for coping with cancer (lower CBI-B scores) immediately after the intervention 
(Day 7). We had expected to find the changes in the psychosocial outcomes for CS in the EW 
group only. A possible explanation for increases in perceived stress and fear of cancer recurrence 
(FCR) in both groups could be that the questions in the surveys may have sensitized CS to 
experience stress and negative emotions. For examples the FCRI-S asked questions such as, 
“how often do you think about the possibility of cancer recurrence?” Answering questions 
pertaining to stressful experiences and emotions can trigger those negative emotions in the minds 
of participants. Since both participants answered the surveys at baseline (Day 2) and immediately 
after the writing intervention (Day 7), participants in both groups could have been sensitized to 
increased stress and FCR. Having increased in stress and FCR could also explain the inverse 
decrease in self-efficacy for coping with cancer found in both groups on Day 7. Further research 
is needed with regards to EW’s differential impact on specific psychosocial outcomes 
immediately after the intervention. We recommend future EW studies to include psychosocial 
outcomes that are closely aligned with aims of the intervention, for example in our study we 
measured of severity of emotions (FCR) that were relevant to our study sample (CS).    
Overall, the results from the aims and hypothesis provided partial support for our 
theoretical model which posited that EW would have a stress-regulating impact for CS as 
measured by their PNI outcomes. The results of this study cannot be interpreted as confirming or 
disconfirming EW’s stress-regulating capacity, but instead as offering evidence for particular 
assumptions while raising questions about others. Specifically, we found evidence for EW's 
ability to impact cortisol secretion in saliva (HPA axis) and reduce fear of cancer recurrence in 
CS during a six week period after the intervention. We support existing consensus in the 
literature with regards to EW’s initial stress-inducing impact on participants immediately after 
  
136 
 
the writing tasks, which is followed by a delayed stress-regulating influence over a six week 
period128,211. Almost three decades of research have provided consistent evidence for EW as a 
short-duration and low-cost intervention that can be easily administered to a variety of clinical 
populations128. EW seems even more attractive with the advent of the internet and EW’s 
adaptability to technology. However, more research evidence is required in the literature with 
regards to the theoretical aspects of EW’s mechanisms of action. This study lends support for the 
emotion-regulation theory for explaining EW’s stress-regulating effects. 
Expressive Writing and Psychoneuroimmunology: Implications for Theory  
 A critical aspect of this study was that we wanted to understand the stress-regulating 
effects of EW from the theoretical perspective of PNI. This study is one of the first studies that 
employed outcome measures for all three parts of the PNI framework, which were the 
psychosocial (P), neuroendocrine (N) and the immune (I) systems. The results of this study 
partially supported the tripartite PNI theoretical model, see Table 32. In the first part, we 
anticipated that through the process of emotion regulation, EW would help CS regulate negative 
emotions (FCR). In the second part, we posited that emotion regulation impact CS 
neuroendocrine response (from the HPA axis and SNS). In the third part, we expected that 
neuroendocrine regulation would decrease inflammation in the immune system. We discuss 
finding from our study with respect to each part of the PNI theoretical framework.  
 EW and psychosocial function: Emotion-regulation.  The disclosure literature as well 
as other clinical studies describe that EW facilitates emotion regulation through two main 
processes, namely emotional habituation and cognitive reappraisal of emotions137. Emotional 
habituation refers to the concept that during EW, participants repeatedly confront their negative 
emotions regarding stressful experiences, thereby the physiological and possibly the perceived 
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intensity of those negative emotions decreases over time137. Empirical studies of EW in the 
patients having  post-traumatic stress disorder (PTSD) indicate that in effective habituation, 
participants initially experience strong negative emotions, with decreases in negative emotion 
within and across writing sessions212-214. Results for this study lend evidence for the emotion 
habituation component of EW’s emotion-regulation mechanism of action. Participants in this 
study reported a significant increase in FCR immediately after their four day writing tasks, and 
then a significant decrease in FCR across 6 weeks. Thus, CS showed habituation by first 
experiencing high FCR after their writing and subsequently having significantly decreased FCR 
after 6 weeks. This is one of the first studies of EW to measure the intensity of a negative 
emotion (FCRI-S) that is specific to a cancer population (CS). We suggest future EW studies to 
adopt population specific measures of the intensity of negative emotions and demonstrate 
habituation by collecting longitudinal data. 
The second component of emotion-regulation theory involves the cognitive reappraisal of 
emotions. The cognitive reappraisal of emotions describes that during EW, participants must 
actively face and process negative emotions which could strengthen their self-efficacy for 
managing those negative emotions137,215. Also, EW provides participants with psychological 
distance to view their stressful experiences and a lens from which they can observe themselves 
better understand, validate and accept their emotional reactions and to those stressful 
experiences137.  Previous research of supportive-expressive group therapy for cancer patients has 
reported that disclosing emotions related to their cancer and fears of dying during group therapy 
sessions improved cancer patients self-efficacy to manage those emotions216. In this study we 
found that inconclusive results with regards to EW’s ability to improve cancer patients self-
efficacy for coping with cancer (measured using the CBI-B). However, the data did indicate a 
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significant effect of time on self-efficacy for coping with cancer. CS who participated in EW had 
lower CBI-B scores immediately after the intervention and significantly higher CBI-B scores six 
weeks after completing EW. This study lends limited support to the cognitive reappraisal 
component of EW’s emotion regulation mechanism of action. Future studies of EW should 
incorporate measures of self-efficacy for managing emotions and test the duration to which EW 
helps participants improve self-efficacy for coping with cancer.    
EW and neuroendocrine function: HPA axis and SNS.  The psychophysiological 
effects of EW have been well documented in an extensive body of research128. EW has been 
shown to have wide-ranging effects on the nervous system and related hormones and 
neuropeptides as well as associated effects on the cardiovascular system217. Research evidence 
demonstrates that EW affects cortisol and epinephrine secretion, heart rate, blood pressure and 
heart rate variability127. The most extensively studied stress-response pathway in PNI research 
has been the HPA axis218. In this study we employed salivary cortisol as our primary outcome 
measure indicating HPA axis activity. Based on findings in previous research, we expected that 
EW would manifest its stress-regulating effects in CS over a period of six weeks. The results 
from this study showed that EW was successful in regulating the stress-response from the HPA 
axis in CS demonstrated by significantly lower salivary cortisol levels in EW group CS 
compared with control writing group CS. This study provides support to the growing evidence-
base for EW’s neuroendocrine effects.   
The impact of EW on the HPA axis can be explained as a resulting effect of the 
emotional habituation described above. The evolution of the HPA axis is specifically related to 
fear and the fight or flight response219. Human beings evolved the fight or flight response to deal 
with  stimuli that threatened our survival during early evolution, such as wild animals. This 
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neurobiological fight or flight response is activated by fear emotions leading to chronic stress 
which keeps the HPA axis activated. This leads to higher levels of blood cortisol which has 
negative impacts on multiple systems in body including the immune system. During EW 
participants repeatedly confront and re-experience their negative emotions which leads to 
desensitization and habituation. Also, EW helps participants gain more self-efficacy to manage 
their emotions. This study demonstrated that EW significantly lowered the negative emotion of 
FCR as well as lowered cortisol in CS over a period of six weeks, see Table 32. This study is an 
important contribution to the literature which demonstrates in the same study that EW was 
effective in regulating negative emotions (FCR) as well as HPA axis activity which will further 
our understanding of EW’s mechanism of action. Future studies should investigate dose-response 
effects of EW intervention on the HPA axis.      
Evaluating dose-response effects of EW on the HPA axis. Studies of other psychosocial 
interventions involving emotional disclosure such as supportive expressive-group therapy and 
cognitive behavioral stress management (CBSM) have shown that emotional expression has been 
successful with reducing serum cortisol levels in cancer patients95,220. Moreover, participants that 
had greater involvement in emotional expression (e.g. lower repressive defensiveness and greater 
expression of negative emotions) during group therapy had steeper cortisol slopes among 
metastatic breast cancer patients78,221,222. Meta-analyses of EW have also indicated to a dose-
response association between EW and health outcomes127,128. This study supports previous 
research indicating that the HPA axis is most responsive to psychosocial interventions208,223. An 
average dose-effect of EW was not estimated in this study since limited measures were employed 
to reduce patient burden. Moving forward, quantitative evidence is needed with regards to dose-
response associations between a) type of EW intervention, b) extent of involvement in EW, c) 
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duration of EW intervention and d) PNI outcomes, that can help guide clinical decisions 
regarding implementing EW in the therapeutic setting. Therefore, future studies should employ 
data collection procedures to assess dose-response effects of EW interventions in persons with 
cancer.   
An innovative aspect of this study was that we also measured the impact of EW on the 
SNS by assessing salivary α-Amylase in CS. However, data revealed no significant stress-
regulating effects of EW on salivary α-Amylase in CS. As described above, this may have been 
because the SNS is a pathway that is more responsive to acute stress and not as responsive to 
chronic stress stimuli. This finding suggest that perhaps EW’s habituation and cognitive 
restructuring may be psychological mechanisms that are successful in reducing burden from 
chronic stress stimuli such as FCR and not acute stress stimuli. However, EW studies in healthy 
participants have demonstrated that the cardiovascular system, which is innervated by the SNS, 
is response to EW224. The negative results with regards to sAA in our study may also be 
attributed to the fact that sAA is a relatively new biomarker in bio-behavioral clinical research 
and data regarding its sensitivity and specificity needs further investigation. Further research is 
needed with regards to EW and SNS activity and we encourage researchers to use biomarkers of 
both HPA and SNS axes to provide a comprehensive picture of EW and stress reactivity.  
EW and immune function: Inflammatory response.  Studies of EW have shown to 
impact all aspects of the immune system. Major advances in immunology research over the past 
decades have allowed researchers to measure various components of the immune system. At the 
broadest level, the immune system in humans consists of a) innate immunity, which includes 
cells (e.g. natural killer cells) inherently present to provide an immediate, but non-specific 
response against toxins or microorganisms, and b) adaptive immunity, which adapts its response 
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to the specific toxins or microorganism to improve detection and has two components, namely 
humoral immunity (mediated by antibodies generated by B lymphocytes) and cell-mediated 
immunity (mediated by T lymphocytes). The earliest research evidence with regards EW’s 
impact on the immune system comes from the landmark EW study in college students that 
demonstrated that EW increased the mitogen-induced T-lymphocyte responses (adaptive 
immunity: cell-mediated)130. Similarly, other studies of EW in college undergraduates have 
found immune impacts of EW on antibodies against Epstein-Barr virus (EBV) and hepatitis B 
antigens, as well as in HIV positive patients EW demonstrated an increase in CD4+ T 
lymphocytes (adaptive immunity: humoral)131-133. With regards to EW’s impact on innate 
immunity, research has found that an EW intervention in patients with depression and anxiety 
patients decreased natural killer (NK) cell activity (innate immunity: NK cells)225.  
However, due to the complex nature of the immune system it is difficult to establish 
whether EW can actually enhance or boost immune function but rather that EW has the ability to 
influence immune behaviors in varied ways. Additionally, due to the heterogeneous immune 
profiles of EW study populations makes inferences regarding EW’s impact on immune function 
problematic. For example, cancer patients and CS have different immune profiles than HIV+ 
patients and healthy individuals and the results of EW’s influence on different immune profiles 
may not comparable. Results from this study indicate that EW was unsuccessful in affecting the 
immune system of CS which was measured by salivary CRP. Although CRP has been regularly 
used as an measure of inflammation, testing CRP levels in saliva is a relatively new biomarker of 
the immune system. CRP is an acute phase reactant and is considered to be a link between innate 
and adaptive immune systems. Further research is needed with regards to EW’s influence on the 
immune pathways of cancer patients and CS. Past research indicates that participants that had 
  
142 
 
greater involvement in the EW disclosure process had a greater immune response. Future studies 
need to specifically explore the extent to which participants involve themselves into the EW 
process as well as individual differences in immune profiles of participants. 
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14 (↑) Significantly higher or (↓) significantly lower in intervention group compared to control group 
    (X) No significant differences between intervention and control groups 
Table 32: Expressive writing and the theoretical framework of PNI  
 
 Psychosocial 
Intervention 
 
Theoretical framework of Psychoneuroimmunology (PNI) 
 
 
 
 
 
 
 
Psychosocial (P) Neuroendocrine (N) Immune (I)  
  
 
 
BOM (Day 2) Respective Outcome Measures  
Writing (Day 3) 
Writing (Day 4) 
Writing (Day 5) 
PSS 
FCRI-S 
CBI-B 
Cortisol 
α-Amylase 
C-Reactive Protein (CRP) 
Writing (Day 6) Possible Mechanisms of Action 
POM1 (Day 7)   
Emotion Regulation 
 
Regulation of neuro-hormonal 
response from HPA and SNS axes 
 
Regulation in secretion of  inflammatory 
molecules of the immune system  
 
  
  
POM2 (Day 49) Results  after the intervention14 
 Psychosocial 
 
(X) PSS 
(↓) FCRIS 
(X) CBIB 
HPA Axis 
 
(↓) Cortisol 
 
SNS Axis 
 
(X) Amylase 
 
 
Immune system 
 
(X) CRP 
Psychosocia
l Stress 
Expressive 
Writing Psychosocial Stress 
Immune system 
Neuroendocrine system 
Habituation/ 
Desensitization  
Insight   
  
144 
 
Recommendations for validating the PNI causal framework. This study provided 
partial support for the theoretical framework of PNI to explain the effects of the psychosocial 
intervention, EW in our sample of CS, see Table 32. In order to advance the science and theory 
of psychosocial interventions such as EW it is critical for researchers to understand the 
mechanisms of action of psychosocial interventions by using PNI as a causal theoretical 
framework. In general, we encourage researchers in this field to pay greater attention to 
methodological and implementation aspects of PNI-based psychosocial interventions for cancer 
patients and survivors. We suggest that future studies of EW and other psychosocial 
interventions can improve validity of evidence for the PNI causal theoretical framework by 1) 
employing outcome measures related to PNI processes, 2) defining the direction of change in 
PNI outcomes, 3) demonstrating statistical interactions between PNI subsystems, 4) accounting 
for missing data for PNI biomarkers, 5) collecting data regarding integrity of biomarkers 
collection procedures, 6) preventing publication bias: reporting negative results.      
1. Employing outcome measures related to PNI processes. In the literature review for this  
study we noted that very few studies of psychosocial interventions specifically used outcome 
measures that were the focus of their intervention, such as the insomnia management cognitive-
behavioral intervention.121 In studies of PNI-based psychosocial therapies, different types of 
psychosocial factors may trigger differential PNI responses and several other external factors can 
influence the findings of a particular study69. An innovative aspect of this study was that we 
employed relevant outcome measures for all three parts of the PNI framework and measured the 
impact of EW on both the HPA axis and SNS. We recommend future studies also employ PNI 
measures associated with the specific aims of the study and measure all three aspects of the PNI 
framework. This will provide research evidence for PNI as a causal theoretical framework for the 
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stress-regulating effects of psychosocial interventions such as EW. Testing all three parts of the 
PNI framework will also assist future reviewers who can collectively appraise findings across 
studies that use PNI process related outcomes and provide a comprehensive understanding of the 
PNI effects of psychosocial intervention across cancer populations including cancer survivors.   
2. Defining the direction of change in PNI outcomes. In our literature review we noted 
that some studies did not clearly report the direction in which they expected their PNI outcome 
measures to change. Postulating a trend in PNI outcomes is difficult in the cancer population, 
because factors such as stage of disease and treatment variations (e.g. chemotherapy vs. 
radiation) can affect PNI measures, particularly immune outcomes.90,226 In this study we defined 
the direction of change for each PNI outcome measure and conducted one-tailed hypothesis 
testing. However, as explained above the neuroendocrine-immune systems are very complex to 
interpret and future intervention studies using PNI outcomes should clearly define the expected 
direction of change with regards to neuro-immune outcomes. Also, large scale epidemiological 
evidence for the normal average levels of PNI measures across specific populations is needed to 
enable researchers to make decisions about the expected direction of change in PNI outcomes.  
3. Demonstrating statistical interactions between PNI subsystems. In this study we 
conducted statistical analyses to determine average differences in PNI outcome measures 
between the EW group and control groups. Due to limitations with regards to study design, we 
did not conduct statistical analyses to test for interactions among the three subsystems of the PNI 
framework. Recent advances in statistical modeling (e.g., structural equation modeling and 
hierarchical linear modeling) can help researchers make better inferences with regards to 
interactions among multiple variables and components of PNI framework. We recommend future 
researchers identify mediators and moderators of the PNI outcomes of psychosocial interventions 
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to understand their mechanisms of action.207,227 Forthcoming studies of psychosocial 
interventions should attempt to demonstrate changes in psychosocial outcomes measures to 
predict changes (or show associations) in neuroendocrine-immune biomarkers over time to 
provide evidence for their mechanism of action. Studies should also attempt to measure the 
strength of association between level of participation in psychosocial interventions (e.g. extent of 
involvement in disclosure interventions) and PNI outcomes.  
 4. Accounting for missing data for PNI biomarkers. In this study we did not encounter 
any significant missing data with regards to completing the saliva measures for testing PNI 
biomarkers. However, we did encounter problems with maintaining our original sample size, 
which has also been reported in other studies of PNI-based psychosocial interventions, where 
studies were able to collect PNI biomarkers from only a smaller subset of their original sample. 
Having a smaller sample size to report certain outcomes, such as PNI biomarkers, can decrease 
the power of the statistical tests used to report results of those outcomes.89 However, since PNI 
biomarkers need to be collected over multiple time points, sometimes blood draws, studies of 
PNI-based psychosocial therapies are faced with the likelihood of having missing data. Hence, 
future interventions should account for attrition and missing data during their power analysis 
(e.g., by oversampling) stage and establish a plan for handling missing data.  
5. Collecting data regarding integrity of biomarkers collection procedures. In this study 
we also encountered a high degree of compliance with the collection procedures for saliva. 
However, since the data were reported by participants, there was no other way of verifying the 
validity of the participant’s responses. Other psychosocial interventions have used similar ways 
of checking adherence to the PNI-measurement protocol; for example, one study gave 
participants wrist watches with preset alarms and asked participants to record the time when they 
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provided saliva samples on measurement tracking forms.114 Researchers should be aware of 
more sophisticated ways of collecting protocol adherence data, such as the use of MEMS™ IV 
tracking caps on the saliva collection containers which have microcircuits that record times and 
dates.118 Research shows that considerable methodological variation exists in relation to timing 
of collection PNI biomarkers, for example diurnal variations in cortisol production.161 Therefore 
forthcoming research should employ more rigorous ways of collecting data with regards to 
assessing the integrity of measurement protocols regarding time-sensitive PNI-based outcomes.   
6. Preventing publication bias: Reporting negative results.  It is important for researchers 
to note that there continues to be discordance in the literature with regards to interpreting results 
related to the neuroendocrine-immune effects of psychosocial interventions for cancer patients. 
A systematic review of PNI-based psychosocial interventions for breast cancer patients 
published in 2009 concluded that there is evidence to suggest that cognitive-behavioral therapies 
impact neuroendocrine and immune measures.64 However, other researchers that reviewed the 
same literature published a critical review in 2010 reporting that the evidence for psychological 
interventions having clinically significant impacts on the immune function of cancer patients is 
still “limited and unconvincing.”228(p21) Therefore, it is important that researchers report negative 
findings with regards to the PNI effects of psychosocial interventions to avoid publication bias 
for positive results and the resulting file drawer effect229.  
Study Limitations  
This study does have some limitations that need to be acknowledged. The first area of 
limitations is related to the outcome measures for this study. The primary outcome of this study 
was salivary cortisol and due to limitations in financial resources, we could not estimate the 
baseline and immediate post-intervention values for salivary cortisol. Although, we found that 
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salivary cortisol was significantly lower in EW group compared to the control group, the 
inferences that can be made from the results regarding our primary outcome are limited due to 
the absence of baseline and Day 7 measures.  Furthermore, although the use of salivary measures 
provides a non-invasive approach, it also comes with methodological and practical problems. For 
example, even a subclinical oral infection can affect levels of salivary biomarkers, especially 
CRP161,230. We tried to eliminate this limitation by educating participants with specific details 
about oral hygiene prior to collecting saliva, see Appendix K. Also, measures of cancer 
participants’ health behaviors, e.g. food habits, exercise, that could be potential moderators of 
PNI outcome measures, were not obtained in this study.  
The second area of limitations in this study is related to the sample characteristics of this 
study. We chose a very specific and narrow cancer population for this study, which was CS that 
were disease-free and in the re-entry phase of survivorship (2-12 months post-radiation). These 
restrictive sampling criteria for this study limit the generalizability of the findings to wider 
clinical populations. Also, due to lower than expected recruitment rates, the sample size for this 
study was small. A larger sample size would have also possibly increased the diversity of our 
sample with regards to variables such as age, gender, race, type of cancer. Furthermore, due to 
the technology component of the EW intervention we may have excluded participants who were 
unable to use computers and the internet and would have benefited from EW using a paper-and-
pencil format. However, data regarding access to the internet and computers has shown a 
consistent upward trend towards internet usage and device ownership across all segments of the 
population, regardless of race, income and age. Also, initiatives such as the “PC PLEDGE 100” 
from public-private institutions such as the Federal Communications Commission (FCC)231 has 
called for corporations to recycle and divert computers to help low-income families get online. 
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Therefore, we expect internet-based interventions such as the one used in this study will soon be 
widely available to marginalized and underserved individuals and populations as well.  
 “Lost in Transition:” Cancer Survivorship and Coping with Cancer 
The numbers of cancer survivors in the United States and the world over have been 
consistently increasing due to advances in early detection and treatments. Patients with cancer 
are now progressively more likely to survive and participate in their normal work and family 
lives, with almost 70% of patients with cancer surviving five years beyond their initial cancer 
diagnosis. Every year there will be a million new cancer patients that join the existing population 
of 13.7 million cancer survivors who are alive today2. These cancer survivors are faced with 
several physical as well as psychological and social (psychosocial) problems and limitations 
during their transition from after completing treatments to reassuming their roles in work and 
family. Health organizations such as the American Cancer Society (ACS), CDC and IOM have 
repeatedly advocated that researchers, health practitioners and policy makers in the oncology 
setting need to raise awareness of and attend to the unmet psychosocial needs of cancer 
survivors1. In this study we attempted to advance the IOM’s recommendations with regards to 
taking steps to improve the science and delivery of psychosocial interventions and identifying 
ways to link cancer patients and providers with appropriate psychosocial interventions.   
What are the psychosocial health needs of cancer survivors? Cancer has a unique 
psychosocial impact on patients different than other chronic illnesses and challenges individuals 
on their mental, emotional and social levels as well raises spiritual and existential questions in 
afflicted individuals. Every phase of the cancer care trajectory, from diagnosis and treatment to 
survivorship or palliative care, poses exceptional tribulations with regards to the psychosocial 
health of cancer patients. Patients transitioning from completing their treatments to long-term 
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follow-up, referred to as cancer survivors in this study, are at high risk for experiencing stress 
and were the focus of this study. Cancer survivors are faced with the early, late and long-term 
impacts of cancer diagnosis and treatments on their physical and psychosocial well-being 
through the rest of their lifespan. Psychosocial health issues in cancer survivors include stress, 
angry rumination, depression, loneliness, fear of cancer recurrence as well as sleep related 
problems such as insomnia or hypersomnia1.  
The incredible complexities of the psychosocial health needs of cancer survivors can 
grasped to a certain degree by studying cancer survivors experiences, such as the following quote 
of from a cancer survivor who had just finished her last radiation treatment,  
After my very last radiation treatment for breast cancer, I lay on a cold steel table 
hairless, half-dressed, and astonished by the tears streaming down my face. I thought I 
would feel happy about finally reaching the end of treatment, but instead, I was sobbing. 
At the time, I wasn't sure what emotions I was feeling. Looking back, I think I cried 
because this body had so bravely made it through 18 months of surgery, chemotherapy, 
and radiation. Ironically, I also cried because I would not be coming back to that familiar 
table where I had been comforted and encouraged. Instead of joyous, I felt lonely, 
abandoned, and terrified. This was the rocky beginning of cancer survivorship for 
me232(p479). 
Other stressors for cancer survivors include follow-up clinical appointments and medical tests 
which often have wait times ranging from several days to weeks for laboratory confirmation. In 
previous research conducted by the first author, these wait times have been metaphorically 
described by cancer survivors as “torture” and being on a “roller coaster”206. Thus, cancer 
survivors have several psychosocial health needs with regards to reducing stress and negative 
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emotions and managing uncertainty. We urge patient advocates, health researchers and 
professionals to recognize that cancer survivors have unique psychosocial health needs during 
the survivorship phase. Therefore, we support the ACS and IOM’s recommendations with 
regards to defining cancer survivorship as a separate phase of cancer care and taking measures to 
address the specific psychosocial needs of cancer survivors1.     
How do we address the psychosocial health needs of cancer survivors? An important 
first step in addressing the psychosocial health needs of cancer survivors is raising awareness 
about psychosocial health needs of cancer survivors amongst oncology care providers. The 
medical management of cancer is very complex and demanding for oncology care providers who 
primarily consider clinical outcomes such as the cancer cell morphology, possible metastases, 
grading and staging the cancer and monitoring the response to specific doses of the cancer 
treatments. However, health outcomes that are important to patients may include quality of life 
and subjective well-being233. The oncology-care literature indicates that while from the 
physicians’ perspective the end goal is the cancer free patient, what the patient is experiencing 
during and after treatments seems insignificant and is often ignored by care providers3. Thus, 
there is a discrepancy between the health outcomes that oncology care providers are concerned 
about and the outcomes valuable to patients. We recommend care providers to consider patient-
centered outcomes in addition to clinical outcomes during cancer treatments and most 
importantly during cancer survivorship. In the current team-based model of oncology care, we 
recommend oncology care providers to include staff trained in dealing with psychosocial issues 
such as psychologists or social workers. Also, psychosocial interventions that can bridge the gap 
between the world-view of the oncology-care providers and perspective of the cancer survivors 
are needed.  
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Psychosocial interventions for cancer survivors: Expressive writing. In our literature 
review we identified two major categories of psychosocial interventions for cancer patients, a) 
cognitive-behavioral and b) complementary medical. We chose expressive writing (EW) as a 
psychosocial intervention (from the cognitive-behavioral interventions group) for reducing stress 
in cancer survivors transitioning of their final radiation treatment. Several aspects of the 
expressive writing intervention are discussed below which make it an appropriate psychosocial 
intervention for cancer survivors during survivorship care.   
EW: Brief and inexpensive. A very convenient feature of EW is that it requires limited 
resources with respect to time and administration. Typically EW interventions require a total of 
1.3-2 hours over four days (20-30 min per day) without any need for booster sessions. This short 
duration is appealing for cancer survivors who may not have large blocks of time to spare for 
stress-management interventions. Moreover, EW can be administered in almost any setting, from 
home to classrooms as well as in-patient and out-patient clinical settings. This makes EW very 
adaptable to relevant environmental constraints. In this study we administered EW online, so CS 
did not spend time travelling to the place of intervention. Also, since EW involves participants 
responding to written instructions, EW requires minimal training and input from trained health 
professionals making it a low-cost intervention. In this study we did not require any trained 
health professionals for administering EW to cancer survivors, although we had a licensed 
clinical social worker on our team to address any possible adverse situations. Our literature 
review found that one study consisting of only three hours of therapeutic interaction with a single 
psychologist116  demonstrated significant changes in immune outcomes. Further research is 
needed to investigate other brief and inexpensive psychosocial interventions involving 
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expressive disclosure for cancer survivors as well as future studies need to define EW’s 
minimum and maximum dose response effect for impacting physical and psychosocial outcomes.  
EW: Coping with cancer. Due to rapid advances in cancer prevention, early detection and 
management, cancer is now considered to be more of a chronic disease rather than an acute life-
threatening condition234. Thus coping with cancer on a long-term basis is an essential aspect of 
living as cancer survivor. After patients with cancer learn to cope with stress of diagnosis and 
treatment, as cancer survivors they must now learn to cope with loneliness and fears of cancer 
recurrence. Studies of coping strategies in cancer survivors have shown that survivors use 
strategies such as a “fighting spirit” attitude, social support, religious faith and spirituality to 
cope with cancer during survivorship235. Expressive writing, as a medium, can help patients cope 
with cancer through problem-focused coping as well as emotion focused coping. The research 
literature suggests that interventions which allow patients to read clinical experiences of other 
patients form a basis for making informed decisions about treatments and follow-up care236. 
Also, studies show that reading about cancer survivorship stories about individuals who were 
diagnosed with cancer and who are now successfully cured and living normal lives can decrease  
cancer survivors anxiety and improve coping237,238.  Thus EW interventions that can connect 
communities of cancer survivors will help provide CS with health information (problem-focused 
coping) as well as provide a sense of social support (emotion-focused coping). Previous research 
indicates that cancer survivors describe benefits of expressing their emotions during the writing 
process, for example, at the conclusion of completing their writing a CS wrote “I realize this 
story was disjointed and rambled on, but it felt good to get off my chest” 206(p.85). Results from 
this study found that cancer survivors that participated in EW had a significant decrease in their 
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fear of cancer recurrence and further research is needed with regards to EW’s coping function in 
CS.  
EW: Health benefits. The positive health benefits of EW have a growing evidence-base in 
the research literature. EW has shown effects on all types of health outcomes, ranging from self-
reported symptoms and psychosocial outcomes such as depression to neuroendocrine and 
immune outcomes such as CD4+ T cells127,239. Also, beneficial health effects of EW are 
consistent across study populations that include healthy individuals as well as diverse clinical 
populations such as, HIV+ patients, cancer patients and survivors, and patients with asthma, 
autoimmune and cardiovascular disorders127,128. The results from this study adds to the research 
evidence for EW’s health benefits specifically for the cancer survivor population. CS are 
particularly at risk for experiencing stress during their transition phase which is approximately 2-
18 months after completing all treatments223. We found that expressive writing was successful as 
a stress-management intervention during this transition phase and CS who participated in EW 
had significantly lower levels of cortisol (regulation of HPA axis response) and reported lower 
fear of cancer recurrence (FCR) in the six weeks after completing their EW intervention. Further 
efforts from researchers and practitioners are needed to study the health benefits of EW 
specifically for CS and deliver EW interventions as part of cancer survivorship care. 
EW: Building relationships between care-providers and cancer survivors. Currently the 
health care system is failing to understand cancer survivors’ experiences and psychosocial needs 
by not including expressive disclosure interventions such as EW in oncology care. Several 
institutional and pragmatic limitations prevent oncology care providers from understanding the 
psychosocial needs cancer survivors and identifying health outcomes important for cancer 
survivors. Expressing emotions and experiences related to cancer is a time-consuming and 
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demanding task that care providers may not prioritize in their schedules. Expressive writing is a 
very practical tool that can enable oncology researchers and care providers to better understand 
the psychosocial needs of cancer survivors. Cancer survivors can write about their stressful 
experiences at their own convenience and time, and then present them to their oncology care 
providers for their perusal. The oncology care providers can learn valuable information with 
regards to the patient experience of survivorship including stressors and issues that concern 
cancer survivors and identify specific health outcomes important for cancer survivors during 
survivorship. These expressive writing narratives can also provide a lens through which 
researchers and oncology-care providers can vicariously experience the world of cancer 
survivors.  Future research should also measure the benefits of incorporating EW interventions 
for the oncology care providers in addition to benefits for cancer survivors. 
EW service delivery: Adaptable to technology and the internet. One of the most dramatic 
revolutions in modern times with regards to individual lifestyles and societies at large has been 
the advent of computers and the internet. In a less than three decades since the internet was first 
offered to the public by internet service providers (ISPs), the world has transformed into a global 
village allowing for human interaction to occur in cyberspace, which include psychosocial 
interventions. Researchers and professionals have been increasingly using the internet to deliver 
psychosocial interventions for patients with cancer and have encouraged other researchers to 
view the internet as an accessible and increasingly popular medium for reaching diverse cancer 
populations149. Patients with cancer have reported that internet-based interventions are 
acceptable and feasible. However, in our literature review we found only two studies used 
communication technology to deliver their interventions to cancer patients which were through 
telephone conversations105,118. An innovative aspect of this study was that we adapted the paper-
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pencil format of EW to an online format which was delivered using the survey software 
Qualtrics.    
There are several advantages to using the online format of EW for cancer survivors. After 
completion of treatments, CS generally have follow-up appointments that range from three to six 
months post-treatment. During this time most CS experience fears and uncertainty and do not 
have ready access to their health care team. In this transition phase, internet-based EW 
interventions can easily be made accessibly to CS which can help them express their thoughts 
and emotions. This will help ease pent-up anxiety and stress in CS as well as reconnect them to 
their health-care team. The EW essays will inform the survivorship-care team with regards to 
symptoms and concerns of CS. Thus, internet-based EW is a very simple and accessible way for 
the health-care team to deliver follow-up care to CS during survivorship. Our internet-based EW 
study was successful in reducing stress measured by lowered salivary cortisol and fear of cancer 
recurrence in cancer survivors 2-12 months post- radiation. However it is important to note that 
our study sample was predominantly well educated and higher income cancer survivors who had 
access to a computer and the internet. The ability and willingness to disclose experience in 
written format online could be attributed to the higher educational and socio-economic level of 
our sample. Future studies should also include oral expressive disclosure prompts to participants 
from diverse educational and socio-economic strata through the internet or by phone.   
Important areas of concern with regards to internet-based EW interventions are audience 
responsiveness to the EW essays and data privacy. Research has shown that patients may alter 
the content of the EW essays based on the audience that is going to read their narratives. EW 
studies for CS should clearly inform participants as to which personnel will read their essays. 
Another are of concern is with regards to data privacy. The conversation with regards to internet 
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privacy continues to concern data providers as well as lawmakers and intelligence agencies. The 
revelations by whistleblower Edward Snowden with regards to the National Security Agency 
(NSA) surveillance240 occurred during the recruitment phase of this study. One potential 
participant for this study expressed concerns with regards to data privacy issues and reported a 
mistrust with the government and associated agencies. We urge researchers to pursue defining 
specific guidelines to ensure confidentiality and privacy of data when adapting psychosocial 
interventions to the internet. Thus, several challenges remain for introducing EW into 
survivorship care and making psychosocial interventions part of the standard of cancer care.3,241  
Psychosocial Interventions in Cancer-Care: Preparing the Health Care System 
A comprehensive and well-organized approach towards post-treatment survivorship care 
is essential. The IOM has described that introducing psychosocial interventions for CS in the 
standard of cancer-care is faced with some major challenges. These challenges include 1) 
deficiency of health care professionals that specialize in care for CS, 2) immense diversity in the 
in psychosocial interventions and insufficient evidence-based guidelines for designing and 
delivering care for CS and 3) inadequate reimbursement for clinical and therapeutic services. In 
this section we discuss some steps to address these challenges in the immediate future.   
Education and training for health professionals. This study concurs with the IOM’s 
concern with regards to the lack of standardization in education and training materials for the 
wide variety of health professionals involved in psychosocial health interventions and services 
for cancer patients3. Psychosocial health professionals range from oncologists and physicians to 
nurses, social workers, psychologists and counselors. It is difficult to estimate the demand for 
psychosocial health services due to the lack of available data. Presently, comprehensive cancer-
care centers have instituted guidelines and standards for health-care professionals to address 
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psychosocial issues in CS and providing CS with survivorship care plans242. However, these 
standards are ambiguous and do not define the specifics with regards to how these educational 
standards will be translated into credit hours, methods, or the delivery of survivorship care242,243. 
A first step towards addressing the gap in psychosocial care for CS is to raise awareness about 
CS unmet psychosocial needs amongst oncology care providers and primary health providers. 
We also recommend comprehensive cancer centers to design specific training modules for health 
professionals interested in specializing in psychosocial oncology care and service delivery for 
CS. Finally, we suggest that knowledge and skills required for the management of psychosocial 
problems of CS during survivorship care be introduced immediately within the current standards 
for educational accreditation and licensure by way of additional curricula and continuing medical 
education credits. 
Defining evidence-based guidelines for intervention studies. An important deficiency 
in the psycho-oncology literature is the absence of evidence-based guidelines for developing 
psychosocial interventions for diverse cancer populations. Defining guidelines for the 
psychosocial management of cancer is more complex and difficult than it is for well-defined 
discrete chronic diseases such as asthma, diabetes, or heart disease. For example breast cancer 
has a considerably different psychosocial impact on patients than prostate or lung cancer. 
Furthermore, the particular psychosocial health care needs may vary for cancer survivors with 
regards to specific cancer sites (breast versus bone), stage of survivorship (re-entry versus long-
term survivorship) and type of cancer treatments (chemotherapy versus radiation). Provided that 
there exist more than a hundred different types of cancer, defining generalized guidelines for 
particular psychosocial interventions is problematic since their efficacy can differ based on 
cancer site, stage and treatments.  In this study we chose a cancer survivors 2-12 months post-
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radiation since they were at risk for post-treatment stress and were an understudied cancer 
population. Our literature review uncovered a wide range of psychosocial interventions that 
could be beneficial to cancer patients. The results of this study found promising but incomplete 
evidence for EW as psychosocial intervention for reducing stress in cancer survivors.   
We recommend that future studies of psychosocial interventions in cancer survivors, that 
employ PNI outcomes, should consider: a) clearly defining activities and therapies involved in 
the intervention; b) specifying duration of the interventions and time estimated for each session, 
including time for booster session(s); c) considering the timing of the intervention delivery with 
regards to treatment regimens (i.e. chemotherapy/ surgery); d) monitoring adherence to the 
intervention protocol; and e) evaluating sustainability of the intervention in routine clinical 
practice. We also urge researchers and policy makers to take action on the IOM’s 
recommendation for developing “standard outcome measures”3(p15) for evaluating the efficacy of 
psychosocial therapies and services for cancer patients.  Collaborative interdisciplinary efforts 
are needed to use similar approaches with regards to descriptions of the cancer populations, 
psychosocial interventions (including components and activities involved), psychometric 
instruments for psychosocial functions, and biomarkers for bio-behavioral outcomes (e.g. 
neuroendocrine-immune). Such efforts will contribute towards building a convincing empirical 
evidence-base for the effectiveness of PNI-based psychosocial therapies for cancer survivors. 
Policies for reimbursing psychosocial services. As described above there are a wide 
variety of services and health professionals that provide psychosocial services for CS. 
Reimbursements for these psychosocial services are difficult due to the regulations that restrict 
insurance payments to health professionals. These restrictions make it difficult for psychosocial 
health service providers to be in same physical location as clinical and surgical oncology 
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professionals. The IOM also states that due to the low quality of health care, simply improving 
reimbursement will not improve health care services, and additional initiatives are needed such 
as quality measurement and improvement activities3. We urge policy makers to include 
provisions for psychosocial health care services and interventions for cancer patients and 
survivors. Recent changes in health policies are encouraging for increasing the availability and 
reach of psychosocial health services in the cancer survivor population.  
The Patient Protection and Affordable Care Act (PPACA) has the potential to deliver one 
of the greatest expansions of coverage for psychosocial health services in a generation by 
requiring that most health insurance plans on the Health Insurance Marketplaces (HIM) to cover 
mental health services244. There are new requirements in the law (in the Mental Health Parity and 
Addiction Equity) that provide benefits for mental health services and expand protections for 
behavioral health to 62 million Americans. Starting in 2014 most health insurance plans will not 
be able to deny coverage because of a pre-existing mental illness. Also, the PPACA aims to 
reduce cancer-care disparities by expanding coverage for Medicaid and eliminating previous 
barriers to health coverage244. Also, the PPACA mandates that health coverage must now include 
preventive mental health services like depression screening for adults. In future steps, we 
recommend policy makers outline protections for specific health services, such as survivorship 
care for defined patient populations, for example CS.  We also support policies that will provide 
guidelines for reimbursement with regards to health professionals, service providers and insurers 
involved in survivorship care and for delivering comprehensive survivorship care plans for CS.  
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Chapter VIII. Conclusion 
In this study we found that a simple and inexpensive online expressive writing (EW) 
intervention was successful in reducing stress in cancer survivors post-radiation. This study 
provides evidence for the potential efficacy of delivering online EW online to cancer survivors 
during survivorship care to aid in stress-management. This study supports to the movement 
towards integrative models of cancer care which seeks to synthesize evidence-based therapies 
that concurrently address the physical as well as psychosocial-spiritual needs of cancer 
patients.245,246  We also support the IOM’s appeal for designing a framework to develop and 
provide cancer care for the whole patient.   
 Bio-psychosocial Model of Health: Providing “Cancer Care for the Whole Patient”  
Several historic social-cultural factors in the science and research community favor 
investments for research and development for therapies impacting “hard” therapeutic outcomes 
such as tumor growth as opposed to “soft” psychosocial outcomes such as quality of life247. This 
bias towards investing primarily in technology driven inventions is demonstrated is by the 
breakthrough innovations in cancer detection and cancer treatments such as targeted 
chemotherapy and robotic surgery, as opposed to only marginal advances in the science and 
delivery of psychosocial interventions3. However, the turn of the 21st Century has given way to a 
considerable transformation in the understanding of disease and health care, particularly in the 
oncology setting. In 2001, a National Research Council (NRC) Committee on Health and 
Behavior overwhelmingly supported the bio-psychosocial model of health by concluding that 
“health and disease are determined by dynamic interactions among biological, psychological, 
behavioral, and social factors,”248(p16) and discussed implications of the science of stress and  
psychoneuroimmunology for patients with cancer. In less than a decade after that report, in 2008, 
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the IOM recommended psychosocial health interventions and services should be a part of the 
standard of cancer care and emphasized the unmet psychosocial needs of cancer survivors3.   
Furthermore, in the past decade health organizations such as the IOM, NCI and ACS 
have made significant efforts to raise awareness with regards to cancer patients psychosocial 
needs and have highlighted the need to include patient-centered outcomes in health decision-
making. The PPACA helped institute the patient-centered outcomes research institute (PCORI) 
which aims to conduct research guided by patients, family members and caregivers, and the 
wider healthcare community to improve health decision-making, delivery and outcomes249. The 
PNI framework and the bio-psychosocial model of health have the potential to provide a bridge 
between clinically relevant outcomes and patient-centered outcomes. Furthermore, the bio-
psychosocial model of health can also serve as a framework for interdisciplinary collaborations 
between stakeholders, social scientists, health professionals and policy makers. We will use the 
results from this study to inform health practitioners, researchers and policy makers interested in 
evaluating the use of psychosocial interventions such as expressive writing in the standard of 
cancer care. It is critical that we encourage conversations with regards to including patient-
centered outcomes in cancer survivorship research and encourage lawmakers to provide better 
protections for patients during survivorship care. 
Dissemination Plan 
The results from the literature review conducted in preparation for this study have been 
published in the peer-reviewed international journal, Integrative Cancer Therapies197. The 
diffusion of findings from the results of this study research will be reported to cancer survivors, 
health practitioners, policy makers and the scientific community at large. We will present the 
findings from this study in the format of seminars and presentations for community oncologists 
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and mental-health professionals including the oncology-care staff and researchers at VCU 
Massey Cancer Center (MCC). We will also conduct awareness workshops to educate 
community health professionals with regards to stress-management interventions for cancer 
survivors and encourage researchers at MCC to introduce psychosocial interventions to reduce 
stress in their oncology practice. The findings of our study will be reported in a manuscript and 
submitted to a peer reviewed medical journal. We will also notify the science media about our 
study by contacting popular media outlets (e.g. Psychology Today) and freelance science 
journalists and reporters. The protocol for expressive writing will be provided to the science 
media, who can provide the writing prompt to readers in their article or give an online link the 
study protocol.  
Findings from our study will be reported to the office of survivorship at the NCI. We will 
inform the American Cancer Society’s cancer survivor network (CSN) with regards to our study 
and educate them about the possibility of conducting online expressive writing groups for cancer 
survivors during their survivorship care. We will also inform site administrators of online cancer 
survivors support groups such as a) Circle of Sharing (https://circleofsharing.cancer.org/default.aspx), b) 
I Can Cope (http://www.cancer.org/icancope/) and c) What Next (https://www.whatnext.com/acs/ ), with 
regards to the feasibility of delivering online expressive writing interventions for cancer 
survivors. Finally, to assist with national dissemination of this study, we will seek to get the 
citations for this study onto NCI/CDC best practices page. We will provide the NCI/CDC with 
all materials with regards to this intervention’s delivery and protocol, and will contain relevant 
information with respect to our expressive writing intervention and other psychosocial 
interventions for cancer survivors. This will ensure that cancer survivors worldwide as well as 
the general public will have access to the EW intervention and the results from our study.  
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Concluding Thoughts 
In conclusion, this study demonstrated that expressive writing can help cancer survivors 
(CS) regulate their stress and negative emotions. This study provided the first author an 
opportunity to interact with individuals who were faced with enormously stressful life events 
during their survivorship. Participants stressors ranged from job loss to family relationships and 
fears of death. However, what was touching was the CS willingness to help others despite their 
own stressors. In one email, a prospective participant wrote, “Let me know if I can help out...I 
don't want my experience to go to waste...,” demonstrating that cancer survivors are often 
concerned with how their experience can help others. It is critical that the science and research 
community to take consistent steps towards raising awareness about psychosocial stress in cancer 
survivors and encourage applied public health interventions for helping cancer survivors, family 
members and caregivers and communities deal with an increasing complex, globalized and 
stressful world. It must be the endeavor of the science and research community to ensure that the 
millions of cancer survivors in the world today are able to lead healthy and productive lives.  
Although this study lends evidence for using expressive writing as a stress-management 
intervention for cancer survivors, it is possible that EW may not be appreciated by all cancer 
survivors. This is an important consideration for researchers and practitioners involved in 
delivering survivorship care. Personalized approaches for managing psychosocial health are 
needed for cancer survivors that will provide CS access to the quality of life they deserve. This 
study has given the first author experience in conducting original research that will hopefully 
inform patient-centered decision-making in addition to clinical decision-making in oncology 
care. Greater commitments are needed from researchers and health practitioners to institute 
compassion and empathy in the delivery of survivorship care. This dissertation is a baby step 
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towards future research which will aim to create more meaningful and deeper relationships 
between cancer survivors and oncology care providers.  
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Sangli (District), Maharashtra, India 
ii) Topiwala National Medical College & 
BYL Nair Charitable Hospital, Mumbai, 
India 
[Medical internship involved one year of 
intensive clinical rotations in the following 
medical disciplines: Community Medicine 
(Urban Health Centre - 2 months; Rural Primary 
Health Care Centre - 1 month), Internal Medicine 
(1½ months), Surgery (1½ months), Obstetrics & 
Gynecology (1½ months), Pediatrics and 
Neonatal Care (1 month), Orthopedics and 
Trauma (15 days), Emergency and Casualty 
Care (15 days), Elective Rotations: 
Ophthalmology (15 days), Diagnostic 
Radiology (15 days)] 
2/2007 – 
3/2008 
Screen writer and creative advisor 
 
Richmond Bloom Company, Mumbai, India 
(Worked on project for a medical education 
DVD series, “Innovative Surgical Clinics”) 
7/2006 – 
8/2007 
Education and Training Smart center, Mumbai, India 9/2005 – 
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Type of employment Institute and Location Dates 
Professional 
 
 
(Trained students with English as a second 
language in software programs such Microsoft 
Word and Excel) 
5/2006 
 
Research Positions Held 
Designation Name of Project Dates 
Primary 
Research 
Coordinator 
“Stress Management for Cancer Survivors Using a 
Technologically Adapted Psychosocial Intervention: A 
Randomized Trial Determining the Effect of Expressive Writing 
on Psychoneuroimmunology Based Outcomes” Dissertation 
Project (PI: Dr. Richard Brown) 
5/2013 – 
present 
Principal 
Investigator (PI) 
“Messages in Cancer Communication” study of cancer patient 
narratives (advised by Dr. Roxanne Parrott) 
6/2009 – 
10/2010 
Co-investigator “Health and Heritage Project,” that aimed to understand family 
communication about genetics and genetically transmitted 
diseases 
(PI: Dr. Roxanne Parrott). 
10/2008 –   
6/2009 
 
 
Teaching Experience 
Teaching Role Name of course Institute Level Dates 
Teaching 
Assistant
*
 
SBHD 634, “Patient-Provider 
Communication” 
VCU
a
 Graduate 1/2013 – 
5/2013 
Teaching 
Assistant
*
 
SBHD 692, “Qualitative Research 
Methods” 
VCU
a
 Graduate 8/2012 – 
12/2013 
Teaching 
Assistant
*
 
CAS 202, “Introduction to 
Communication Theory” 
PSU
b
 Undergraduate 8/2010 – 
12/2010 
Primary 
Instructor
#
 
CAS100 A, “Effective Speech” PSUb Undergraduate 8/2009 – 
8/2010 
*
Role: Instructed laboratory sections, which involved designing activities for experiential 
learning of subject material and graded written work and class assignments.
 
#
Role: Developed syllabus, designed class activities and assessments and assigned final grades. 
a
: Virginia Commonwealth University 
b
: Pennsylvania State University 
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Expertise in Technology and Software Programs 
Type of Software Name of software program/application 
Graphical User Interface 
(GUI) Operating Systems 
Computer-terminal keyboard based: Windows 9x, XP, Vista, 7 and 
8; Linux; 
Mac OS Tiger and Mountain Lion 10x 
Touch screen based (e.g. smartphones/tablets): Android, iOS, 
Windows Phone 
Cross-platform Cloud 
Data Storage 
Applications and 
Ecosystems 
Dropbox, SugarSync, Box, Just cloud, SkyDrive, Google Drive, 
SpiderOak, iCloud, Amazon Cloud Drive 
Word-processors and 
Text/Graphic Editors 
Microsoft Office (v97-2003, v2007, v2010, v2013), Adobe Acrobat 
Professional (v8, v9, vX,) Google Docs, Open Office v3, Office 
Libre v3&4, Scrivener v1, v2 
Web-based Survey 
Delivery And Data 
Collection Suites 
Qualtrics, REDCap, SurveyMonkey, LimeSurvey 
Quantitative Data 
Analysis 
Microsoft Excel (v97-2003, v2007, v2010, v2013), SPSS v21, JMP 
Qualitative Data Analysis Atlas.ti, NVivo 
Bibliography and 
Reference Management 
EndNote, RefWorks, Mendeley 
Email services and clients Gmail, Outlook, Yahoo, GMX-Mail, Mail.com 
 
Community Service and Applied Work 
 President, Social and Behavioral Health Student Association (SBHSA), Virginia 
Commonwealth University School of Medicine, 2012 – present. 
 Social activities chair for Social and Behavioral Health Student Association (SBHSA), 
Virginia Commonwealth University School of Medicine, 2011 – 2012. 
 Provided education and counseling for patients with chronic diseases, in particular 
patients with hypertension, diabetes, chronic pain and sleep disorders at Government 
Medical College, Miraj, Sangli (District) India, and T.N. Medical College and B.Y.L. 
Nair Charitable hospital, 2007 – 2008. 
 Participated in public health programs for educating middle-school children, in the age 
range of 10-16 years, about personal hygiene and nutrition in over 20 schools in rural 
Maharashtra, India, 2007. 
 Developed a “doctor-patient sharing” initiative, which involved encouraging patients to 
communicate with medical students, interns and residents about their disease and 
treatment experiences, in the in-patient surgical wards of Grant Medical College and Sir 
J.J. Group of Hospitals, Mumbai, India, 2005 – 2006. 
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Community Service and Applied Work… contd. 
 
 Participated as a student speaker in the annual medical college debate competitions that 
engaged the medical student community on issues pertaining to medical ethics and public 
health problems, 2006. 
o Awarded best speaker for debates concerning 1) medical eugenics and 2) public-
health implications of prostitution and sex-work, 2006. 
 Scripted and performed in a street play for an annual World AIDS day (Dec 1, 2004) 
public health initiative for rural and disadvantaged communities near Miraj City, (India) 
that was broadcasted on local and regional television networks. Street play was designed 
to raise awareness about HIV/AIDS, affect community member’s perceptions to reduce 
stigma related to HIV/AIDS for afflicted individuals, 2004. 
 
 
------------------------------------------------------------------------------ 
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Kellie E. Carlyle, Ph.D., M.P.H. 
Assistant Professor and Graduate Program Director 
Department of Social and Behavioral Health, Virginia Commonwealth University School of 
Medicine 
Address: One Capitol Square, 830 E. Main St., 9th Floor, Rm. 924, Richmond, VA 23219 
Phone: 804.628.4623 (O); 804.828.5440 (F); Email: kecarlyle@vcu.edu 
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Richard F. Brown PhD 
Assistant Professor 
Department of Social and Behavioral Health, Virginia Commonwealth University School of 
Medicine 
Chair, Massey Cancer Center, PRMS Cancer Prevention and Control Subcommittee 
Co-Director, Massey Cancer Center Patient/Community Centered Outcomes Core 
Address: One Capitol Square, 9th Floor, 830 East Main Street, P.O Box 980149, Richmond, VA 
23298 
Phone: 804 628 3340 (O); 804 828 5440 (F); Email: rbrown39@vcu.edu 
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Laura A. Siminoff, PhD 
Professor and Chair 
Department of Social and Behavioral Health, Virginia Commonwealth University School of 
Medicine Theresa A. Thomas Memorial Foundation Chair in Cancer Prevention and Control, 
VCU Massey Cancer Center 
Address: One Cap Square, Room 914, P.O. Box 980149, Richmond, VA 23298 
Phone: (804) 828-5135; Fax: (804) 828-5440; Email: lasiminoff@vcu.edu 
--------------------------------------------------------------- 
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Angela Starkweather, Ph.D., ACNP-BC, CNRN 
Associate Professor, Acute Care Nurse Practitioner 
Department Chair, Adult Health & Nursing Systems 
Virginia Commonwealth University School of Nursing 
Address: Virginia Commonwealth University P.O. Box 980567, Richmond, VA 23298-0567 
Phone: (804) 828-3986; E-mail: astarkweathe@vcu.edu 
--------------------------------------------------------------- 
 
Nancy L. McCain, DSN, RN, FAAN 
Nursing Alumni Distinguished Professor 
Address: Virginia Commonwealth University, P.O. Box 980567, Richmond, VA 23298-0567 
Phone: (804) 828-3444; E-mail: nlmccain@vcu.edu 
--------------------------------------------------------------- 
 
Michelle Miller-Day, PhD 
Professor 
Wilkinson College of Humanities and Social Sciences 
Department of Communication Studies 
Office: Doti Hall 213, Chapman University, Orange CA 
Phone: (714) 516-4686 
Email: millerda@chapman.edu 
--------------------------------------------------------------- 
 
Roxanne L. Parrott, PhD 
Distinguished Professor of Communication Arts and Sciences 
219 Sparks Building, University Park, PA 16802 
Email: rlp18@psu.edu 
Office Phone: (814) 865-6255 
--------------------------------------------------------------- 
 
Jon F. Nussbaum, PhD 
Professor of Communication Arts and Sciences & Human Development and Family Studies 
234 Sparks Building, University Park, PA 16802 
Office Phone: (814) 863-3619; Email: jfn5@psu.edu 
--------------------------------------------------------------- 
 
Rachel A. Smith, PhD 
Associate Professor: Communication Arts & Sciences and Human Development & Family 
Studies; Investigator: Center for Infectious Disease Dynamics (Huck Institute) and the 
Methodology Center (HHD), W-252 Millenium Science Complex, University Park, PA 16802 
Office Phone: (814) 867-4651; Email: ras57@psu.edu 
 
